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Introduction: No grip, no growth: the 
conceptual basis of excessive proteolysis 
in the treatment of cancer 
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Summary 
The formation of new blood vessels, called angiogenesis, is critical for a tumor to grow 
beyond a few mm3 in size. During angiogenesis, a provisional matrix promotes endothelial 
cell adhesion, migration, proliferation and survival. Synthesis and degradation of this matrix 
closely resemble processes that occur during coagulation and fibrinolysis. Degradation of 
the matrix and fibrinolysis are tightly controlled and balanced by stimulators and inhibitors of 
the plasminogen activation system. Here we give an overview of these processes during 
tumor progression. Furthermore, we postulate a novel way to inhibit angiogenesis by 
removal of the matrix through specific and localized overstimulation of the plasminogen 
activation system.   
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Preclinical and clinical data have demonstrated that angiogenesis, the formation of new 
blood vessels from pre-existing ones, is essential for the growth of tumors and their 
metastasis. Therefore, the discovery or development of molecules that inhibit angiogenesis 
may lead to a better treatment of cancer1. Since the late 19th century abnormalities in the 
hemostatic system have frequently been reported in cancer patients, including 
thromboembolic and bleeding disorders2. The recent finding that a number of potent 
naturally occurring inhibitors of angiogenesis, such as antiangiogenic anti-thrombin III3 and 
angiostatin4, are derived from proteins that play a role in hemostasis has strengthen the idea 
that the hemostatic system plays a crucial role in angiogenesis and tumor growth5. It has 
become apparent that coagulation and fibrinolysis support the formation and degradation of 
a provisional matrix, which facilitates angiogenesis. The critical role of the coagulation and 
fibrinolytic system makes them excellent tools for antiangiogenic and antitumorigenic 
therapy. Here we will review the role of the fibrinolytic system in angiogenesis and tumor 
growth. We discuss components of this system, evaluate its inhibitors for use in 
antiangiogenic therapy and provide a novel hypothesis for inhibiting angiogenesis. 
 
Angiogenesis  and the format ion of  a prov is ional  matr ix  
The formation of a provisional extracellular matrix is a hallmark of angiogenesis. This occurs 
after vascular injury, during inflammation, and in tumors6;7. Angiogenic factors that are 
produced by the tumor, most notably vascular endothelial growth factor (VEGF), induce 
hyperpermeability resulting in the extravasation of plasma proteins, including fibrinogen, 
prothrombin, vitronectin and many others. In addition, angiogenic factors, including VEGF, 
induce expression of tissue factor on the endothelial cells8. Tissue factor, which is not only 
present on stimulated endothelial cells, but also in the subendothelial matrix and on many 
tumor cells triggers the formation of fibrin9;10. Exposure of tissue factor leads to thrombin 
activation, and as a result fibrin is formed by polymerization of thrombin cleaved fibrinogen. 
Together with other adhesive proteins, such as vitronectin, laminin and fibronectin, fibrin 
forms the provisional matrix. The provisional matrix supports tissue remodeling, wound 
healing, angiogenesis and tumor growth (reviewed in 11). Fibrin and the other components of 
the extracellular matrix are involved in the regulation of cell proliferation, migration and 
survival or apoptosis through interactions with adhesion molecules on the cell surface. 
Important adhesion molecules include the receptors for fibrin and vitronectin, the integrins 
αvβ3 and αvβ5 (reviewed in 12). These interactions of the endothelial cells with the provisional 
matrix are crucial. Vitronectin can protect endothelial cells from apoptosis13, while antibodies 
against its receptor αvβ3 induce apoptosis14;15. Through interactions with plasminogen 
activator inhibitor 1 (PAI-1) and other components of the plasminogen activation system 
vitronectin is also an important regulator of plasmin formation and thereby controls the 
proteolysis of the provisional matrix. During angiogenesis the provisional matrix is 
continuously remodeled by balanced degradation and resynthesis (Figure 1).  
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The generation and subsequent breakdown closely resemble the processes of coagulation 
and fibrinolysis. 
 
The p lasminogen act ivat ion system 
The plasminogen activation system, which regulates the formation of the serine protease 
plasmin and subsequent fibrinolysis, has been shown to play an important role in the 
breakdown of the provisional matrix. Angiogenic growth factors induce the expression of 
tissue-type plasminogen activator (tPA) and urokinase-type plasminogen activator (uPA) on 
the surface of endothelial cells16;17. Both tPA and uPA are serine-proteases that can 
generate plasmin by proteolytic cleavage of its zymogen plasminogen. Plasminogen, like 
fibrinogen and other plasma components of the provisional matrix, is synthesized in the liver 
and deposited in response to hyperpermeability. The formation of plasmin is essential for 
invasion and migration of endothelial cells into the tissue to be vascularized. The 
plasminogen activation system is not limited to endothelial cells. While tPA is almost 
exclusively expressed by endothelial cells18, uPA also facilitates migration of other cells like 
epithelial cells, fibroblasts and tumor cells19;20. A variety of cell types can bind components 
of the fibrinolytic system, including plasminogen21, plasmin22, uPA23 and tPA24. Annexin II, a 
cellular receptor of tPA, enhances tPA activity more than 50-fold25. Plasminogen 
Figure 1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Coagulation and fibrinolysis on the cell surface. Upon stimulation by VEGF, components that initiate 
and control coagulation and fibrinolysis are upregulated. The continuous formation and breakdown 
of the provisional matrix is of great importance for cell viability, growth and motility. Matrix 
components support adhesion of endothelial cells and degradation of the matrix is necessary for 
migration. RGD, amino acids involved in binding of extracellular matrix proteins by integrins; PAI, 
plasminogen activator inhibitor; αvβ3, integrin receptor for vitronectin and fibrin(ogen). 
Introduction      5 
 
concentration is increased on the cell surface by binding to α-enolase26;27. Besides fibrin, 
plasminogen can bind a variety of extracellular matrix proteins, including laminin, fibronectin, 
vitronectin and collagen28-30. Plasmin causes proteolysis of the extracellular matrix by 
degrading fibrin into fibrin degradation products (FDP), called fibrinolysis, and other matrix 
proteins directly. In addition, plasmin can activate several metalloproteinases (MMP’s) which 
further degrade the extracellular matrix. Activation of plasminogen is tightly controlled by 
several protease inhibitors, plasminogen activator inhibitors 1 and 2 (PAI-1 and PAI-2) and 
α2-antiplasmin31;32. Plasmin, if not bound to fibrin or the cell surface, is rapidly inhibited by 
α2-antiplasmin33. 
 
Lys ine res idues and lys ine b ind ing s i tes  
Interactions of plasminogen with its receptors and extracellular matrix proteins are mediated 
by five kringle domains that are present in plasminogen. These kringle domains contain high 
affinity binding sites for lysine residues, especially when these residues are located at the 
carboxy-terminus of proteins (see below). Plasmin always cleaves after a lysine residue and 
thereby generates a free carboxy-terminal lysine residue. In the case of fibrin, free carboxy-
terminal lysine residues bind new plasminogen molecules and tPA with high affinity resulting 
in an increased rate of plasminogen activation34;35. In contrast to uPA, the activity of tPA 
depends on the presence of such cleaved fibrin fragments (FDP). Thus, partially degraded 
fibrin, containing carboxy-terminal lysine residues serves as cofactor in the enhanced 
formation of plasmin (Figure 2). The carboxy-terminal lysine residues are of critical 
importance since their removal by carboxypeptidase B type enzymes can completely 
abrogate the cofactor function36-38. 
 
Thrombin-act ivatab le  f ibr ino lys is  inh ib i tor  (TAFI)  
TAFI, also known as plasma procarboxypeptidase B, procarboxypeptidase U or 
procarboxypeptidase R, is a recently identified regulator of the plasminogen activation 
system (reviewed in 39). Like plasminogen and fibrinogen, TAFI is made by the liver. TAFI is 
activated following coagulation and cleaves carboxy-terminal lysine and arginine residues 
from plasmin degraded fibrin40. This prolongs the clot lysis time due to a decrease in the rate 
of plasminogen activation41;42. TAFI can be activated in vitro by high concentrations of 
trypsin43, thrombin41 or plasmin44. Activation by plasmin can be improved by heparin45. Most 
importantly, activation of TAFI by thrombin is increased 1250-fold in the presence of 
thrombomodulin38;46, a receptor expressed on endothelial cells. Since thrombomodulin 
expression can be upregulated by VEGF47 it is likely that the activity of TAFI is regulated 
during angiogenesis. Recently, in vivo studies revealed that inhibition of TAFI by potato 
carboxypeptidase inhibitor can enhance tPA induced thrombolysis48-51. Others have shown 
that TAFI is a repressor of plasminogen function during pulmonary clot lysis and peritoneal 
inflammation-induced leukocyte migration in mice with a compromised plasminogen 
background52. Taken together, TAFI is expected to control plasmin-mediated proteolysis of 
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Ant i - f ib r ino ly t ic  therapy and cancer  
Given plasmin’s pivotal role in angiogenesis and tumor growth, drugs that target the 
formation of plasmin are expected to affect angiogenesis and cancer progression. Indeed, 
results from many studies have revealed promising antiangiogenic and antitumorigenic 
activity of inhibitors that affect plasmin formation. Several agents that inhibit fibrinolysis 
either by interfering with plasminogen activation or plasmin activity have been tested both in 
vivo and in vitro (Table I).  
 
Tranexamic ac id  
Tranexamic acid (Cyclokapron) is a lysine analogue that blocks the interaction between 
lysine residues and the lysine binding sites that are present in the kringle domains of 
plasminogen. Several preclinical as well as clinical studies have reported promising effects 
of this drug on cancer growth. Tranexamic acid was shown to inhibit growth of human lung, 
ovarian and renal carcinoma’s transplanted in nude mice. Inhibition was apparently caused 
by increased fibrin depositions at the advancing border of tumors due to reduced fibrinolytic 
activity53. Profound effects of tranexamic acid were seen on growth of lung, breast, 
hepatoma and ovarian carcinomas in other mice models54;55. In a study by Tanaka et al.56 
remarkable effects (60%) on the occurrence of metastases of Lewis lung carcinoma in mice 
Figure 2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The tPA-mediated plasminogen activation system. The inactive zymogen plasminogen can be 
activated into the serine protease plasmin by tissue-type plasminogen (tPA) which in turn degrades 
fibrin. The activity of tPA is greatly enhanced by fibrin degradation products (FDP) which are 
obtained after plasmin cleavage of fibrin. The stimulatory activity of FDP is critically dependent on 
the presence of carboxy-terminal lysine residues. Thrombin-activatable Fibrinolysis Inhibitor (TAFI) 
can block the activity of FDP by removing carboxy-terminal lysines. Aprotinin (Trasylol®) and 
tranexamic acid (Cyclokapron®) inhibit fibrinolysis by blockage of plasmin activity and co-factor 
function of FDP respectively. 
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were seen when mice were treated with 500 mg/kg twice daily. In human mammary 
carcinoma and melanoma cells, tranexamic acid inhibited the binding of plasmin and 
plasminogen to the cell surface57. Another lysine analogue, ε-aminocaproic acid (εACA), 
decreased the tPA-mediated fibrinolytic activity of Co115 colon carcinoma cells in vitro58. 
Tumor-induced corneal angiogenesis could be significantly reduced by tranexamic acid and 
εACA59. Furthermore, εACA has been shown to inhibit glioma tumor growth in a mouse 
model60 and in vitro angiogenesis61. Stabilization of active TAFI by εACA, determined by 
using a small substrate for TAFI, may give an additional inhibitory effect on fibrinolysis and 
angiogenesis43. A few promising clinical studies have been carried out to test the effect of 
tranexamic acid in humans. Patients with ovarian cancer showed stable disease with a 
median survival of 12.5 months after treatment with 4-6 gr/day tranexamic acid62. In another 
study six out of eleven stage II or IV ovarian cancer patients responded to tranexamic acid 
therapy after surgical tumor debulking63. Taken together, since tranexamic acid has 
profound effects on angiogenesis and tumor growth and has no serious side effects it is a 
potential candidate angiogenesis inhibitor. Better results might be obtained by continuous 
treatment with tranexamic acid. In contrast to daily administration, continuous delivery of 
angiogenesis inhibitors has been shown to be much more effective64.  
 
Inh ib i tors  of  uPA 
Inhibitors of uPA that either affect uPA activity or prevent uPA binding to its receptor have 
been successfully applicated in vitro and in vivo. Antibodies against uPA block tumor 
metastasis in the chorioallantoic membrane assay65. Furthermore, antibodies against uPA 
were used to inhibit metastasis and tumor growth in mice models66-68. Growth and formation 
of metastases of human cancer cell lines was inhibited after treatment with an uPA 
antagonist69. Non-catalytic uPA was coupled to IgG and tested in vivo. In an experimental 
metastases model, treatment with this fusion protein resulted in a decreased number of 
micrometastases in the lung ranging between 5 and 30% of vehicle-treated mice. This 
demonstrates that competitive inhibition of uPA can arrest metastasis and primary tumor 
growth. Furthermore, establishment of primary tumors was abrogated since a single dose of 
uPA-IgG administered 1 h prior to tail vein injection of the cells reduced lung colony 
formation to just 3.5% of vehicle-treated SCID mice69. Min et al.70 obtained comparable 
results using a similar approach. Ligation of the EGF domain of uPA to IgG resulted in a 
potent antagonist of uPA which inhibited capillary tube formation, bFGF induced 
neovascularization and B16 melanoma growth in syngenic mice. A similar construct was 
made by Lu et al.71;72 who fused the amino-terminal fragment of uPA to human serum 
albumin. This construct inhibited in vitro tumor cell invasion and endothelial cell mobility and 
deformability. Inactive uPA, generated by PCR mutagenesis, that retains receptor binding 
reduced prostate cancer neovascularization and growth73. Prevention of in vitro tube 
formation in three-dimensional fibrin matrices was achieved with soluble uPAR and 
antibodies that inhibit uPA activity61.  
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Table 1. Antiangiogenic and antitumorigenic compounds that deregulate the plasminogen activation 
system. For optimal angiogenesis to occur, plasmin formation and action needs to be under stringent 
control of activators, including tPA, and inhibitors, such as PAI-1 and α2-antiplasmin. A shift in the 
balance, by either increasing the levels or activity of inhibitors or by enhancing the formation of 
plasmin have been shown to have profound effects on either endothelial cell adhesion, migration, 
angiogenesis, metastasis or tumor growth. 
 
Compound/Mechanism Effect in vivo / in vitro 
N-terminal fragment of uPA fused to IgG, uPA 
antagonist 
arrests metastasis, inhibits establishment of primary tumors and 
micrometastases69 
N-terminal fragment of uPA fused to IgG (m1-
48Ig), uPA antagonist 
in vivo suppression of basic fibroblast growth factor-induced 
neovascularization and B16 melanoma growth in syngenic mice70 
N-terminal fragment of uPA ligated to HSA (ATF-
HSA), uPA antagonist 
in vitro inhibition of tumor cell invasion in matrigel, changes in cell 
morphology and remodeling of cytoskeleton71;72 
Soluble uPAR in vitro inhibition of human microvascular endothelial cells 
capillary formation in matrigel61 
PAI-1 extended half-life, uPA inhibitor inhibits prostate cancer xenografts74 
p-Aminobenzamidine inhibits growth of a human prostate tumor in mice and migration of 
endothelial cells in matrigel74;75 
Amiloride inhibits growth of a human prostate tumor in SCID mice74 
Anti-catalytic uPA inhibits the formation of lung metastasis of Lewis lung carcinoma 
and suppresses invasion of tumor cells through matrigel66 
Anti-catalytic (human) uPA no invasion of human carcinoma HEp3, however, no reduced 
incidence of distant metastasis in mice68 
Anti-catalytic (human) uPA no inhibition of human carcinoma HEp3 at the site of primary 
inoculation on the chorioallantoic membrane, but prevention of 
metastasis to the embryo lung65 
Inactive recombinant murine u-PA that retains 
receptor binding 
inhibits prostate cancer neovascularization, metastasis and 
growth in rat73 
Aprotinin (Trasylol), inhibitor of plasmin and other 
serine proteases 
inhibits invasion of endothelial cells on the human amniotic 
membrane76, tube formation in matrix gels61;77and metastasis of 
Lewis lung carcinoma in mice78 
Tranexamic acid (Cyclocapron) and ε-
aminocaproic acid (εACA), lysine-analogue which 
inhibits binding of plasminogen to its substrates 
inhibits invasion and migration of endothelial cells on the human 
amniotic membrane76, antiangiogenic in the cornea assay in 
rabbits59 and in vitro angiogenesis61. Inhibits growth of V2 
carcinoma in rabbits79 of Lewis lung carcinoma in mice56, of 
(human) tumors in mice53-55;60;80. Beneficial effects in humans 
have been reported62;63;78;80-86 
α2-Antiplasmin, inhibitor of plasmin inhibits in vitro tumor cell invasion through the human amniotic 
membrane76 
Angiostatin and other fragments of plasmin, 
unknown mode of action (see text) 
inhibits proliferation and migration of endothelial cells, 
neovascularization in the corneal assay and subcutaneous 
tumors4;74;87-92 
Endostatin, unknown mode of action (see text) inhibits primary tumor growth and metastasis93-95, angiogenesis in 
CAM96 and endothelial cell proliferation and migration97, induces 
endothelial cell apoptosis98 
Streptokinase and tPA, plasminogen activators 
which increase fibrinolysis 
inhibits pulmonary tumor seeding in an animal model99;100 
Potato carboxypeptidase inhibitor (PCI), inhibitor 
of TAFI, enhances fibrinolysis51 
inhibits the growth of several human pancreatic adenocarcinoma 
cell lines in nude mice101  
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Others have used a physiological inhibitor of plasminogen activation, PAI-1, which half-life 
was extended by mutation74. Synthetic inhibitors of uPA activity like p-aminobenzamidine 
and amiloride showed a clear decrease in tumor-growth rate compared to untreated 
mice74;75. These results demonstrate that blockage of uPA by uPA inhibitors can reduce 
tumor size in experimental animals. Agents, such as aprotinin, which inhibit plasmin activity 
directly, can also inhibit metastasis78. 
 
Angiostat in  
The observation that in some cases removal of a primary tumor in patients may lead to the 
rapid growth of previously undetected metastases102;103 suggests that primary tumors make 
factors that may inhibit the outgrowth of distant tumors104. Based on this concept the 
angiogenesis inhibitor angiostatin was found4. Angiostatin is a proteolytic fragment of 
plasmin(ogen) and consists of kringle 1-4 of plasminogen. The molecule was purified from 
urine of tumor-bearing mice using lysine affinity chromatography. Systemic administration of 
angiostatin blocked neovascularization and growth of metastasis in the absence of the 
primary tumor. At higher doses, angiostatin can inhibit growth of primary tumors as well89;90. 
Continuous delivery of angiostatin has been shown to be more effective in inhibiting 
angiogenesis than bolus injection64. In vitro, angiostatin inhibits bFGF-induced endothelial 
cell proliferation and migration4;105. In vivo generation from plasmin(ogen) has been 
demonstrated and can be achieved by several proteases106-110. Angiostatin binds to the α/β-
subunits of ATP synthase on the surface of endothelial cells causing cytolysis111. Presently, 
the biological relevance of these findings is unclear. It is not unlikely that angiostatin exerts 
its effect by binding integrin ligands present in the extracellular matrix112 thereby inducing 
changes in intracellular signalling113. Alternatively angiostatin may effect plasmin-mediated 
proteolysis through non-competitive inhibition of tPA activity114. However, also profibrinolytic 
effects have been described for kringle 1-3, which can block the interaction of plasmin with 
α2-antiplasmin115. Finally, angiostatin binds tissue factor and may regulate the formation of a 
provisional matrix through an effect on coagulation116. In conclusion, although direct effects 
on endothelial cells are described, angiostatin might be involved in the generation and 
breakdown of the provisional matrix as well. 
 
Endostat in  
In 1997 a carboxy-terminal fragment of collagen XVIII, named endostatin, was identified that 
proved to be a potent inhibitor of endothelial cell proliferation and angiogenesis97. Endostatin 
was purified from conditioned media of hemangioendothelioma (EOMA) cells using a 
heparin affinity column. Like plasminogen and fibrinogen, collagen XVIII is made by 
hepatocytes117. Generation of endostatin can be achieved by cleavage of collagen by 
cathepsin L118, matrilysin119 or elastase120. Endostatin has distinct antiangiogenic and 
antitumoral activities in several animal models121. When administered to mice bearing Lewis 
lung carcinoma, T241 fibrosarcoma or B16F10 melanoma, recombinant mouse endostatin 
caused tumor regression without developing drug resistance93. However, contrary to this, no 
10 Chapter 1 
 
antiangiogenic effect of endostatin was seen in other studies122-125. This still remaining 
paradox has lead to discussions about the efficacy of endostatin126. A complicating factor is 
that endostatin is used in a soluble, as well in an insoluble form. Although both forms can 
inhibit tumor growth, only the insoluble form induced complete regression of subcutaneous 
tumors93. Different structural forms of endostatin have distinct bioactivities and may 
therefore produce their antiangiogenic effects through distinct mechanisms127;128 
Recombinant mouse endostatin produced by mammalian cells was shown to bind to heparin 
with a K(d) of 0.3 µM, suggesting that this interaction may play a role in its antiangiogenic 
activity. Mutations in endostatin that affect heparin binding abolished endostatin-mediated 
inhibition of bFGF-induced angiogenesis in a chicken chorioallantoic membrane assay96. 
However, binding of endostatin to blood vessels was independent of heparan sulfate and 
endostatin did not compete with bFGF129. We have recently found a powerful molecular 
activity for endostatin that provides an explanation how endostatin may act as an 
antitumorigenic compound127;128. Because endostatin is a fragment of an extracellular matrix 
component, exerts its effects via the tumor vasculature and has a carboxy-terminal lysine, 
we examined whether endostatin can regulate plasmin formation. Using a subcutaneous 
colon carcinoma model we found that the antitumor activity of endostatin was completely 
abolished when mice were also treated with carboxypeptidase B. This suggests an 
important role for carboxy-terminal lysines in endostatin. The finding that endostatin purified 
from plasma of cancer patients lacks the carboxy-terminal lysine and is inactive in inhibiting 
endothelial cell proliferation130 is in agreement with our findings. We established that 
endostatin binds plasminogen and stimulated tPA-mediated plasmin formation in a lysine- 
dependent manner. Like has been shown for fibrin, binding of endostatin to tPA could not be 
inhibited by carboxypeptidase B or lysine analogues. Our results point to a novel mechanism 
in which overstimulation of the plasminogen system may inhibit angiogenesis and tumor 
growth (see below). 
 
Can hyper f ibr ino lys is  inh ib i t  angiogenesis  ?  
Currently a well excepted model to explain angiogenesis and the angiogenic switch is based 
on a balance between stimulators and inhibitors. Depending on the levels of stimulators and 
inhibitors a tumor will grow or stay dormant4;104;131. uPA and tPA are currently referred to as 
pro-angiogenic, whereas PAI is called an inhibitor of angiogenesis5;132-135. It has been 
suggested that angiogenic factors which induce angiogenesis induce endothelial expression 
of both uPA and PAI-1, with a slight excess in favor of the protease136. However, 
paradoxically PAI-1 has been correlated with a poor prognosis for many cancers (reviewed 
in 137). Furthermore, in PAI-1 knockout mice invasion of malignant keratinocytes and 
angiogenesis was abrogated, which could be restored by a PAI-1 expressing adenoviral 
vector138. This shows an important and essential pro-angiogenic role for PAI-1. Another 
example is the inhibitor thrombospondin, which was found to be essential for pathological 
angiogenesis during wound healing in knockout mice139. We state that these “negative” 
regulators of angiogenesis are indispensable and stabilize this balanced process by limiting  
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excessive proteolysis (see below). We propose an hemostasis model for angiogenesis. Our 
model considerates angiogenesis depending on a perfect balance of coagulation and 
fibrinolysis (Figure 3). Disturbation of this balance by inhibition, but also by overstimulation 
of fibrinolysis might prevent angiogenesis. This implicates that widely accepted pro-
angiogenic factors like uPA, tPA and plasmin can be antiangiogenic as well when 
administered at higher doses.  
The concept of plasmin-mediated inhibition of tumor growth is supported by our recent 
finding that continuous systemic treatment of mice with tPA, which efficiently generates 
plasmin in vivo and is used clinically in patients with myocardial infarction, also inhibits tumor 
growth (data not shown). Moreover, others have demonstrated in vitro that induction of 
plasminogen activation leads to endothelial cell detachment142, inhibition of cell adhesion143 
or endothelial cell destruction144. Enhanced formation of plasmin, through administration of 
tPA or streptokinase (another plasminogen activator), also reduced pulmonary tumor 
seeding in an experimental animal model99;100. In addition, maspin, another stimulator of 
tPA, inhibits angiogenesis145;146. Our model may explain the observation that the absence of 
Figure 3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Angiogenesis is a continuous balanced process.  Many tumors contain fibrin depositions140;141 and 
elevated levels of plasminogen activators and PAI-1 (reviewed in 137). In cancer patients levels of 
fibrinogen degradation products as well as complexes between plasmin and α2-antiplasmin are 
elevated. This indicates an increased turn-over of fibrinogen and plasminogen. During angiogenesis 
the provisional matrix is continuously degraded and resynthesized, called remodeling. This process 
is similar to coagulation and fibrinolysis. Generation of a temporary matrix is induced by tissue 
factor (coagulation) which is followed by degradation through plasmin (fibrinolysis) (left panel). The 
formation of fibrin polymers and release of fibrin degradation products after plasmin mediated 
proteolysis is a highly regulated and balanced process required for endothelial cell growth and 
angiogenesis. Overstimulation of tissue-type plasminogen activator which leads to excess plasmin 
formation and hyperfibrinolysis can disturb this balance and prevent angiogenesis (right panel). 
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PAI, which may lead to increased plasminogen activator activity and plasmin formation, 
prevents vascularization and tumor invasion138. Additionally, patients with peripheral tumors 
that are reduced by tumor necrosis factor alpha (TNFα) show elevated concentrations of 
tPA147-149 and increased levels of plasmin-α2 antiplasmin (PAP)148 and fibrin degradation 
products (FDP) 148;150. Increased levels of PAP and FDP strongly suggest active fibrinolysis 
that correlates with tumor reduction. There might also be an additive effect of plasminogen 
activator activity on the migration of macrophages151. Inhibition of macrophage mobility will 
deprive tumor cells from growth factors. Similarly, excessive fibrinolysis might affect platelet 
interactions with fibrin in the tumor vasculature, thereby inhibiting angiogenesis152. Taken 
together, we propose that molecules that lead to excessive proteolysis in the tumor may be 
powerful antiangiogenic and antitumorigenic agents. 
 
Crypt ic  f ragments  
An increasing number of proteolytic fragments, some of which may be generated naturally, 
are described with potent antiangiogenic activity. These include angiostatin4, endostatin97, 
antiangiogenic anti-thrombin III3, restin153, canstatin154, kringle 5 of plasminogen87 and 
thrombin fragment 1 and 2156. We found that fragments of fibrin (FDP) also possess 
antitumorigenic activity, possibly via a tPA-mediated mechanism similar to endostatin 
(chapter 8). At present it is unclear why these fragments are generated by tumors, whether 
they have a normal physiological role, and whether these fragments are generated during 
other (patho)-physiological processes in which angiogenesis is involved. Because FDP have 
an important regulatory role in the control of fibrinolysis it may be that in analogy, other 
endogenous “cryptic” fragments serve a similar and normal physiological role, regulating 
tissue remodeling by controlling coagulation or fibrinolysis. These factors may only act 
antiangiogenic because they are administered at doses that excess endogenous levels, 
thereby disturbing strictly balanced proteolysis. 
 
Conclud ing remarks 
The interaction of endothelial cells and extracellular matrix forms an important area of 
investigation. Based on the concept that degradation of the extracellular matrix is a critical 
step in the progression of cancer, therapeutic strategies have been developed to prevent 
this. Inhibitors of metalloproteinases have shown biological activity in preclinical models and 
are currently tested in phase III clinical trials. A significant limitation of this approach is that 
the use of proteolytic inhibitors will never lead to removal of tumor stroma and therefore of 
the tumor itself.  In fact, ultimately, the tumor and its stroma need to be removed by 
proteolysis. We would argue that drugs that enhance proteolysis may give far better results 
and may induce tumor regression. In this review we discussed that excessive localized 
proteolysis may be achieved by specifically activating tPA at the sites of angiogenesis. The 
feasibility of this approach has been demonstrated in preclinical models. The conceptual 
basis of localized excessive proteolysis (“no grip, no growth”) will facilitate the development 
of an array of compounds that may be used in angiogenesis-related diseases. 
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Outline of the thesis 
The research described in this thesis was aimed to further clarify the role of the plasminogen 
activation system in angiogenesis and cancer as a potential target for therapy.  First, we 
investigated the role of components of this system in corneal angiogenesis and tumor 
growth. Second, we attempted to elucidate the working mechanism of the tumor growth 
inhibitor endostatin. Taken together, we addressed the following subjects: 
 
1. The corneal angiogenesis model is widely used for (anti)angiogenic research. To 
what extent are components of the fibrinolytic system involved in corneal 
angiogenesis? In chapter 2 we present the results of studies in mice deficient of 
plasminogen, plasminogen activator (tPA, uPA) or a regulator of plasminogen 
activation (PAI-1, TAFI). 
2. The plasminogen system is activated during tumor growth. What is the role of a 
novel regulator of plasminogen activation, thrombin-activatable fibrinolysis inhibitor 
(TAFI), in tumor growth and metastasis?  The effects of TAFI-deficiency on 
experimental tumor growth and metastasis formation are described in chapter 3. 
3. Circulating markers of active coagulation and fibrinolysis and abnormal plasma 
levels of hemostatic proteins are often present in cancer patients, possibly leading 
to thrombotic and hemorrhagic events. This have prompted us to measure TAFI 
antigen and activity levels in plasma of patients with prostate cancer. In chapter 4 
the results are presented. 
4. The working mechanism of the angiogenesis inhibitor endostatin is presently 
unknown. Endostatin is used in a soluble and insoluble form. Although both forms 
have been shown to inhibit tumor growth, the induction of complete tumor 
regression has only been reported for the insoluble form. Likely, these forms have 
different bioactivities. We determined the biological (chapter 5) and structural 
(chapter 6,7) differences between soluble and insoluble endostatin. Furthermore, 
we tested the hypothesis that endostatin acts through the induction of excessive 
proteolysis (chapter 5). 
5. We found that endostatin is a cofactor of tPA-mediated plasminogen activation. For 
a long time, fibrin fragments (fibrin degradation product, FDP) have been known as 
stimulators of tPA-mediated fibrinolysis. Can FDP also inhibit tumor growth? To 
address this question, we determined the effects of FDP treatment on endothelial 
cells and subcutaneous tumor growth (chapter 8). 
6. Could our observations be of value for the use of endostatin and other 
antiangiogenic fragments? In chapter 9 we discuss the possible implications of our 
results. 
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Summary 
The plasminogen activation system has been implicated in angiogenesis and angiogenesis-
dependent diseases such as cancer, atherosclerosis and ocular diseases. The identification 
and development of inhibitors of angiogenesis offer new possibilities for the treatment of 
these diseases. To clarify the role of proteins involved in the regulation of fibrinolysis during 
corneal angiogenesis, we have studied corneal vessel formation in mice deficient for 
urokinase-type plasminogen activator (uPA), tissue-type plasminogen activator (tPA), 
plasminogen, plasminogen activator inhibitor-1 (PAI-1) and thrombin-activatable fibrinolysis 
inhibitor (TAFI). Our results corroborate earlier findings that angiogenesis in the mouse 
cornea is dependent on PAI-1 and plasminogen. The absence of tPA, uPA or TAFI did not 
affect the formation of new vessels in the cornea.  
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Introduction 
Angiogenesis, the formation of new blood vessels from existing vasculature, is involved in 
normal development but also in a variety of pathologies such as cancer, atherosclerosis and 
ocular diseases1;2. During angiogenesis endothelial cells are activated and proteolytically 
dissect their way through the basement membrane, proliferate and migrate towards an 
angiogenic signal. Subsequently, the endothelial cells remodel into a new vessel. Proteolytic 
enzymes involved in matrix degradation include matrix metalloproteinases (MMP’s) and the 
serine proteases of the plasminogen activation system, including tissue-type plasminogen 
activator (tPA), urokinase-type plasminogen activator (uPA) and plasmin3;4. The expression 
of these enzymes is induced by angiogenic factors, including VEGF and bFGF5-7. Plasmin 
contributes to angiogenesis directly by cleaving fibrin and other matrix components and 
indirectly by activating matrix-degrading metalloproteinases and angiogenic growth factors, 
such as transforming growth factor β8, hepatocyte growth factor9, vascular endothelial 
growth factor10 and basic fibroblast growth factor11. 
Plasmin cleaves its substrates behind a lysine or arginine, which then become carboxy-
terminal. These carboxy-terminal basic amino acid residues in fibrin provide new binding 
sites for plasminogen, facilitate its efficient activation by plasminogen activators and initiate 
a positive feedback loop12-15. Lysine analogues such as ε-aminocaproic acid (εACA) and 
tranexamic acid (Cyclokapron) or carboxypeptidase B-treatment efficiently prevent plasmin 
formation. At present, several reports have shown that plasminogen also interacts with 
proteins unrelated to fibrin. Similar to plasmin-cleaved fibrin, plasminogen-binding proteins 
like annexin II16 and enolase17, which are expressed by a variety of cell types, are involved 
in carboxy-terminal lysine or arginine-dependent plasminogen activation. The importance of 
carboxy-terminal basic amino acid residues in angiogenesis has been concluded from 
studies with ε-aminocaproic acid and tranexamic acid18-21. 
Plasminogen activation is regulated by thrombin-activatable fibrinolysis inhibitor (TAFI, also 
known as procarboxypeptidase U, -R, or plasma procarboxypeptidase B, EC 3.4.17.20)22 
and plasminogen activator inhibitor-1 (PAI-1)23. PAI-1 directly blocks the activity of tPA and 
uPA. TAFI is a carboxypeptidase B-type proenzyme that upon activation by thrombin22, 
plasmin24 or trypsin25 removes carboxy-terminal lysines of fibrin and cellular binding sites of 
plasminogen causing reduced plasminogen binding and activation26;27. Thrombin-mediated 
activation of TAFI is strongly increased in the presence of both soluble and endothelial cell-
bound thrombomodulin28. 
During the past decades, angiogenesis research has focussed on the isolation and 
characterization of inhibitors that might be of therapeutic value for the treatment of cancer 
and other angiogenesis-related diseases. The plasminogen activation system is a potential 
target of antiangiogenic treatment. For instance, the angiogenesis inhibitor angiostatin is a 
fragment of plasminogen29 and endostatin is a stimulator of tPA-mediated plasminogen 
activation30;31. In addition, a variety of strategies to inhibit plasminogen activation and 
angiogenesis have been employed (reviewed in 32). The identification of various 
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angiogenesis inhibitors has prompted the development of angiogenesis models to test their 
anti- or proangiogenic efficacy. At present, the corneal angiogenesis assay is widely used 
and considered one of the best in vivo models to study angiogenesis because of the 
avascularity of the cornea2. Here we studied the role of plasminogen, uPA, tPA, PAI-1 and 
TAFI in corneal neovascularization using plasminogen-/-, uPA-/-, tPA-/-, PAI-1-/- and TAFI-/- 
mice.  
 
Materials and methods 
Animals  
Mice deficient for uPA, tPA, plasminogen, PAI-1 and littermate wildtype controls (i.e. 
identical phenotype apart from deleted gene) were kindly provided by Prof. P. Carmeliet 
(Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for 
Biology, Leuven, Belgium). These and TAFI-deficient mice were described previously33-36. 
All animals were maintained under specified pathogen free conditions, received food and 
water ad libitum and were kept on a 12-hour light/dark cycle. All experiments were 
performed in accordance with guidelines of the University’s Animal Experimental Committee, 
University Medical Center Utrecht, The Netherlands.  
 
Corneal  angiogenesis  assay 
The corneal angiogenesis assay was performed as described previously37. Mice (6-8 weeks 
of age) were anaesthetized by intraperitoneal administration of a mixture of Hypnorm (0.3 
mg/mouse; Janssen-Cilag, Brussels, Belgium) and Dormicum (12.5 mg/mouse, Roche, 
Brussels, Belgium). In addition, corneas were anaesthetized by local administration of 4 
mg/ml oxybuprocaine (0.4%) eye drops. Corneal micro pockets were created with surgical 
blade #10, a modified keratotome and a pair of microscopic forceps. Micro pellets were 
constructed as described previously37. Briefly, a suspension of 100 ng bFGF (Life 
technologies, Rockville, MD), sucrose aluminium sucralfate and Hydron (IFN Sciences New 
Brunswick, NJ) was prepared and applied to a sterilized nylon mesh (approximate pore size 
0.4 x 0.4 mm). This suspension was allowed to dry, after which the fibers of the mesh were 
separated under sterile conditions; same size pellets were selected for implantation. The 
pellets were deposited into the micro pocket at a distance of 0.9-1.1 mm from the limbus 
vasculature. Eyes were treated with aknemycin ointment to prevent infection and 
dehydration of the cornea. Six days after pellet implantation, mice were anaesthetized as 
described above and correct position (0.9-1.1 mm from the limbus) of the pellet was 
confirmed in all eyes. Angiogenesis in the cornea was measured as corneal neovascular 
surface area (A). The surface area of newly formed blood vessels was calculated using the 
formula 0.2 x π x maximal vessel length (VL) x the contiguous circumferential zone of 
neovascularization (CN = clock hours, 1 clock hour equals 30 degrees of arc)38. 
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Stat is t ica l  ana lys is  
The area of vessel growth in control mice was considered 100%. Neovascularization in other 
groups was expressed as percentage of that in control mice. All data were expressed as the 
normalized mean ± SEM. The significance of differences was determined by unpaired 
student’s t-test; P < 0.05 was considered to be statistically significant.  
 
Results 
Corneal  neovascular izat ion in  mice def ic ient  for  p lasminogen act ivators ,  
uPA and tPA 
Angiogenic growth factors such as bFGF and VEGF induce the expression of plasminogen 
activator (uPA and tPA) by endothelial cells5-7. To investigate the effects of plasminogen 
activator (uPA and tPA)-deficiency on bFGF-induced corneal angiogenesis we performed 
the cornea neovascularization assay in uPA-deficient, tPA-deficient and control mice. In 
response to bFGF, new blood vessels formed from the limbal plexus reaching the implanted 
pellet six days after implantation (Figure 1a). Triangular vessel growth was observed from 
the limbus (base) towards the pellet (apex). In all uPA- and tPA-deficient mice, bFGF 
induced the formation of new blood vessels reaching the pellet at day 6 (Figure 1b). In uPA-
deficient mice, mean vessel area was slightly but not significantly decreased when 
compared to control mice (uPA-/-: 86.0 ± 6.1%, n = 5; control: 100.0 ± 3.5%, n = 24, p = 
0.36). The observed slight decrease in vessel area was due to a decreased number of clock 
hours. In tPA-deficient mice, the area of newly formed vessels was similar to that in control 
mice (tPA-/-: 91.7 ± 6.8%, n = 6; control: 100.0 ± 3.5%, n = 24, p = 0.53). 
Figure 1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Corneal neovascularization in uPA-/-, tPA-/- and control mice.  (A) Photograph of a control mouse 
cornea 6 days after bFGF-coated pellet implantation.  (B) bFGF-induced vessel formation in 
corneas of uPA-/- (n = 5), tPA-/- (n = 6) and control (n = 24) mice was analyzed 6 days after pellet 
implantation and quantified. Corneal angiogenesis was unaffected in the absence of tPA or uPA. 
Values are the normalized mean ± SEM. 
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Both uPA and tPA can activate plasminogen. Therefore, the observed progression of vessel 
growth in mice lacking uPA and tPA could be due to complementary bioactivity of these 
enzymes. In addition, plasminogen activation is not necessarily dependent on the presence 
of tPA or uPA since alternative pathways exist that can activate plasminogen into 
plasmin39;40. To directly determine the role of plasmin(ogen) in corneal angiogenesis, we 
analyzed corneal vessel growth in plasminogen-deficient mice (Figure 2). In plasminogen-
deficient mice, we observed a significant reduction in vessel growth compared to control 
mice (plasminogen-/-: 79.0 ± 3.8%, n = 6; control: 100.0 ± 3.5%, n = 24, p = 0.007). These 
results indicate a functional role for plasminogen in corneal angiogenesis. 
 
Corneal  neovascular izat ion in  mice def ic ient  for  inh ib i tors  o f  p lasminogen 
act ivat ion,  TAFI  and PAI-1 
Plasminogen activation is regulated by plasminogen activator inhibitor-1 and thrombin-
activatable fibrinolysis inhibitor (TAFI). PAI-1 deficiency is associated with significantly 
decreased corneal vessel formation (PAI-/-: 19.0 ± 2.0%, n = 6; control: 100.0 ± 3.5%, n = 
24, p < 0.001) (Figure 3). Possibly, uncontrolled plasminogen activation caused by the 
absence of PAI-1 could lead to reduced angiogenesis. To further explore this hypothesis we 
examined corneal neovascularization in mice lacking another inhibitor of plasminogen 
activation, TAFI (Figure 3). Corneal vessel formation in response to bFGF in TAFI-deficient 
mice was similar to vessel growth observed in controls (TAFI-/-: 98.1 ± 11.2%, n = 5; control: 
100.0 ± 3.5%, n = 24, p = 0.17). 
Figure 2. 
Corneal neovascularization in plasminogen-/- and 
control mice.  bFGF-induced vessel formation in 
corneas of plasminogen-/- (n = 6) and control (n = 
24) mice was analyzed 6 days after pellet 
implantation and quantified. Plasminogen-
deficiency significantly reduced corneal 
angiogenesis. Values are the normalized mean ± 
SEM. P-values are indicated in the figure. 
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Figure 3.   
Corneal neovascularization in PAI-1-/-, TAFI-/- and 
control mice.  bFGF-induced vessel formation in 
corneas of PAI-/- (n = 6), TAFI-/- (n = 5) and control 
(n = 24) mice was analyzed 6 days after pellet 
implantation and quantified. Corneal 
angiogenesis was highly attenuated in mice 
lacking PAI-1 and normal in TAFI-/- mice. Values 
are the normalized mean ± SEM. P-values are 
indicated in the figure. Control   PAI-1-/- TAFI-/-
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Discussion 
The corneal neovascularization model is frequently used to study angiogenesis in vivo and 
to test potential angiogenesis inhibitors. Numerous studies have indicated an important role 
of the fibrinolytic system in disease-related angiogenesis. In the present study we 
investigated the role of different components of the fibrinolytic system in corneal 
angiogenesis. Plasminogen is present in the human cornea41, maintains the normal mouse 
cornea by preventing from ligneous conjunctivitis42 and is involved in corneal wound 
healing43. In addition, mechanically wounding of the cornea induced the expression of tPA 
and uPA by the corneal epithelium in rabbits44. We found that plasminogen, tPA, uPA and 
TAFI are not essential for efficient corneal vessel formation. However, plasminogen-
deficiency caused a significant reduction of corneal angiogenesis. Angiogenesis was largely 
reduced in the absence of PAI-1 but was normal in TAFI-deficient mice.  
uPA proteolytic function is considered to be important for angiogenesis. Using an uPA-
peptide that blocks the interaction of uPA with its cellular receptor, uPAR, McGuire et al.45 
have shown inhibitory effects in a mouse model of ischemia-induced retinal 
neovascularization. Others have shown that the uPAR-binding domain of uPA is a potent 
inhibitor of bFGF-induced neovascularization in a subcutaneously implanted matrigel plug 
and B16 melanoma growth in mice46. In addition, prostaglandin E1-induced corneal 
angiogenesis in rabbits was decreased upon intraperitoneal treatment with amiloride, an 
inhibitor of uPA activity47. Based on these antiangiogenic effects of compounds that block 
uPA function, one would expect that corneal angiogenesis is largely diminished in mice 
lacking uPA. Choroidal neovascularization is blocked in uPA-deficient mice48. Recently, Oh 
et al.49 showed a slight reduction of corneal vessel formation in uPA-deficient mice. 
However, we show here and others have done previously50, that corneal angiogenesis is 
normal in uPA-deficient mice. These results therefore indicate that the antiangiogenic effects 
of uPA inhibitors in vivo may be largely due to other activities than direct uPA inhibition.  
tPA is stored in endothelial cells of the microvasculature51 and secreted upon activation by 
angiogenic factors7. tPA has been implicated in capillary formation in vitro in collagen52 but 
not in fibrin53. In addition, capillary sprouting in collagen and matrigel of vascular explant 
cultures obtained from tPA- and plasminogen-deficient mice was almost completely 
abrogated54. Furthermore, tPA is required for efficient vascularization of pancreatic tumors55 
and is essential in choroidal neovascularization48. In contrast, tPA-deficiency did not affect 
angiogenesis in collagen induced by malignant keratinocytes in mice56. It has been 
suggested that tPA has a role in protecting newly formed blood vessels that would be prone 
to extracellular matrix-induced coagulation4. However, we did not observe an effect on 
corneal angiogenesis in tPA-deficient mice.  
Possibly, like has been shown previously to occur during vascularization induced by 
malignant keratinocytes56, a compensatory mechanism that upregulates tPA in uPA-deficient 
mice and uPA in tPA-deficient mice may exist. Moreover, plasminogen activation is not 
necessarily dependent on the presence of tPA or uPA but might be compensated by other 
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enzymes such as coagulation factor XIIa39 or kallikrein40. Therefore we directly investigated 
plasminogen function in corneal angiogenesis using plasminogen-deficient mice. Our results 
suggest a role, albeit minor, of plasmin-mediated matrix degradation during vessel formation 
in the cornea. Our data confirm results from a recent study by Oh et al.49 showing that 
plasminogen-deficiency significantly reduced corneal neovascularization. Remarkably, 
although it is widely accepted that plasminogen is an important mediator of angiogenesis, 
this process can occur in the absence of plasminogen.  
In previous studies, we have shown that corneal neovascularization was almost completely 
inhibited by continuous treatment with angiostatin, a fragment of plasminogen37. Stack et al. 
57 have shown that angiostatin inhibited invasion of endothelial and melanoma cells in vitro 
by blocking tPA-mediated matrix-enhanced plasminogen activation. Our results suggest that 
the antiangiogenic effect of angiostatin in vivo may not only be mediated through inhibition of 
plasminogen function.  
Plasminogen activation is negatively controlled by both PAI-1 and TAFI. It has previously 
been shown that PAI-1 has an important function in the growth of human melanoma58 and 
mouse fibrosarcoma59. These reports further showed that the lack of PAI-1 directly affected 
angiogenesis in the cornea59 and a matrigel implant58. In a model of vessel wall remodeling 
after oxidative arterial injury, neovascularization was defective in the absence of PAI-160. 
Others have shown that PAI-1 is essential for subretinal choroidal angiogenesis induced by 
laser photocoagulation61 and tumor cell induced angiogenesis in collagen in mice56. Based 
on experiments in mice deficient of both PAI-1 and vitronectin these authors concluded that 
PAI-1 is mainly involved in the prevention of excessive proteolysis. Interestingly, increased 
plasmin activity has been associated with detachment of endothelial62 and smooth muscle 
cells63, inhibition of keratinocyte adhesion64, endothelial cell destruction65 or regression of 
capillary tubes66 in vitro. 
We hypothesized that similar to the effects in mice lacking PAI-1, TAFI-deficiency would also 
lead to increased proteolysis and aberrant angiogenesis. However, in contrast to PAI-1, the 
absence of TAFI did not affect vessel formation in the cornea. We propose two possible 
explanations for the lack of effects in the absence of TAFI. First, TAFI is activated but 
proteins that neutralize increased plasminogen activation in TAFI-deficient mice, including 
PAI-1, α2-antiplasmin or other carboxypeptidases, compensate for the absence of TAFI. 
Second, TAFI is not activated and does not regulate plasminogen activation in corneal 
angiogenesis. Alternatively, increased plasminogen activation in the absence of TAFI does 
not influence corneal angiogenesis. At present, no tools are available to measure activated 
TAFI in blood or tissues. Our observation that TAFI-deficiency does not affect corneal 
angiogenesis support a role for PAI-1 different from regulation of plasminogen activation. 
Besides its anti-proteolytic activity, PAI-1 is also involved in vitronectin-mediated cellular 
adhesion67. 
Taken together, we show that corneal angiogenesis is independent of uPA- or tPA-mediated 
plasminogen activation. Although plasmin was not essential for vessel formation, 
plasminogen-deficiency had significant effects. Corneal neovascularization was largely 
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dependent on PAI-1 but unaffected in the absence of another regulator of plasminogen 
activation, TAFI. 
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Summary 
Many studies have indicated that the plasminogen activation system may have a prominent 
role in cancer. Activation of the zymogen plasminogen into the serine protease plasmin by 
plasminogen activator is mediated by carboxy-terminal basic amino acids in fibrin, including 
lysines and arginines. Activated thrombin-activatable fibrinolysis inhibitor (TAFI) is a 
circulating carboxypeptidase B-type enzyme that removes carboxy-terminal lysine or 
arginine residues in fibrin, resulting in decreased plasminogen activation and attenuated 
fibrinolysis. To directly determine whether TAFI is involved in primary tumor growth and 
metastasis formation we examined the effects of TAFI-deficiency on subcutaneous growth 
and experimentally or spontaneously induced pulmonary metastasis formation of different 
tumor cell types in mice. In all tumor models TAFI-deficiency did not affect the formation and 
growth of primary and metastasized tumors. 
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Introduction 
Apart from its role in fibrinolysis the plasminogen activation system is implicated in tumor 
development and metastasis of experimental tumors and human cancers1-3. Increased 
levels of plasminogen activator, plasmin-α2-antiplasmin, plasminogen activator inhibitor 
(PAI-1) and fibrin degradation products have been observed in plasma of cancer patients 
and these components are of prognostic value in human cancer1;4-8. The plasminogen 
activation system controls cell migration and invasion by plasmin-mediated matrix 
proteolysis. A major plasmin substrate, fibrin, is found in the provisional matrix of tumors9;10. 
Moreover, fibrin is important for metastasis of circulating tumor cells11-13. Plasmin activity is 
not restricted to the dissolution of extracellular matrix.  In addition to this, plasmin regulates 
tumor growth and metastasis by the activation of matrix metalloproteases (MMP) and growth 
factors such as transforming growth factor β14 and hepatocyte growth factor15, mobilises 
vascular endothelial growth factor (VEGF)16 and basic fibroblast growth factor (bFGF)17 and 
could play a role in the formation of plasminogen breakdown products with antiangiogenic 
properties, including angiostatin and kringle 518. Taken together, substantial evidence points 
to an important role of the plasminogen activation system in tumor progression. 
Plasmin, that is formed through activation of the zymogen plasminogen by plasminogen 
activators, tissue-type plasminogen activator (tPA) and urokinase-type plasminogen 
activator (uPA), is a serine protease that cleaves its substrates behind a basic amino acid 
(lysine or arginine). The generally free carboxy-terminal lysines or arginines provide high 
affinity binding sites for plasminogen and facilitate efficient activation by plasminogen 
activators19-24. This subsequently leads to the formation of novel plasminogen binding sites 
resulting in an amplification loop for plasminogen activation25. In addition, the carboxy-
terminal lysine on the A-chain of urokinase promotes the activation of plasminogen26. 
Hence, lysine analogues such as ε-aminocaproic acid (εACA) and tranexamic acid 
(cyclokapron) efficiently prevent plasmin formation27-29. Besides cleaved fibrin or other 
plasmin-cleaved extracellular matrix components, a variety of cell types also have carboxy-
terminal lysine-dependent binding sites for plasminogen, like annexin II30 and alpha-
enolase31, that regulate plasminogen activation. The possible importance of carboxy-
terminal lysine residues in cancer can be inferred from studies with εACA or cyclokapron 
(reviewed in32). These lysine analogues inhibit angiogenesis, tumor cell metastasis and 
primary tumor growth. Moreover, beneficial effects of these compounds have been reported 
in cancer patients33;34. 
Activated thrombin-activatable fibrinolysis inhibitor (TAFI, also called carboxypeptidase U, R 
or plasma procarboxypeptidase B, EC 3.4.17.20) is a carboxypeptidase B-type enzyme that 
regulates plasminogen activation by cleaving carboxy-terminal arginyl and lysyl residues 
from partially degraded fibrin, thereby attenuating plasminogen activation35;36. In vitro, TAFI 
can be activated by trypsin37, plasmin38 and thrombin35. Activation of TAFI by plasmin can 
be improved by heparin39. Activation of TAFI by thrombin is increased 1250-fold in the 
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presence of thrombomodulin40;41. Thrombomodulin is expressed on endothelial cells and in 
tumors42-46 and is a prognostic factor in human cancer47;48. 
Recently, we have shown that TAFI regulates cutaneous wound healing49, a process that is 
dependent on activation of the plasminogen system50.  In mice lacking TAFI, skin wound 
closure was inappropriately organized and slightly delayed and epithelial migration and 
invasion were altered. Given the importance of the plasminogen activation system in tumor 
growth and metastasis, we hypothesized that TAFI also plays a regulatory role in cancer 
growth and could be a potential new target for anti-cancer drugs. In the present work, we 
have investigated the role of TAFI in subcutaneous tumor growth and experimental- and 
spontaneous metastasis formation using TAFI-deficient mice. 
 
Materials and methods 
Mice  
TAFI-/- (generated as described in49) and TAFI+/+ littermate mice, 6-8 weeks of age, were 
maintained under standard conditions, kept on a 12-h light/dark cycle and received food and 
water ad libitum. Mice used for experiments with B16-BL6 melanoma cells were inbred into 
the C57BL/6 background (Harlan, Leicestershire, England) for four generations. Mice used 
in all other experiments were inbred into C57BL/6 for six generations. Genotypes of the mice 
were determined by polymerase chain reaction analysis of DNA obtained from ear biopsies 
and verified by ELISA using anti-mouse TAFI antibodies. Experiments were performed 
according to the guidelines of the Utrecht Animal Experimental Committee, University 
Medical Center Utrecht. 
Tumor ce l l  l ines 
The B16-BL6 melanoma cell line was kindly provided by Dr. K.L. Sim (Entremed Inc., 
Rockville, Maryland). The T241 fibrosarcoma and Lewis lung carcinoma (LLC) cell lines 
were a generous gift of Dr. T. Udagawa (Children's Hospital, Harvard Medical School, 
Boston, Massachusetts). B16-BL6 and LLC cells were cultured in vitro by subconfluent 
passage in Dulbecco’s modified Eagle medium (DMEM, Gibco BRL, Invitrogen Corporation, 
UK) containing 10% fetal calf serum (FCS), L-glutamine and antibiotics in a humidified 10% 
CO2 environment. The T241 fibrosarcoma cells were maintained in McCoy’s 5A modified 
medium (Gibco BRL, Invitrogen Corporation, UK) supplemented with 10% FCS, antibiotics, 
L-glutamine, MEM non-essential amino acids, MEM amino acids and MEM vitamins in a 
humidified 10% CO2 environment. These tumor cell lines were derived from C57BL/6 mice 
and thus should be H2 histocompatible with all mice used in this study (TAFI-deficient mice 
were derived from C57BL/6 and 129 mice both of which are homozygous for the b allele at 
the H2 locus). 
Growth of  subcutaneous tumors 
Confluent B16-BL6 melanoma cells were washed with phosphate-buffered saline (PBS) and 
incubated with 0.25% trypsin, 0.53 mM EDTA solution (Gibco BRL, Invitrogen Corporation, 
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UK) for 1 minute at 37oC. Trypsin was inactivated by the addition of 5 ml DMEM containing 
10% FCS. The volume was brought to 50 ml with PBS. After centrifugation the cells were 
washed two times with 50 ml PBS. 100 µl of resuspended cells (1.0 x 107/ml PBS) were 
injected subcutaneously between the shoulder blades ~3 cm from the tail. T241 
fibrosarcoma and Lewis lung carcinoma were propagated in C57BL/6 mice. Mice with 600-
1200 mm3 tumors were sacrificed and cleaned with betadine and ethanol. Tumor tissue was 
excised and a suspension of tumor cells in 0.9% saline was made by passage of viable 
tumor tissue through a sieve and a series of sequentially smaller needles of a diameter of 
22-30 gauge. The final concentration of trypan blue negative tumor cells was adjusted to 1 x 
107 cells/ml and 100 µl was injected subcutaneously. Palpable tumors were measured using 
a calliper and tumor volume was calculated using the formula: width2 x length x 0.52. 
 
Exper imenta l  pu lmonary metastas is  format ion 
Confluent B16-BL6 melanoma cells were washed with phosphate-buffered saline (PBS) and 
incubated with 0.25% trypsin, 0.53 mM EDTA solution (Gibco BRL, Invitrogen Corporation, 
UK) for 1 minute at 37oC. Trypsin was inactivated by the addition of 5 ml DMEM containing 
10% FCS. The volume was brought to 50 ml with PBS. After centrifugation the cells were 
washed two times with 50 ml PBS. The cells were resuspended in 5 ml PBS and cell viability 
was determined using trypan blue. Using a 27-gauge needle, 5 x 104 melanoma cells in 200 
µl PBS were injected into the lateral tail vein. Fourteen days after inoculation of tumor cells 
all mice were euthanized by CO2 inhalation. Lungs were isolated and placed in 4% neutral 
buffered formalin. The lungs were separated into individual lobes and the number of surface 
metastatic foci was counted under a dissecting microscope. 
 
Spontaneous pulmonary metastas is  format ion 
Eleven days after subcutaneous LLC transplantation, the mice were anaesthetized using a 
mixture of Hypnorm® (0.3 mg/mouse intraperitoneal; Janssen-Cilag, Brussels, Belgium) and 
Dormicum® (12.5 mg/mouse intraperitoneal; Roche , Brussels, Belgium). The skin overlying 
the tumor was cleaned with betadine and ethanol. Primary tumors were surgically removed 
and the incision was closed using vicryl 5/0. Fourteen days later, the lungs and lymph nodes 
were isolated. Surface metastases were highlighted by incubation in Bouin’s fixative for 24 
h. The lungs were separated into individual lobes and the number of surface metastatic foci 
was counted under a dissecting microscope. 
 
Histo log ic  analys is  
Subcutaneously located tumors and lungs were embedded in paraffin after fixation in 4% 
neutral buffered formalin. 3µ sections were stained with hematoxylin and eosin according to 
established methods and evaluated for the presence of histological differences between 
either subcutaneous and pulmonary tumor deposits and/or between TAFI-deficient and 
wildtype mice. 
 
40 Chapter 3 
 
Figure 1.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Effect of TAFI-deficiency on primary tumor growth. 1 x 106 B16-BL6 melanoma (A), T241 
fibrosarcoma (B) or Lewis lung carcinoma (C) cells were injected into the subcutaneous dorsa of 
mice and tumor volume was determined by calipation. No significant differences in tumor growth 
were observed between TAFI-deficient and wildtype mice. □ , TAFI-/-; ■ , wildtype. (D) 
Representative example of subcutaneous LLC of a TAFI-deficient mouse (left panel) and a wildtype 
mouse (right panel) 11 days after transplantation. Upper panel: skin side facing up, Lower panel: 
basal side facing up. 
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Results 
Effect  of  TAFI-def ic iency on subcutaneous tumor  growth 
To determine the role of TAFI in primary tumor growth B16-BL6 melanoma, T241 
fibrosarcoma or Lewis lung carcinoma (LLC) cells were injected subcutaneously into the 
dorsal skin of TAFI-deficient and wildtype mice. All mice had palpable tumors by day 5. 
Tumor burdens derived from all three cell lines did not differ significantly in TAFI-deficient 
from those in wildtype mice (Figure 1a-c). All three tumor types grew in parallel regardless of 
TAFI-genotype. At day 19, B16-BL6 tumors in TAFI-deficient mice were 1406 ± 451 mm3 
(mean ± SEM, n=5) compared to 1339 ± 262 mm3 in wildtype mice (n=4; p = 0.73, Mann-
Whitney U test) (Figure 1a). The tumor volumes of T241 fibrosarcoma and LLC were 1280 ± 
159 mm3 (n=5, TAFI-/-) compared to 1513 ± 249 mm3 at day 12 (n=9, TAFI+/+; p = 0.36, 
Mann-Whitney U test) (Figure 1B) and 1181 ± 225 mm3 (n=10, TAFI-/-) compared to 1375 ± 
417 mm3 at day 11 respectively (n=7, TAFI+/+; p = 0.74, Mann-Whitney U test) (Figure 1c). In 
contrast to tumors derived from B16-BL6 melanoma and T241 fibrosarcoma cells, the 
growth of LLC primary tumors was associated with overlying skin redness caused by 
progressive ulceration. This was independent of TAFI-genotype (Figure 1d). Thus, TAFI-
deficiency did not significantly affect the onset and kinetics of primary tumor growth. 
 
Establ ishment  of  exper imenta l  lung metastases in  TAFI-def ic ient  mice 
Experimental metastasis formation of tumor cells is dependent on the formation and 
subsequent removal of thrombi consisting of tumor cells, platelets and fibrin12. To determine 
whether these processes are influenced by TAFI we injected 5 x 104 B16-BL6 melanoma 
cells into the tail vein of TAFI-deficient and wildtype mice and counted the number of surface 
pulmonary nodules at day 14 following injection. B16-BL6 melanoma cells were able to 
metastasize and establish visible pulmonary tumor foci in both TAFI-deficient and wildtype 
mice (Figure 2a,b). No significant difference between the number (TAFI-/-: 92 ± 25, n = 11; 
TAFI+/+: 89 ± 20, n = 6; p = 0.88, mean ± SEM, Mann-Whitney U test) (Figure 2c) and size 
distribution (n = 449 foci in TAFI-/-, n = 413 foci in TAFI+/+; p = 0.57, Kolmogorov-Smirnov 
test) of metastases in TAFI-deficient and wildtype mice was observed  (Figure 2d). 
 
Estab l ishment  of  spontaneous metastases in TAFI-def ic ient  mice 
To determine the role of TAFI in spontaneous metastasis formation we transplanted Lewis 
lung carcinoma tumors subcutaneously and analyzed metastasis formation in lungs and 
regional lymph nodes of TAFI-deficient and wildtype mice 14 days after primary tumor 
resection. We did not observe regrowth of the primary tumor. The formation of lymph node 
metastases was clearly visible 14 days after primary tumor resection. Visual inspection 
revealed that lymphatic spread of tumor cells was macroscopically present in 7 of 9 (78%) 
TAFI-deficient mice compared to 5 of 5 (100%) wildtype mice (p = 0.5, χ2 analysis). Lung 
metastases were present in TAFI-deficient and wildtype mice (Figure 3a), suggesting that 
TAFI is not essential for lymphatic or hematogenous metastasis. Quantification of the 
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number (TAFI-/-: 17 ± 6, n = 9; TAFI+/+: 20 ± 8, n = 5; p = 0.80, mean ± SEM, Mann-Whitney 
U test) (Figure 3c) and size distribution (n = 52 foci in TAFI-/-, 122 foci in TAFI+/+; p = 0.24, 
Kolmogorov-Smirnov test) of  metastatic foci in lungs of TAFI-deficient and wildtype mice 
revealed no significant difference (Figure 3d). These results indicate that TAFI does not 
contribute to the efficiency of this tumor to colonize lung tissue. 
 
Figure 2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Effect of TAFI-deficiency on experimental pulmonary 
metastasis formation. 5 x 104 B16-BL6 melanoma cells 
were injected intravenously in TAFI-deficient and 
wildtype mice by tail vein injection. Lungs were isolated 
after 14 days, fixed and pulmonary metastasis 
formation was quantified by counting the number of 
tumor foci. (A,B) Representative examples of lungs with 
metastatic foci of B16-BL6 melanoma in wildtype (A) 
and TAFI-deficient mice (B) 14 days after intravenous 
injection. (C) The number of pulmonary nodules in 
TAFI-deficient and wildtype mice was not significantly 
different. (D) TAFI-deficiency does not affect the size 
distribution of pulmonary metastases of B16-BL6. 
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Figure 3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Effect of TAFI-deficiency on spontaneous pulmonary metastasis formation. TAFI-deficient and 
wildtype mice underwent primary tumor resection 11 days after subcutaneous transplantation of 
LLC. After 14 days the lungs were removed and fixed in Bouin’s fixative. (A,B) Representative 
examples of metastatic pulmonary foci 14 days after tumor resection, indicating the presence of 
both small and large tumor nodules in wildtype (A) and TAFI-deficient (B) mice. (C) Quantification of 
the number of pulmonary metastatic foci revealed no significant difference between TAFI-deficient 
and wildtype mice. (D) Size distribution of individual metastatic foci is not altered by TAFI. 
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Figure 4. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Histological analysis of primary tumors in TAFI-deficient (A,C,E,G) and wildtype (B,D,F,H) mice. 
Primary tumors of LLC were isolated 11 days after transplantation, paraffin embedded, sectioned 
and stained with hematoxylin/eosin. (A,B) Tumors in TAFI-deficient and wildtype mice both consist 
of closely packed anaplastic cells of different sizes with ample cytoplasm and show numerous 
normal as well as abnormal mitoses (arrows). (C,D) Tumors in both genotypes exhibited diffuse 
invasion into and destruction of adjacent muscle tissue. Arrows indicate normal muscle, arrowheads 
indicate tumor cell invasion surrounding individual myocytes. (E-F) Tumor invasion of the dermis. 
Arrows indicate normal epidermis, arrowheads indicate infiltrating tumor cells in dermis. (G,H) 
Tumor invasion of the epidermis eventually leads to loss of keratinocytes and severe skin ulceration 
in both genotypes. Arrows indicate intact epidermis at the border of the ulceration, arrowheads 
indicate crust formation, asterisks indicate the tumor. 
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Tumor development in TAFI-deficient mice    45 
 
Histo log ica l  analys is  of  pr imary tumors and lung metastases of  LLC 
Primary tumors and spontaneous lung metastases from TAFI-deficient and wildtype mice 
were analyzed in more detail. No histological differences between tumors arisen in the 
presence or absence of TAFI were observed. The primary tumors showed all the histological 
characteristics of rapid growth. They existed of highly mitotic anaplastic cells having 
pleomorphic nuclei with conspicuous nucleoli and ample cytoplasm. Numerous normal as 
well as abnormal mitoses were observed independent of TAFI-genotype (Figure 4a,b). In 
larger nodules the central parts were necrotic. In addition, no differences were detected in 
the ability of tumor cells to invade skin tissue in the presence or absence of TAFI. All tumors 
diffusely invaded subcutaneous muscle tissue (Figure 4c,d), the dermal (Figure 4e,f) and 
epidermal layers of the skin, resulting in skin destruction and subsequent skin ulceration 
(Figure 4g,h). Detailed analyses of the lungs revealed the presence of both parenchymal 
and pleural metastases with cellular characteristics similar to the primary tumor (Fig 5a,b). 
Again, differently sized anaplastic cells with large vesicular nuclei containing multiple 
nucleoli and normal as well as abnormal mitotic figures could be identified in TAFI-deficient 
and wildtype mice (Fig 5c,d). However, the number of mitotic figures in these pulmonary 
nodules was less and the cells have an increased amount of cytoplasm when compared with 
the primary tumor. In addition, many tumor nodules had large necrotic areas associated with 
local hemorrhage (Fig 5a,b). Taken together, microscopic analyses of LLC tumors and lung 
metastases demonstrated that the absence of TAFI did not influence tumor architecture and 
invasive capacity. 
Figure 5.  
 
Histological analysis of 
lung metastases in TAFI-
deficient (A,C) and wild-
type (B,D) mice. Lungs 
were isolated 14 days 
after primary tumor 
resection, paraffin em-
bedded, sectioned and 
stained with hemato-
xylin/eosin. 
(A-D) Detailed analyses 
of the lungs revealed the 
presence of both paren-
chymal and pleural meta-
stases composed of pleo-
morphic anaplastic cells 
having vesicular nuclei 
with multiple nucleoli and 
showing normal and abnormal mitotic figures (arrows) in TAFI-deficient and wildtype mice. Many 
tumor nodules had large necrotic areas associated with local hemorrhage (arrowheads). 
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Discussion 
The findings presented here show that primary tumor growth and metastasis can 
successfully occur in the absence of TAFI. Moreover, our results indicate that primary and 
metastatic tumor growth is not affected by the absence of TAFI.  
It is well established that components of the hemostatic system, including fibrin and 
plasminogen play a role in tumor development. Why doesn’t TAFI-deficiency affect  tumor 
growth? We tested our hypothesis that TAFI controls tumor development using B16-BL6 
melanoma, T241 fibrosarcoma and Lewis lung carcinoma (LLC) cells because it has been 
established that the growth of these tumors is sensitive to coagulation and fibrinolytic protein 
deficiencies51-54. Subcutaneous growth of T241 fibrosarcoma is strongly reduced in mice 
lacking plasminogen52. In this study it was shown that plasminogen-deficient mice fail to 
suppress the accumulation of tumor-infiltrating macrophages, which is normally regulated by 
tumor cell-mediated plasminogen activation. However, the same study revealed that a 
combined deficiency of the plasminogen activators, uPA and tPA, or the absence of uPA 
alone just slightly decreased tumor growth in this model. Tumor growth was normal in mice 
lacking tPA or PAI-1. In contrast, using the same model, Gutierrez et. al.51 have shown that 
primary tumor growth is critically dependent on uPA and PAI-1. In addition, they found that 
spontaneous metastasis of T241 fibrosarcoma cells to the lung and brain is almost 
completely abolished in the absence of uPA and PAI-1. Others have shown that 
hematogenous metastasis formation but not primary growth of LLC is reduced in PAI-1 
overexpressing mice55. These effects were associated with increased expression of PAI-1 in 
the primary tumor and lungs, suggesting that proteolytic inhibition might explain the inhibition 
of metastasis. In another study, experimental pulmonary metastasis formation and primary 
growth of B16-BL6 melanoma cells in the hind limb of mice lacking PAI-1 was not affected56. 
Further studies in plasminogen-deficient mice by Degen’s group revealed that plasminogen 
also contributes to the subcutaneous growth of LLC54. Plasminogen-deficiency reduced the 
growth of LLC and dissemination to regional lymph nodes and prolonged the survival after 
primary tumor resection. In addition, primary tumors were less ulcerating and less 
hemorrhagic in plasminogen-deficient mice compared to wildtype mice. Plasminogen-
deficiency did not affect spontaneous pulmonary metastasis of LLC. Similar to T241 
fibrosarcoma, LLC infiltration into adjacent skin tissues was unaffected in plasminogen-
deficient mice. Moreover, the effects on subcutaneous tumor growth were small and have 
been contradicted in a recent publication from the same group where they reported that 
plasminogen does not determine the subcutaneous growth of LLC and T241 fibrosarcoma57. 
Thus, plasminogen-deficient mice are able to generate sufficient proteolytic activity for 
efficient tumor development and metastasis. However, in another anatomical location, the 
footpad, plasminogen-deficiency severely suppressed LLC and T241 fibrosarcoma tumor 
growth. Interestingly, tumor vessels in mice lacking plasminogen were occluded by 
microvascular thrombi that were absent in mice also deficient for fibrinogen. In addition, 
tumor growth was restored in mice lacking both plasminogen and fibrinogen57. Recent 
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experiments in fibrinogen-deficient mice and the use of a specific thrombin inhibitor have 
directly proven that fibrinogen and thrombus formation are essential for efficient metastatic 
seeding of circulating LLC and B16-BL6 tumor cells, either after intravenous injection or 
originating from a primary tumor11;53.  
We hypothesized that TAFI-deficiency would influence tumor development, for example 
through increased plasmin formation. Unbalanced plasmin formation inhibits tumor 
growth58;59 and fibrinolytic therapy has been shown to potentially inhibit pulmonary seeding 
of intravenously injected mammary carcinoma cells in rats60;61. Conceivably, the absence of 
TAFI might increase fibrin degradation and premature thrombus removal, causing 
decreased experimental and spontaneous metastasis formation. Disturbance of tightly 
controlled plasminogen activation might cause decreased primary tumor growth and tumor 
cell migration resulting in the formation of less experimental and spontaneous 
metastasis32;62. On the other hand, increased plasminogen activation in the absence of TAFI 
could cause increased matrix degradation in the primary tumor resulting in increased tumor 
growth, efficient entrance of tumor cells into the circulation and elevated spontaneous 
metastasis formation. However, none of these possible effects were seen. 
We suggest several potential explanations for the lack of differences in tumor growth and 
metastasis in TAFI-deficient mice. First, TAFI activation does not result in a significant 
change in plasmin formation that can influence the growth and metastasis formation in these 
cancer and metastasis models. For example, enhanced plasmin formation due to the 
absence of TAFI may not result in a significant increase in plasmin activity due to the 
presence of α2-antiplasmin that inhibits the additional plasmin. Alternatively, other proteins, 
including PAI-1 or other carboxypeptidases or mechanisms exist that may neutralize the 
effect of TAFI-deficiency on plasmin activation or activity.  An alternative explanation for the 
lack of effect on tumor growth is that excess plasmin in TAFI-deficient mice has no effect at 
all in the models used. Similar observations were reported by others who studied TAFI in a 
pulmonary fibrinolysis model and in leukocyte migration63, processes that are also activated 
in cancer. The inhibitory effects that accompanied TAFI-deficiency in these models were 
elucidated in and restricted to plasminogen-compromised mice. In other words, the 
plasminogen system may already be maximally involved in these processes. Similarly and 
as a consequence, tumor growth might have become insensitive to additional plasminogen 
activation. A second explanation for the lack of effect of TAFI-deficiency is that TAFI is not 
activated at all and does not regulate plasminogen activation in cancer and metastasis. 
Unfortunately, at present no tools are available to determine the presence of activated TAFI 
in mouse or human cancer tissues. We made an attempt to investigate the presence of 
activated TAFI in tumor-bearing mice by intravenous injection of a synthetic substrate for 
activated TAFI. Analysis of the amount of cleaved substrate in plasma isolated 10 minutes 
later, did not reveal a significant difference between TAFI-deficient and wildtype mice. Thus 
as of yet, we cannot draw a conclusion on the activation state of TAFI. 
In conclusion, our findings show that TAFI is not needed for primary experimental tumor 
growth and metastasis formation. 
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Summary 
Prostate cancer has historically been associated with hemostatic abnormalities. High plasma 
levels of markers of fibrinolysis indicate that the plasminogen activation system is activated 
in patients with prostate cancer. Thrombin-activatable fibrinolysis inhibitor (TAFI) is a B-type 
carboxypeptidase present in blood that can inhibit plasminogen activation. We hypothesized 
that TAFI may regulate activation of the fibrinolytic system in prostate cancer patients. This 
study was undertaken to investigate whether TAFI antigen and activity levels are influenced 
in patients with prostate cancer. We found that circulating plasma antigen and activity levels 
of TAFI are normal in prostate cancer patients and independent of the presence of 
metastases. Furthermore, TAFI levels were not associated with progression of the disease 
or with the presence of thrombosis. Our results suggest that TAFI does not play a major role 
during prostate cancer. 
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Introduction 
It is well recognized that cancer patients have a high incidence of hemostatic complications 
such as disseminated intravascular coagulation1, venous thromboembolism2 and 
hemorrhage3. It has been reported that advanced prostate cancer is responsible for up to 
25% of incidences of disseminated intravascular coagulation, presenting as a bleeding 
tendency with or without venous thrombosis4. There is also substantial evidence that the 
hemostatic system is involved in cancer progression and the formation of metastases. For 
example, proteins involved in maintaining hemostasis also regulate angiogenesis to support 
tumor growth. Clinical studies investigating the role of the hemostatic system in prostate 
cancer have indicated the presence of abnormal levels of proteins of the coagulation and 
fibrinolytic systems such as antithrombin III5;6, prothrombin fragment 1 and 27, thrombin-
antithrombin III (TAT) complexes7;8, plasmin-α2-antiplasmin (PAP) complexes8, plasminogen 
activator inhibitor (PAI-1)6 and fibrin degradation products7-9. These abnormalities often 
reflect tumor malignancy and correlate with disease prognosis. The prevalence of these 
circulating markers is rather low in patients with primary cancer but high in patients with 
advanced prostate cancer7;8;10. Adamson and colleagues have shown that the levels of fibrin 
degradation products correlate with bone scan positivity in prostate cancer patients9. Thus, 
activation of the fibrinolytic system is seen in patients with prostate cancer. 
Proteolytic enzymes involved in fibrinolysis are the serine proteases of the plasminogen 
activation system, tissue-type plasminogen activator (tPA), urokinase-type plasminogen 
activator (uPA) and plasmin11. Both tPA and uPA generate plasmin by proteolytical cleavage 
of its zymogen plasminogen. Plasmin cleaves its substrates behind a lysine or arginine, 
which then become carboxy-terminal. Such carboxy-terminal basic amino acid residues in 
fibrin provide high affinity binding sites for plasminogen and facilitate efficient plasminogen 
activation by tPA and uPA12-15.  
Thrombin-activatable fibrinolysis inhibitor (TAFI), also known as carboxypeptidase U, R or 
plasma procarboxypeptidase B (EC 3.4.17.20) links the coagulation and fibrinolytic systems 
and regulates fibrinolysis in vitro16 and in vivo17-20. When converted into its active form by 
thrombin16, plasmin21 or trypsin22, TAFI is a carboxypeptidase B-type enzyme that 
specifically cleaves carboxy-terminal lysine or arginine residues from proteins. TAFI-
mediated removal of these carboxy-terminal amino acids from fibrin attenuates efficient 
plasminogen activation into plasmin23. Thrombin-mediated activation of TAFI is stimulated 
1250-fold by the endothelial cell receptor thrombomodulin24. Circulating TAFI antigen levels 
broadly vary between different healthy individuals and correlate with TAFI activity and clot 
lysis time25;26. Recently, several studies have been reported that indicate an association 
between elevated TAFI levels and thrombosis27-31. Reduced TAFI activity, but not TAFI 
antigen, in patients with acute promyelocytic leukemia was possibly due to proteolytic 
inactivation by excess fibrinolytic activity32.  
In the past, ε-aminocaproic acid (εACA), a lysine analogue that inhibits plasminogen 
activation, has been successfully used for the treatment of hemostatic complications in 
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prostate cancer patients33. This indicates that the plasminogen activation system and 
particularly carboxy-terminal lysines play an important role in these complications. We 
hypothesize that TAFI may influence cancer growth and/or hemostatic complications in 
patients with prostate cancer. Here we measured the plasma TAFI antigen and TAFI activity 
levels in patients with primary and metastasized prostate cancer. 
 
Materials and methods 
Pat ients  and cont ro ls  
We collected samples from 119 patients with prostate cancer. For controls, plasma samples 
were collected from 22 males with no evidence of cancer. Blood was collected by 
venepuncture in 3.2% (w/v) sodium citrate (1:10) (Venoject, Terumo Europe N.V. Leuven, 
Belgium). The samples were centrifuged for 15 minutes (2000g) and the supernatant was 
stored at –80oC until use. In all samples from cancer patients routine prostate specific 
antigen (PSA) was determined. 
 
Measurement  of  TAFI  ant igen and act iv i ty  
TAFI antigen was determined with an enzyme-linked immunosorbent assay (ELISA) as has 
been described34. TAFI activity in plasma was measured as follows. Plasma was diluted 5 
times in 50 mM Hepes, pH 7.4. Activation of TAFI was performed at room temperature by 
the addition of 5 µl of plasma to 50 µl activation buffer containing 50 mM Hepes, pH 7.4, 40 
nM rabbit lung thrombomodulin (American Diagnostica, Greenwich, CT), 10 nM thrombin 
(Enzyme Research Laboratories, South Bend, IN), 20 mM CaCl2 and 8 mM hippuryl-Arg 
(Bachem, Bubendorf, Switzerland), a substrate for activated TAFI. After 30 minutes, the 
reaction was stopped by 50 µl 1M HCl. After the addition of internal standard (20 µl of 22.5 
µM O-methylhippuric acid) cleaved substrate was extracted with 300 µl ethylacetate, air-
dried, dissolved in 150 µl 50 mM K3PO4, 20% acetonitril, pH 3.5 and analyzed using high 
performance liquid chromatography (HPLC; XTerra MS C18 3.5 µm, 4.6 x 100 mm column, 
Waters Chromatography BV, Ettenleur, The Netherlands). To distinguish between 
constitutive active carboxypeptidase (carboxypeptidase N) and active TAFI in plasma, 
carboxypeptidase activity sensitive to a potato carboxypeptidase inhibitor (CPI) was 
considered to be TAFI activity. 
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Results and discussion 
Pat ients  
Hundred and nineteen prostate cancer patients and twenty-two age-matched controls 
without evidence of cancer were investigated. Hundred and four of the patients had 
metastases to distant organs and fifteen patients had cancer limited to the prostate. The 
mean age in the group of non-metastatic prostate cancer patients was 64 yr (range, 44 - 74 
yr) and in the group of patients with metastases 67 yr, (range, 42 - 87 yr). The control 
population included patients with a mean age of 60 yr (range, 40 - 88 yr). The median serum 
PSA levels in the patients with prostate cancer were 154 ng/ml (range, 0 – 9513 ng/ml) in 
the group with metastases and 0.8 ng/ml (range, 0 – 30 ng/ml) in the non-metastatic patient 
group. 
 
TAFI leve ls  
TAFI antigen and activity levels in the control group were normalized and considered 100%. 
When expressed as a percentage of that in controls (100 ± 3%, n=22), the mean TAFI 
antigen level in primary prostate cancer patients was 101 ± 3% (mean ± SEM, n=15) and 
101 ± 1% (n=104) in metastasized prostate cancer patients (Figure 1a). Compared to 
controls (100 ± 3%, n=22), TAFI activity in plasma of primary prostate cancer patients was 
99 ± 3% (mean ± SEM, n=14) and 102 ± 2% (n=104) in patients with metastasized prostate 
cancer  (Figure 1b). These results indicate that TAFI levels did not change in prostate 
cancer patients. We hypothesized that TAFI may only be significantly affected in prostate 
cancer patients with high circulating levels of an indicator of prostate cancer activity, 
prostate specific antigen (PSA). However, TAFI antigen and activity did not correlate with 
PSA in patients with local tumor burden or metastases (not shown). In control subjects, TAFI 
antigen and activity will be highly correlated with each other. In other words: TAFI activity is 
fully determined by the amount of TAFI antigen. We investigated whether prostate cancer 
influences the relation between TAFI antigen and TAFI activity. We found that, although 
TAFI activity correlated with TAFI antigen in all groups, this correlation was strongly reduced 
in patients with metastases (Pearson correlation in control: 0.6; primary prostate cancer: 0.6; 
metastatic prostate cancer: 0.4) (Figure 2a-c). This observation could not be explained by 
disease progression (PSA levels). TAFI antigen or activity levels were not associated with 
the incidence of thrombosis. 
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Figure 1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
TAFI antigen and activity levels were measured in plasma of prostate cancer patients and controls. 
TAFI antigen and activity levels are expressed as percentage of control. TAFI antigen (A) and 
activity (B) levels are not different between patients with primary prostate cancer, metastasized 
prostate cancer and controls. 
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Plasma levels of TAFI antigen and TAFI activity 
are associated. (A-C) TAFI activity correlated with 
TAFI activity in all groups. However, when 
compared to controls and patients with primary 
prostate cancer, antigen/activity correlation was 
decreased in patients with metastases (control: 
0.6; primary prostate cancer: 0.6; metastatic 
prostate cancer: 0.4). 
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Discussion 
Abnormalities of the coagulation and fibrinolytic systems are frequently found in cancer 
patients. Here we show that circulating plasma levels and activity of a regulator of 
fibrinolysis, TAFI, are normal in prostate cancer patients with or without evidence of 
metastases.  
Our findings are somewhat unexpected. Based on the fact that the coagulation (thrombin) 
and/or fibrinolytic (plasmin) system are induced in prostate cancer patients, we expected 
that TAFI would be activated and consumed. Alternatively, TAFI levels could be negatively 
affected by inactivation of the enzyme through cleavage by increased plasmin present in 
prostate cancer patients. However, we did not observe abnormal TAFI antigen or activity 
levels in these patients. In the past, only one other similar study has been reported in 
patients with cancer. Although patients with acute promyelocytic leukemia (APL) had normal 
TAFI antigen levels, Meijers et al.32 have shown that a large amount of TAFI circulated in a 
form that could not be activated. The authors suggest that hyperfibrinolysis is responsible for 
the decreased activity of TAFI in these patients. When compared to prostate cancer, APL is 
associated with an even higher activation state of the fibrinolytic system. Apparently, the 
relatively low amount of activated plasminogen in prostate cancer patients, compared to 
patients with APL, does not affect TAFI. 
Taken together, the growth and metastasis of prostate cancer and the hemostatic 
complications that are often observed in prostate cancer patients are not associated with 
changes in TAFI. Moreover, prostate cancer does not seem to affect the activation of 
circulating TAFI. 
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Summary 
Endostatin is a fragment of collagen XVIII that acts as an inhibitor of tumor angiogenesis 
and tumor growth. Antitumor effects have been described using both soluble and insoluble 
recombinant endostatin. However, differences in endostatin structure are likely to cause 
differences in bioactivity. In the present study we have investigated the cellular effects of 
insoluble endostatin. We previously found that insoluble endostatin shows all the hallmarks 
of amyloid aggregates and potently stimulates tPA-mediated formation of the serine 
protease plasmin. We here show that amyloid endostatin induces plasminogen activation by 
endothelial cells, resulting in vitronectin degradation and plasmin-dependent endothelial cell 
detachment. Endostatin-mediated stimulation of plasminogen activation, vitronectin 
degradation and endothelial cell detachment is inhibited by carboxypeptidase B indicating an 
essential role for carboxy-terminal lysines. Our results suggest that amyloid endostatin may 
inhibit angiogenesis and tumor growth by stimulating the fibrinolytic system. 
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Introduction 
Angiogenesis, the formation of new capillaries from pre-existing blood vessels, is important 
during various pathological processes, including inflammation and tumor growth. 
Antiangiogenic therapy is being considered as a potentially powerful new therapy for cancer 
and other angiogenesis-dependent diseases. Endostatin is one of the most potent inhibitors 
of angiogenesis and can induce tumor regression in mice1. Clinical trials are currently 
ongoing2;3. Originally, endostatin was purified from conditioned medium of murine 
hemangioendothelioma (EOMA) cells as a proteolytically cleaved fragment of collagen XVIII. 
Generation of endostatin can be achieved by cleavage of collagen by cathepsin L4, 
matrilysin5 or elastase6.  
Endostatin has distinct antiangiogenic and Antitumor activities in several animal models7. 
Tumor growth was significantly inhibited by intraperitoneal or subcutaneous injection of 
endostatin without induction of acquired drug resistance1;8. In addition, rat endostatin 
induced significant inhibition of carcinogen induced mammary tumor growth9. Endostatin is 
also bioactive using delivery approaches such as DNA vaccination and viral expression10;11. 
However, contrary to this, no antiangiogenic effect of endostatin was seen in other studies 
despite high serum levels12-15. This paradox has lead to discussions about the efficacy of 
endostatin16. Until now, this paradox remains unsolved. Possibly, the outcome of endostatin 
treatment will depend on its structure (see below) and/or the presence of factors provided at 
the site of action. 
A variety of molecular mechanisms have been proposed to underlie endostatin activity. 
Endostatin blocks vascular endothelial growth factor mediated signalling through KDR/Flk-
117 and induces endothelial cell apoptosis, associated with decreased levels of anti-
apoptotic proteins Bcl-2 and BclXL18. Endostatin can bind tropomyosin, an actin stabilizing 
protein, and has been suggested to disrupt microfilament integrity ultimately causing 
endothelial cell apoptosis19. Direct effects of endostatin on cell adhesion may be caused by 
suppression of integrin function20;21. Other studies have implicated that endostatin acts on 
the proteolytic system by binding and inhibiting active metalloproteinase (MMP)-222;23 or 
down regulating the urokinase plasminogen activator system24. However, it is not clear to 
what extent these activities contribute to the antiangiogenic and antitumor effects of 
endostatin in vivo. 
A complicating factor is that endostatin is used in a soluble, as well in an insoluble form. 
Whereas both forms have been reported to inhibit tumor growth, the regression of tumors 
has only been reported with insoluble endostatin1. Different structural forms of endostatin 
have distinct bioactivities and may therefore produce their antiangiogenic effects through 
distinct mechanisms. The structure of soluble, globular endostatin has been elucidated25;26. 
Recently we found that endostatin is a protein with high propensity to form amyloid fibers 
through extensive cross-β sheet formation27;28. Moreover, we established that only insoluble 
endostatin but not soluble endostatin stimulates tPA-mediated plasminogen activation and 
induces cell toxicity27;28. Here we have studied the effect of insoluble endostatin, to which we 
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refer as amyloid endostatin, on endothelial cell-mediated plasmin formation and cell 
adhesion. 
 
Materials and methods 
Prote ins and reagents  
The cDNA for murine endostatin (kindly provided by dr. Fukai, Boston) was amplified by 
PCR and cloned into the prokaryotic expression vector pET15b (Novagen, WI). 
Recombinant murine endostatin was produced by Escherichia coli as described1 and 
resuspended in phosphate-buffered saline (PBS). Soluble Pichia pastoris-produced 
endostatin was provided by Entremed, Inc. (Rockville, Maryland). Plasminogen was from 
Sigma® Chemical Co (St. Louis, MO) or purified from plasma as described29, tPA and 
plasmin substrate S-2251 were from Chromogenix AB (Mölndal, Sweden), pefabloc tPA 
was from Pentapharm AG (Switzerland), porcine pancreas carboxypeptidase B was from 
Boehringer Mannheim® (Mannheim, Germany), potato carboxypeptidase inhibitor and rabbit 
polyclonal antibody against vitronectin were from Calbiochem® (La Jolla, CA). Anti-
plasminogen monoclonal antibody and anti-tPA polyclonal antibodies were from American 
Diagnostica (Greenwich, CT). 
 
Preparat ion of  yeast -produced amylo id  endostat in  
Pichia pastoris-produced endostatin (Entremed, Inc. Rockville, Maryland) was denatured by 
dialyses against 8 M urea, 10 mM Tris (pH 7.5) and 10 mM β-mercaptoethanol. The 
denaturing buffer was subsequently removed by extensive dialysis against H2O. Amyloid 
endostatin became visible as a white precipitate. 
 
Binding exper iments  
Binding of plasminogen and tPA was carried out in 96-well microtiter plates coated overnight 
at room temperature with 50 µl amyloid endostatin (20 µg/ml) or fibrin fragments (DESAFIB-
X®, Chromogenix, 20 µg/ml) in coating buffer (15 mM Na2CO3, 35 mM NaHCO3, 0.02 % 
NaN3, pH 9.6). The wells were blocked with 3% bovine serum albumin (BSA) in PBS for one 
hour and washed three times with PBS containing 0.3% BSA (PBS/BSA). Where indicated 
the wells were treated with porcine pancreas carboxypeptidase B (50 µg/ml) for one hour at 
37 °C in PBS containing 3% BSA and washed 3 times with PBS/BSA. Plasminogen and tPA, 
at various concentrations, were allowed to bind for one hour. After 3 washes, bound 
plasminogen or tPA were detected with specific anti-plasminogen and anti-tPA antibodies 
followed by peroxidase conjugated secondary antibodies. Peroxidase activity was measured 
using ortho-phenylenediamine as substrate. The reaction was stopped by the addition of 1 
M H2SO4 and absorbance was measured at 490 nm.  
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Measurement  of  p lasmin act iv i ty  
The reactions were performed at 37°C in HBS buffer (20 mM Hepes, 4 mM KCl, 137 mM 
NaCl, 3 mM CaCl2, 0.1 % BSA, pH 7.4) containing 50 µg/ml of plasminogen with various 
concentrations of amyloid endostatin, DESAFIB®-X or with a control sample. The reactions 
were started by the addition of tPA at a final concentration of 30 U/ml. At several time points, 
20 µl samples were taken and the reaction was stopped with 20 µl buffer containing 150 mM 
ε-aminocaproic acid (εACA) and 150 mM EDTA. Plasmin activity was determined in 96-well 
plates after the addition of 20 µl chromogenic substrate S-2251 at a final concentration of 
1.6 mM. Increase in absorbance was measured at 405 nm for 10 min. When applicable test 
samples were preincubated for 30 minutes with 25 µg/ml carboxypeptidase B and/or  50 
µg/ml potato carboxypeptidase inhibitor. 
Plasminogen activation by endothelial cells was determined by SDS-PAGE analysis and 
western blotting. Conditioned medium was concentrated five times with nanosep 10K 
Omega (Pall Life Science, Portsmouth, UK). Plasmin activity was analyzed by adding 10 µl 
of concentrated conditioned medium to S-2251 (1.25 mM) and subsequent reading at 405 
nm. 
 
Cel l  cu l ture 
Bovine pulmonary arterial endothelial cells (BPAEC, CCL-209) were obtained from the 
American Type Culture Collection (Rockville, MD) and cultured in Dulbecco’s Modified Eagle 
Medium (Gibco BRL, Invitrogen Corporation, UK) with the supplement of 10% FCS and 
antibiotics. BPAEC were seeded onto 48-well culture plates (Costar Inc. NY) and grown to 
confluency in culture medium. The cells were washed two times with PBS and incubated 
with yeast-produced amyloid endostatin in Human Endothelial-SFM Basal Growth Medium 
(Gibco BRL, Invitrogen Corporation, UK) supplemented with antibiotics. 
 
Assay of  endothe l ia l  ce l l  detachment  
BPAEC were incubated with amyloid endostatin in the presence or absence of plasminogen. 
Were indicated, 50 µg/ml carboxypeptidase B was used for complete blockage of 
plasminogen activation and 20 µM Pefabloc tPA was used to inhibit tPA activity. After 24 
hours the cells were photographed using phase contrast microscopy. The supernatant was 
stored for further analyses. Cell detachment was analyzed by encircling the non-cell area in 
four different photographs using Adobe® Photoshop® version 6.0 (Adobe Systems Inc., CA, 
USA) and subsequently quantified by calculating the percentual coverage of the selected 
area using Optimas 6.0 software (DVS, Breda, The Netherlands). 
 
Tumor exper iments  
Male 6 to 8 week old BALB/c mice (General Animal Laboratory, University Medical Center  
Utrecht, Utrecht, The Netherlands) were used. All mice were fed a diet of animal chow and 
water ad libitum. Experiments were performed according to the guidelines of the Utrecht 
Animal Experimental Committee, University Medical Center (Utrecht, The Netherlands). 
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Mice were inoculated subcutaneously with 1x106 C26 colon carcinoma cells in 200 µl PBS. 
Escherichia coli-derived amyloid endostatin (20 mg/kg/day) or control solvent was given by 
daily subcutaneous injection, starting just after tumor cell injection and stopped at the end of 
the experiment. This results in this model in approximately 50% inhibition of tumor growth.  
Carboxypeptidase B was given continuously using a mini-osmotic pump (Alzet® pump, Alza, 
Palo Alto, California, USA, type 2002 [14 days]) containing 200 µl carboxypeptidase B at a 
concentration of 5 mg/ml. The pump was implanted subcutaneously in the dorsal skin fold. 
In mice bearing subcutaneous tumors, absence of contact between tumor deposit and pump 
was assured by implanting the pump in the contralateral side. Animals received an initial 
subcutaneous bolus injection of 40 µg carboxypeptidase B in 100 µl PBS at the time of 
tumor cell injection. Tumor diameters were determined on day 13 by calliper and tumor 
volume was calculated with the formula width2 x length x 0.52. Significance of differences in 
tumor growth among groups was determined by the unpaired Students t test. P < 0.05 was 
considered to be statistically significant. Values represent mean number ± SEM. 
 
Results 
Amylo id  endostat in s t imulates p lasmin format ion 
We previously showed that denatured endostatin forms amyloid fibrils and stimulates tPA-
mediated plasminogen activation in vitro27. We show here that amyloid endostatin stimulates 
tPA-mediated plasminogen activation in a dose dependent manner (Figure 1a). Stimulation 
of tPA-mediated activation of plasminogen by amyloid endostatin was as potent as 
stimulation by fibrin fragments, the classical stimulator of tPA-mediated plasminogen 
activation (Figure 1b). No activation of plasminogen was observed in the absence of tPA 
and amyloid endostatin alone did not convert the chromogenic substrate (not shown). 
Figure 1.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Amyloid endostatin-stimulated tPA-mediated plasminogen activation is concentration dependent. 
Different concentrations of amyloid endostatin (A) and fibrin fragments (B) were added to 
plasminogen. Plasminogen activation was started by addition of tPA. At the indicated time points 
samples were taken and plasmin activity was analyzed using the chromogenic substrate S-2251. 
These figures show a representative experiment out of five independent experiments. 
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Amylo id  endostat in b inds p lasminogen and tPA  
Because endostatin is a stimulator of plasminogen activation by tPA, we tested whether 
amyloid endostatin was able to bind plasminogen and tPA. Both plasminogen and tPA 
bound to immobilized amyloid endostatin in a dose-dependent and saturable manner (Figure 
2a). Binding of tPA to amyloid endostatin (apparent dissociation constant (Kd) = 1.6  ± 0.3 
nM) was similar to the binding of tPA to fibrin degradation products (Kd = 2.3 ± 0.4 nM) (Fig 
2b). The affinity of plasminogen for amyloid endostatin (Kd = 2.7 ± 0.6 nM) was about 10 
times higher than the affinity of plasminogen for fibrin fragments (Kd = 28.4  ± 5.8 nM). 
 
Carboxypept idase B inh ib i ts  the tPA-st imulatory  act iv i ty  of  amylo id  
endostat in  
The binding of plasminogen and tPA to fibrin is mediated by the lysine-binding sites in the 
kringle domains of plasminogen and tPA and by carboxy-terminal lysine residues that are 
generated in fibrin during plasmin digestion30. Therefore, we investigated the importance of 
carboxy-terminal lysines in amyloid endostatin-mediated plasmin formation. To this end we 
used the porcine pancreas carboxypeptidase B (CpB) that removes basic (arginine and 
lysine) amino acids from proteins. Treatment with CpB reduced amyloid endostatin-
stimulated plasminogen activation (Figure 3). The inhibitory effect of CpB on amyloid 
endostatin was greatly diminished by the addition of a specific carboxypeptidase inhibitor 
(CPI), indicating that the effect of CpB is due to carboxypeptidase activity. Binding analyses 
revealed that CpB treatment of amyloid endostatin abrogated plasminogen binding for more 
Figure 2.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Amyloid endostatin binds to plasminogen and tPA. Binding of plasminogen (A) and tPA (B) to 
immobilized amyloid endostatin or fibrin fragments was measured by ELISA. Binding was detected 
using specific antibodies against plasminogen or tPA followed by peroxidase-conjugated secondary 
antibodies and substrate addition. 
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than 90%, but had little or no effect on tPA binding. In line with this, plasminogen binding to 
amyloid endostatin was blocked by the lysine analogue ε-aminocaproic acid (not shown). 
These results clearly show that carboxy-terminal lysines are essential for efficient tPA-
mediated plasminogen activation. 
 
Amylo id  endostat in s t imulates p lasminogen act ivat ion by endothe l ia l  ce l ls  
We next determined whether amyloid endostatin can stimulate plasminogen activation 
mediated by endothelial cells, a biological source of tissue-type plasminogen activator. 
Different concentrations of amyloid endostatin were added to confluent monolayers of 
endothelial cells in the presence of 0.4 µM plasminogen. After 24 hours, the medium was 
analyzed by western blotting. Plasminogen cleavage by plasminogen activator results in the 
formation of plasmin, which migrates at approximately 50 kD in gel electrophoresis. In 
contrast to soluble endostatin, amyloid endostatin treatment significantly enhanced cell-
mediated plasmin formation (Figure 4a). Cells treated without amyloid endostatin did not 
convert plasminogen into plasmin. Also in endothelial cell-mediated plasminogen activation 
induced by amyloid endostatin, we found a similar dependence of amyloid endostatin activity 
on the presence of carboxy-terminal lysines. Addition of 50 µg/ml carboxypeptidase B totally 
abolished plasminogen activation (Figure 4b). Determination of chromogenic substrate 
conversion by concentrated medium indicated that plasmin was active (Figure 4c).  
 
Amylo id  endostat in  causes endothe l ia l  ce l l  detachment  and ext racel lu la r  
matr ix  degradat ion 
Sofar, we have shown that amyloid endostatin stimulates plasminogen activation both in 
vitro and on endothelial cells. Increased plasmin formation has been implicated in 
endothelial cell detachment31-34. Therefore, we studied the effects of amyloid endostatin on 
endothelial cell adhesion in the absence and presence of different plasminogen 
concentrations (Fig 5). While amyloid endostatin or plasminogen alone did not induce cell 
Figure 3. 
 
Carboxypeptidase B blocks amyloid 
endostatin-induced tPA-mediated plas-
minogen activation. The formation of 
plasmin was induced by 4 µM amyloid 
endostatin. Prior to the start of the 
reactions with tPA, carboxypeptidase B 
was added for 30 minutes at 37oC. 
Carboxypeptidase inhibitor (CPI) was 
included to demonstrate that the effect of 
carboxypeptidase B was the result of 
specific activity. The figure shows a 
representative experiment out of five 
independent experiments. 
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detachment (Figure 5a-c) co-treatment of the endothelial cells with plasminogen resulted in 
dramatic contraction of the cell bodies and complete rounding up of the cells (Figure 5d). 
Addition of carboxypeptidase B inhibited amyloid endostatin-mediated plasmin formation 
(Fig 4b) and subsequent cell detachment (Figure 5e). To asses the involvement of tPA in 
endostatin-induced plasminogen activation and cell detachment, 20 µM Pefabloc tPA was 
used to inhibit tPA activity. This tPA inhibiting peptide completely inhibited plasmin-mediated 
cell detachment indicating an essential role for tPA in these processes (Figure 5f). 
Treatment with soluble endostatin alone (Figure 5g) or in combination with plasminogen 
(Figure 5h) had no effects. 
The observed detachment of endothelial cells could be mediated by extracellular matrix 
degradation. Vitronectin (serum spreading factor) is an important component of the 
extracellular matrix involved in cell attachment and cell spreading. Vitronectin can be  
Figure 4.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Amyloid endostatin stimulates endothelial cell mediated plasminogen activation. Plasmin formation 
in culture medium of control cells (C) and cells treated with 30 µM of amyloid endostatin (EAm) or 30 
µM of soluble endostatin (Es) was analyzed by SDS-PAGE and western blotting using anti-human 
plasminogen antibody. (B) Addition of carboxypeptidase B (CpB) completely blocked amyloid 
endostatin-induced plasmin formation. (C) Plasmin activity was determined in culture medium of 
amyloid endostatin-treated cells using chromogenic substrate S-2251. 
A 
Plasminogen
Plasmin
Es C EAm 
0 10 20 30
0
5
10
15
- CpB
+ CpB
µM EAm
Pl
as
m
in
 a
ct
iv
ity
( ∆∆ ∆∆
m
O
D
/m
in
)
C
B 
- 
EAm + +
CpB + -
- - 
+ 
Plasminogen
Plasmin
72 Chapter 5 
 
Figure 5.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Amyloid endostatin causes endothelial detachment. Bovine pulmonary arterial endothelial cells were 
cultured to confluency and incubated with 30 µM of amyloid endostatin (EAm) in the presence of 
different concentrations of plasminogen (Pg). After 24 hours the cells were photographed. (A) 
Control-treated endothelial cells. (B) 30 µM EAm or (C) 0.6 µM plasminogen did not induce 
endothelial cell detachment. (D) Cell contraction and rounding up induced by 30 µM EAm and 0.6 µM 
plasminogen co-treatment. Addition of (E) 50 µg/ml carboxypeptidase B or (F) 20 µM Pefabloc tPA 
completely blocked EAm-induced endothelial cell detachment. Soluble endostatin in the absence (G) 
or presence (H) of plasminogen had no effects. (I) Cell detachment was quantified as described in 
the material and methods section. Values represent mean number ± SEM. (J) Vitronectin (Vn) 
degradation was analyzed by western blotting. VnDP, Vn degradation product. 
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degraded by plasmin35. Vitronectin degradation was studied in lysates of amyloid endostatin-
treated endothelial cells by western blotting. Whereas only small amounts of vitronectin 
degradation products were generated in the presence of plasminogen alone, co-treatment 
with amyloid endostatin potently increased vitronectin degradation (Fig 5j). 
Carboxypeptidase B, which blocked plasmin formation (Figure 4b), also abrogated 
vitronectin degradation.    
 
Inh ib i tory  act iv i ty  of  amylo id  endostat in  on subcutaneous tumor  growth is  
rever ted by carboxypept idase B  
To determine the possible role for carboxy-terminal lysine residues in the antitumor effect of 
amyloid endostatin in vivo we treated mice with amyloid endostatin in the absence or 
presence of CpB. Treatment was started directly after tumor cell injection and stopped on 
day 13. Amyloid endostatin-treated mice showed approximately 50% reduced growth of a 
subcutaneous colon carcinoma (P = 0.046 treatment versus control), while the presence of 
carboxypeptidase B completely abolished this reduction (Figure 6). The antitumor effect of 
CpB alone was not significant (P = 0.229 CpB versus control).  
 
Discussion 
The formation of plasmin by activation of its zymogen plasminogen is associated with 
degradation of the extracellular matrix as it occurs in the dissolution of blood clots, tissue 
remodeling, invasive growth of cancer cells and angiogenesis36-39. Plasmin mediates 
proteolysis of the extracellular matrix by degrading fibrin and other matrix molecules. In 
addition, plasmin mediates proteolysis indirectly by the activation of metalloproteinases, 
which further degrade the extracellular matrix. During angiogenesis, extracellular matrix 
components regulate cell proliferation, migration and survival through interactions with 
Figure 6. 
 
Inhibition of tumor growth by amyloid 
endostatin is abolished by carboxypeptidase 
B treatment. Mice (n=4/group) were 
inoculated subcutaneously with 1x106 C26 
colon carcinoma cells and treated daily with 
amyloid endostatin or control solvent in the 
presence or absence of carboxypeptidase B 
as indicated. The inhibitory effect of amyloid 
endostatin on tumor growth was completely 
blocked by continuous administration of 
carboxypeptidase B.  The experiment shown 
is a representative of three independent 
experiments. 
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adhesion molecules on the cell surface. Important adhesion molecules include the receptors 
for fibrin and vitronectin, the integrins αvβ3 and αvβ540. Plasmin has been implicated as an 
important modulator of the interactions between cells and the extracellular matrix32;41. 
Plasmin may also liberate cytokines, such as TGFβ42, from inactive precursors and could 
play a role in the formation of plasminogen breakdown products with antiangiogenic 
properties, including angiostatin and kringle 543. Thus plasmin is a key enzyme in the 
angiogenic process.  
Here, we have demonstrated that amyloid endostatin, a cofactor for tPA-mediated 
plasminogen activation, induces endothelial cell-mediated plasmin formation resulting in 
vitronectin degradation, cell remodeling and detachment.  
Numerous studies revealed high expression of tPA in several human tumors44-48. 
Therapeutic administration of amyloid endostatin may result in stimulation of tPA activity that 
is produced in the tumor. In light of this, it is interesting to note that tPA expression by 
endothelial cells is induced by angiogenic factors, including basic fibroblast growth factor 
(bFGF) and vascular endothelial growth factor (VEGF)49. Overstimulation of the 
plasminogen activation system may result in excessive matrix degradation. Induction of 
plasminogen activation has lead to endothelial cell detachment31, inhibition of cell 
adhesion32, endothelial cell destruction33 or regression of capillary tubes34. Vitronectin plays 
an important role in endothelial cell survival50. We found that vitronectin, a main adhesive 
matrix protein present in serum and deposited in the extracellular matrix of cultured 
endothelial cells is degraded upon treatment with amyloid endostatin. Its breakdown may 
cause cell detachment and subsequent apoptosis. 
With the discovery of tPA as a general cross-β sheet-binding protein27 we have identified a 
molecule that may contribute to the cellular effects induced by amyloid proteins like 
endostatin. Indeed, a specific inhibitor of tPA activity completely blocked plasmin-mediated 
changes of endothelial cell morphology induced by amyloid endostatin.  
We noted that several other antiangiogenic peptides, like amyloid endostatin can stimulate 
tPA-mediated plasminogen activation. Stimulatory activity towards plasminogen activation 
and antiangiogenic activity has been described for a cleaved or denatured conformation of 
antithrombin, aaATIII51;52, prothrombin fragments53;54, thrombospondin55-58, maspin59;60 and 
amphoterin61;62. This could implicate that a common antiangiogenic pathway may exist that 
is induced by tPA binding proteins (see also chapter 9). Clinical studies underscore that high 
tPA levels are associated with good prognosis in cancer patients63-65. 
In fibrin, the generation of carboxy-terminal lysines is key to the efficient activation of 
plasminogen, as they form high affinity binding sites for plasminogen and, less so, tPA. The 
importance of carboxy-terminal lysines in endostatin-mediated plasminogen activation and 
subsequent detachment of endothelial cells was shown since addition of carboxypeptidase 
B totally abrogated endostatin activity. Physiologically, plasminogen activation induced by 
partially degraded fibrin is regulated by thrombin-activatable fibrinolysis inhibitor (TAFI), a 
carboxypeptidase B-type enzyme present in blood66;67. We found that stimulation of tPA-
Amyloid endostatin induces plasmin-mediated endothelial cell detachment    75 
 
mediated plasminogen activation by endostatin was similarly inhibited by activated TAFI (not 
shown). Thus, TAFI could function as a regulator of the antitumor activity of endostatin.    
In line with our in vitro data, co-treatment of mice with endostatin and carboxypeptidase B 
abolished the inhibitory effect of endostatin. We can not exclude that other carboxypeptidase 
B sensitive pathways involved in endostatin bioactivity may be affected, but these results 
strongly suggest that the plasminogen activation system plays an important role in 
endostatin function.  
Our suggestion that increased plasminogen activation might be responsible for at least part 
of the endostatin effect on tumor growth is supported by data of others. Tumor 
vascularization and tumor invasion is prevented in the absence of PAI-1 when increased 
levels of plasmin are likely to be formed68;69. In addition, high concentrations of tPA are 
generated and PAP levels are elevated in patients with peripheral tumors that regress in 
response to tumor necrosis factor alpha (TNFα)70;71.  
Taken together, overstimulation of tPA by agents such as amyloid endostatin may result in 
excessive matrix degradation thereby preventing angiogenesis and tumor growth72. This is a 
novel pathway to intervene in tumor growth and warrants further study. 
 
Acknowledgements 
This research was supported in part by the Dutch Cancer Society (grant 99-2114 to 
M.F.B.G.G.) and grant 96.088 from the Netherlands Heart Foundation. J.C.M.M. is an 
Established Investigator of the Netherlands Heart Foundation (grant D96.021). 
 
References 
 1.  Boehm, T., Folkman, J., Browder, T., and O'Reilly, M. S. Antiangiogenic therapy of experimental 
cancer does not induce acquired drug resistance. Nature, 390: 404-407, 1997. 
 2.  Ryan, D. P., Penson, R. T., Ahmed, S., Chabner, B. A., and Lynch, T. J., Jr. Reality testing in 
cancer treatment: the phase I trial of endostatin. Oncologist, 4: 501-508, 1999. 
 3.  Herbst, R. S., Hess, K. R., Tran, H. T., Tseng, J. E., Mullani, N. A., Charnsangavej, C., Madden, 
T., Davis, D. W., McConkey, D. J., O'Reilly, M. S., Ellis, L. M., Pluda, J., Hong, W. K., and 
Abbruzzese, J. L. Phase I study of recombinant human endostatin in patients with advanced solid 
tumors. J Clin Oncol, 20: 3792-3803, 2002. 
 4.  Felbor, U., Dreier, L., Bryant, R. A., Ploegh, H. L., Olsen, B. R., and Mothes, W. Secreted 
cathepsin L generates endostatin from collagen XVIII. EMBO J, 19: 1187-1194, 2000. 
 5.  Lin, H. C., Chang, J. H., Jain, S., Gabison, E. E., Kure, T., Kato, T., Fukai, N., and Azar, D. T. 
Matrilysin cleavage of corneal collagen type XVIII NC1 domain and generation of a 28-kDa 
fragment. Invest Ophthalmol Vis Sci, 42: 2517-2524, 2001. 
 6.  Wen, W., Moses, M. A., Wiederschain, D., Arbiser, J. L., and Folkman, J. The generation of 
endostatin is mediated by elastase. Cancer Res, 59: 6052-6056, 1999. 
 7.  Sim, B. K., MacDonald, N. J., and Gubish, E. R. Angiostatin and endostatin: endogenous 
inhibitors of tumor growth. Cancer Metastasis Rev, 19: 181-190, 2000. 
 8.  O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. 
R., Olsen, B. R., and Folkman, J. Endostatin: an endogenous inhibitor of angiogenesis and tumor 
growth. Cell, 88: 277-285, 1997. 
76 Chapter 5 
 
 9.  Perletti, G., Concari, P., Giardini, R., Marras, E., Piccinini, F., Folkman, J., and Chen, L. Antitumor 
activity of endostatin against carcinogen-induced rat primary mammary tumors. Cancer Res, 60: 
1793-1796, 2000. 
10.  Chen, Q. R., Kumar, D., Stass, S. A., and Mixson, A. J. Liposomes complexed to plasmids 
encoding angiostatin and endostatin inhibit breast cancer in nude mice. Cancer Res, 59: 3308-
3312, 1999. 
11.  Feldman, A. L., Restifo, N. P., Alexander, H. R., Bartlett, D. L., Hwu, P., Seth, P., and Libutti, S. K. 
Antiangiogenic gene therapy of cancer utilizing a recombinant adenovirus to elevate systemic 
endostatin levels in mice. Cancer Res, 60: 1503-1506, 2000. 
12.  Steele, F. R. Can "negative" be positive? Mol Ther, 5: 338-339, 2002. 
13.  Eisterer, W., Jiang, X., Bachelot, T., Pawliuk, R., Abramovich, C., Leboulch, P., Hogge, D., and 
Eaves, C. Unfulfilled promise of endostatin in a gene therapy-xenotransplant model of human 
acute lymphocytic leukemia. Mol Ther, 5: 352-359, 2002. 
14.  Pawliuk, R., Bachelot, T., Zurkiya, O., Eriksson, A., Cao, Y., and Leboulch, P. Continuous 
intravascular secretion of endostatin in mice from transduced hematopoietic stem cells. Mol Ther, 
5 : 345-351, 2002. 
15.  Jouanneau, E., Alberti, L., Nejjari, M., Treilleux, I., Vilgrain, I., Duc, A., Combaret, V., Favrot, M., 
Leboulch, P., and Bachelot, T. Lack of antitumor activity of recombinant endostatin in a human 
neuroblastoma xenograft model. J Neurooncol, 51: 11-18, 2001. 
16.  Marshall, E. Cancer therapy. Setbacks for endostatin. Science, 295: 2198-2199, 2002. 
17.  Kim, Y. M., Hwang, S., Kim, Y. M., Pyun, B. J., Kim, T. Y., Lee, S. T., Gho, Y. S., and Kwon, Y. G. 
Endostatin blocks vascular endothelial growth factor-mediated signaling via direct interaction with 
KDR/Flk-1. J Biol Chem, 277: 27872-27879, 2002. 
18.  Dhanabal, M., Ramchandran, R., Waterman, M. J., Lu, H., Knebelmann, B., Segal, M., and 
Sukhatme, V. P. Endostatin induces endothelial cell apoptosis. J Biol Chem, 274: 11721-11726, 
1999. 
19.  MacDonald, N. J., Shivers, W. Y., Narum, D. L., Plum, S. M., Wingard, J. N., Fuhrmann, S. R., 
Liang, H., Holland-Linn, J., Chen, D. H., and Sim, B. K. Endostatin binds tropomyosin. A potential 
modulator of the antitumor activity of endostatin. J Biol Chem, 276: 25190-25196, 2001. 
20.  Furumatsu, T., Yamaguchi, N., Nishida, K., Kawai, A., Kunisada, T., Namba, M., Inoue, H., and 
Ninomiya, Y. Endostatin Inhibits Adhesion of Endothelial Cells to Collagen I via alpha(2)beta(1) 
Integrin, a Possible Cause of Prevention of Chondrosarcoma Growth. J Biochem (Tokyo), 131: 
619-626, 2002. 
21.  Rehn, M., Veikkola, T., Kukk-Valdre, E., Nakamura, H., Ilmonen, M., Lombardo, C., Pihlajaniemi, 
T., Alitalo, K., and Vuori, K. Interaction of endostatin with integrins implicated in angiogenesis. 
Proc Natl Acad Sci U S A, 98: 1024-1029, 2001. 
22.  Kim, Y. M., Jang, J. W., Lee, O. H., Yeon, J., Choi, E. Y., Kim, K. W., Lee, S. T., and Kwon, Y. G. 
Endostatin inhibits endothelial and tumor cellular invasion by blocking the activation and catalytic 
activity of matrix metalloproteinase. Cancer Res, 60: 5410-5413, 2000. 
23.  Lee, S. J., Jang, J. W., Kim, Y. M., Lee, H. I., Jeon, J. Y., Kwon, Y. G., and Lee, S. T. Endostatin 
binds to the catalytic domain of matrix metalloproteinase-2. FEBS Lett, 519: 147-152, 2002. 
24.  Wickstrom, S. A., Veikkola, T., Rehn, M., Pihlajaniemi, T., Alitalo, K., and Keski-Oja, J. 
Endostatin-induced modulation of plasminogen activation with concomitant loss of focal 
adhesions and actin stress fibers in cultured human endothelial cells. Cancer Res, 61: 6511-6516, 
2001. 
25.  Hohenester, E., Sasaki, T., Olsen, B. R., and Timpl, R. Crystal structure of the angiogenesis 
inhibitor endostatin at 1.5 A resolution. EMBO J, 17: 1656-1664, 1998. 
26.  Ding, Y. H., Javaherian, K., Lo, K. M., Chopra, R., Boehm, T., Lanciotti, J., Harris, B. A., Li, Y., 
Shapiro, R., Hohenester, E., Timpl, R., Folkman, J., and Wiley, D. C. Zinc-dependent dimers 
observed in crystals of human endostatin. Proc Natl Acad Sci U S A, 95: 10443-10448, 1998. 
Amyloid endostatin induces plasmin-mediated endothelial cell detachment    77 
 
27.  Kranenburg, O., Bouma, B., Kroon-Batenburg, L. M., Reijerkerk, A., Wu, Y. P., Voest, E. E., and 
Gebbink, M. F. Tissue-Type Plasminogen Activator Is a Multiligand Cross-beta Structure 
Receptor. Curr Biol, 12: 1833-1839, 2002. 
28.  Kranenburg, O., Kroon-Batenburg, L. M., Reijerkerk, A., Wu, Y. P., Voest, E. E., and Gebbink, M. 
F. Recombinant endostatin forms amyloid fibrils that bind and are cytotoxic to murine 
neuroblastoma cells in vitro. FEBS Lett, 539: 149-155, 2003. 
29.  Deutsch, D. G. and Mertz, E. T. Plasminogen: purification from human plasma by affinity 
chromatography. Science, 170: 1095-1096, 1970. 
30.  Fleury, V. and Angles-Cano, E. Characterization of the binding of plasminogen to fibrin surfaces: 
the role of carboxy-terminal lysines. Biochemistry, 30: 7630-7638, 1991. 
31.  Ge, M., Tang, G., Ryan, T. J., and Malik, A. B. Fibrinogen degradation product fragment D 
induces endothelial cell detachment by activation of cell-mediated fibrinolysis. J Clin Invest, 90: 
2508-2516, 1992. 
32.  Reinartz, J., Schafer, B., Batrla, R., Klein, C. E., and Kramer, M. D. Plasmin abrogates alpha v 
beta 5-mediated adhesion of a human keratinocyte cell line (HaCaT) to vitronectin. Exp Cell Res, 
220: 274-282, 1995. 
33.  Sugimura, M., Kobayashi, H., and Terao, T. Plasmin modulators, aprotinin and anti-catalytic 
plasmin antibody, efficiently inhibit destruction of bovine vascular endothelial cells by 
choriocarcinoma cells. Gynecol Oncol, 52: 337-346, 1994. 
34.  Davis, G. E., Pintar Allen, K. A., Salazar, R., and Maxwell, S. A. Matrix metalloproteinase-1 and -9 
activation by plasmin regulates a novel endothelial cell-mediated mechanism of collagen gel 
contraction and capillary tube regression in three-dimensional collagen matrices. J Cell Sci, 114: 
917-930, 2001. 
35.  Chain, D., Kreizman, T., Shapira, H., and Shaltiel, S. Plasmin cleavage of vitronectin. 
Identification of the site and consequent attenuation in binding plasminogen activator inhibitor-1. 
FEBS Lett, 285: 251-256, 1991. 
36.  Duffy, M. J. Plasminogen activators and cancer. Blood Coagul Fibrinolysis, 1: 681-687, 1990. 
37.  Kramer, M. D., Reinartz, J., Brunner, G., and Schirrmacher, V. Plasmin in pericellular proteolysis 
and cellular invasion. Invasion Metastasis, 14: 210-222, 1994. 
38.  Pintucci, G., Bikfalvi, A., Klein, S., and Rifkin, D. B. Angiogenesis and the fibrinolytic system. 
Semin Thromb Hemost, 22: 517-524, 1996. 
39.  Bell, W. R. The fibrinolytic system in neoplasia. Semin Thromb Hemost, 22: 459-478, 1996. 
40.  Eliceiri, B. P. and Cheresh, D. A. The role of alphav integrins during angiogenesis: insights into 
potential mechanisms of action and clinical development. J Clin Invest, 103: 1227-1230, 1999. 
41.  Dano, K., Andreasen, P. A., Grondahl-Hansen, J., Kristensen, P., Nielsen, L. S., and Skriver, L. 
Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res, 44: 139-266, 1985. 
42.  Odekon, L. E., Blasi, F., and Rifkin, D. B. Requirement for receptor-bound urokinase in plasmin-
dependent cellular conversion of latent TGF-beta to TGF-beta. J Cell Physiol, 158: 398-407, 
1994. 
43.  Gately, S., Twardowski, P., Stack, M. S., Cundiff, D. L., Grella, D., Castellino, F. J., Enghild, J., 
Kwaan, H. C., Lee, F., Kramer, R. A., Volpert, O., Bouck, N., and Soff, G. A. The mechanism of 
cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin. Proc Natl 
Acad Sci U S A, 94: 10868-10872, 1997. 
44.  De Petro, G., Tavian, D., Copeta, A., Portolani, N., Giulini, S. M., and Barlati, S. Expression of 
urokinase-type plasminogen activator (u-PA), u-PA receptor, and tissue-type PA messenger 
RNAs in human hepatocellular carcinoma. Cancer Res, 58: 2234-2239, 1998. 
45.  Lindgren, M., Johansson, M., Sandstrom, J., Jonsson, Y., Bergenheim, A. T., and Henriksson, R. 
VEGF and tPA co-expressed in malignant glioma. Acta Oncol, 36: 615-618, 1997. 
78 Chapter 5 
 
46.  Hackel, C., Czerniak, B., Ayala, A. G., Radig, K., and Roessner, A. Expression of plasminogen 
activators and plasminogen activator inhibitor 1 in dedifferentiated chondrosarcoma. Cancer, 79: 
53-58, 1997. 
47.  Gris, J. C., Schved, J. F., Marty-Double, C., Mauboussin, J. M., and Balmes, P. 
Immunohistochemical study of tumor cell-associated plasminogen activators and plasminogen 
activator inhibitors in lung carcinomas. Chest, 104: 8-13, 1993. 
48.  Yamashita, J., Inada, K., Yamashita, S., Nakashima, Y., Matsuo, S., and Ogawa, M. Tissue-type 
plasminogen activator is involved in skeletal metastasis from human breast cancer. Int J Clin Lab 
Res, 21: 227-230, 1992. 
49.  Pepper, M. S., Ferrara, N., Orci, L., and Montesano, R. Vascular endothelial growth factor (VEGF) 
induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial 
cells. Biochem Biophys Res Commun, 181: 902-906, 1991. 
50.  Isik, F. F., Gibran, N. S., Jang, Y. C., Sandell, L., and Schwartz, S. M. Vitronectin decreases 
microvascular endothelial cell apoptosis. J Cell Physiol, 175: 149-155, 1998. 
51.  O'Reilly, M. S., Pirie-Shepherd, S., Lane, W. S., and Folkman, J. Antiangiogenic activity of the 
cleaved conformation of the serpin antithrombin. Science, 285: 1926-1928, 1999. 
52.  Machovich, R. and Owen, W. G. Denatured proteins as cofactors for plasminogen activation. Arch 
Biochem Biophys, 344: 343-349, 1997. 
53.  Rhim, T. Y., Park, C. S., Kim, E., and Kim, S. S. Human prothrombin fragment 1 and 2 inhibit 
bFGF-induced BCE cell growth. Biochem Biophys Res Commun, 252: 513-516, 1998. 
54.  Machovich, R., Komorowicz, E., Kolev, K., and Owen, W. G. Facilitation of plasminogen activation 
by denatured prothrombin. Thromb Res, 94: 389-394, 1999. 
55.  Volpert, O. V., Lawler, J., and Bouck, N. P. A human fibrosarcoma inhibits systemic angiogenesis 
and the growth of experimental metastases via thrombospondin-1. Proc Natl Acad Sci U S A, 95: 
6343-6348, 1998. 
56.  Silverstein, R. L., Leung, L. L., Harpel, P. C., and Nachman, R. L. Complex formation of platelet 
thrombospondin with plasminogen. Modulation of activation by tissue activator. J Clin Invest, 74: 
1625-1633, 1984. 
57.  Silverstein, R. L., Nachman, R. L., Leung, L. L., and Harpel, P. C. Activation of immobilized 
plasminogen by tissue activator. Multimolecular complex formation. J Biol Chem, 260: 10346-
10352, 1985. 
58.  Silverstein, R. L., Harpel, P. C., and Nachman, R. L. Tissue plasminogen activator and urokinase 
enhance the binding of plasminogen to thrombospondin. J Biol Chem, 261: 9959-9965, 1986. 
59.  Zou, Z., Anisowicz, A., Hendrix, M. J., Thor, A., Neveu, M., Sheng, S., Rafidi, K., Seftor, E., and 
Sager, R. Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells. 
Science, 263: 526-529, 1994. 
60.  Sheng, S., Truong, B., Fredrickson, D., Wu, R., Pardee, A. B., and Sager, R. Tissue-type 
plasminogen activator is a target of the tumor suppressor gene maspin. Proc Natl Acad Sci U S A, 
95: 499-504, 1998. 
61.  Huttunen, H. J., Fages, C., Kuja-Panula, J., Ridley, A. J., and Rauvala, H. Receptor for Advanced 
Glycation End Products-binding COOH-terminal Motif of Amphoterin Inhibits Invasive Migration 
and Metastasis. Cancer Res, 62: 4805-4811, 2002. 
62.  Parkkinen, J. and Rauvala, H. Interactions of plasminogen and tissue plasminogen activator (t-
PA) with amphoterin. Enhancement of t-PA-catalyzed plasminogen activation by amphoterin. J 
Biol Chem, 266: 16730-16735, 1991. 
63.  de Witte, J. H., Sweep, C. G., Klijn, J. G., Grebenschikov, N., Peters, H. A., Look, M. P., van 
Tienoven, T. H., Heuvel, J. J., Bolt-De Vries, J., Benraad, T. J., and Foekens, J. A. Prognostic 
value of tissue-type plasminogen activator (tPA) and its complex with the type-1 inhibitor (PAI-1) 
in breast cancer. Br J Cancer, 80: 286-294, 1999. 
Amyloid endostatin induces plasmin-mediated endothelial cell detachment    79 
 
64.  Grebenschikov, N., Geurts-Moespot, A., De Witte, H., Heuvel, J., Leake, R., Sweep, F., and 
Benraad, T. A sensitive and robust assay for urokinase and tissue-type plasminogen activators 
(uPA and tPA) and their inhibitor type I (PAI-1) in breast tumor cytosols. Int J Biol Markers, 12: 6-
14, 1997. 
65.  Kim, S. J., Shiba, E., Kobayashi, T., Yayoi, E., Furukawa, J., Takatsuka, Y., Shin, E., Koyama, H., 
Inaji, H., and Takai, S. Prognostic impact of urokinase-type plasminogen activator (PA), PA 
inhibitor type-1, and tissue-type PA antigen levels in node-negative breast cancer: a prospective 
study on multicenter basis. Clin Cancer Res, 4: 177-182, 1998. 
66.  Bajzar, L., Manuel, R., and Nesheim, M. E. Purification and characterization of TAFI, a thrombin-
activable fibrinolysis inhibitor. J Biol Chem, 270: 14477-14484, 1995. 
67.  Stewart, R. J., Fredenburgh, J. C., Rischke, J. A., Bajzar, L., and Weitz, J. I. Thrombin-activable 
fibrinolysis inhibitor attenuates (DD)E-mediated stimulation of plasminogen activation by reducing 
the affinity of (DD)E for tissue plasminogen activator. A potential mechanism for enhancing the 
fibrin specificity of tissue plasminogen activator. J Biol Chem, 275: 36612-36620, 2000. 
68.  Bajou, K., Noel, A., Gerard, R. D., Masson, V., Brunner, N., Holst-Hansen, C., Skobe, M., 
Fusenig, N. E., Carmeliet, P., Collen, D., and Foidart, J. M. Absence of host plasminogen activator 
inhibitor 1 prevents cancer invasion and vascularization. Nat Med, 4: 923-928, 1998. 
69.  Bajou, K., Masson, V., Gerard, R. D., Schmitt, P. M., Albert, V., Praus, M., Lund, L. R., Frandsen, 
T. L., Brunner, N., Dano, K., Fusenig, N. E., Weidle, U., Carmeliet, G., Loskutoff, D., Collen, D., 
Carmeliet, P., Foidart, J. M., and Noel, A. The plasminogen activator inhibitor PAI-1 controls in 
vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for 
antiangiogenic strategies. J Cell Biol, 152: 777-784, 2001. 
70.  Silverman, P., Goldsmith, G. H., Jr., Spitzer, T. R., Rehmus, E. H., and Berger, N. A. Effect of 
tumor necrosis factor on the human fibrinolytic system. J Clin Oncol, 8: 468-475, 1990. 
71.  Merryman, P., Tannenbaum, S. H., Gralnick, H. R., Yu, K., Arnold, W. S., Alexander, H. R., 
Fraker, D., and Horne, M. K., III Fibrinolytic and coagulant responses to regional limb perfusions 
of tumor necrosis factor, interferon-gamma, and/or melphalan. Thromb Haemost, 77: 53-56, 1997. 
72.  Reijerkerk, A., Voest, E. E., and Gebbink, M. F. No grip, no growth: the conceptual basis of 
excessive proteolysis in the treatment of cancer. Eur J Cancer, 36: 1695-1705, 2000. 

 Chapter 6 
 
Recombinant endostatin forms amyloid 
fibrils that bind and are cytotoxic to 
murine neuroblastoma cells in vitro 
 
Onno Kranenburg 
Loes M.J.  Kroon-Batenburg 
Ar ie  Rei jerkerk  
Ya-Ping Wu 
Emi le  E.  Voest  
Mar t i jn  F .B.G.  Gebbink 
 
 
FEBS Let ters  539:  149-155,  2003  
82 Chapter 6 
 
Summary 
Endostatin is a fragment of collagen XVIII that acts as an endogenous inhibitor of 
angiogenesis and tumor growth. Antitumor effects have been described using both soluble 
and insoluble recombinant endostatin. However, differences in endostatin structure are likely 
to cause differences in bioactivity. In the present study we have investigated the structure 
and cellular effects of insoluble endostatin. We found that insoluble endostatin shows all the 
hallmarks of amyloid aggregates. Firstly, it binds Congo red and shows the characteristic 
apple-green birefringence when examined under polarized light. Secondly, electron 
microscopy shows that endostatin forms short unbranched fibrils. Thirdly, X-ray analysis 
shows the abundant presence of cross-β sheets, the tertiary structure that underlies 
fibrillogenesis. None of these properties were observed when examining soluble endostatin. 
Soluble endostatin can be triggered to form cross-β sheets following denaturation indicating 
that endostatin is a protein fragment with an inherent propensity to form amyloid deposits. 
Like β-amyloid, found in the brains of patients with Alzheimer’s disease, amyloid endostatin 
binds to and is toxic to neuronal cells, whereas soluble endostatin has no effect on cell 
viability. Our results demonstrate a previously unrecognized functional difference between 
soluble and insoluble endostatin, only the latter acting as a cytotoxic amyloid substance.                  
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Introduction 
In recent years cancer therapy has seen the development of a new class of drugs: inhibitors 
of the formation of new blood vessels (‘angiogenesis’) which thereby limit blood supply to 
tumors. A number of antiangiogenic compounds have proven to be effective in eradicating 
tumors in mouse models and are now being further tested in clinical trials (reviewed in1-4). 
Endostatin, a naturally occurring fragment of collagen XVIII, is considered to be one of the 
most effective inhibitors of angiogenesis3. Early studies with bacterially produced (insoluble) 
endostatin have shown its potent inhibitory effect on tumor growth5;6. Although soluble 
endostatin (produced in yeast) can also inhibit tumor growth, permanent tumor regression 
has only been reported when using insoluble endostatin3. Effects of endostatin on 
endothelial cell proliferation6, apoptosis7-9 and migration10;11 have been described, but it is 
not clear to what extent these activities contribute to the antiangiogenic and antitumor 
effects of endostatin in vivo. Moreover, it remains unclear why endostatin therapy works so 
well in some experiments3 but remains ineffective in others12-15 (and our own unpublished 
data). Different structural forms of endostatin are likely to have distinct bioactivities. Soluble 
and insoluble endostatin may therefore produce their antiangiogenic effects through distinct 
mechanisms. In the present report we set out to investigate the structural and biological 
differences between soluble and insoluble endostatin. Whereas the structure of soluble, 
globular endostatin has been elucidated16;17, the structure of insoluble endostatin has not. 
Insoluble proteins may occur as amorphous aggregates but they may also occur as highly 
ordered ‘amyloid’ deposits18. In the latter case, the polypeptide backbones are in a β-sheet 
conformation and are stacked through intermolecular (rather than intramolecular) hydrogen 
bonds, thus forming a ‘cross-β sheet’19. We found that endostatin is a protein with high 
propensity to form amyloid fibers through extensive cross-β sheet formation. Fibrillar 
endostatin binds to neuronal cells and causes neuronal cell death whereas soluble 
endostatin does not. Our results suggest that endostatin induces apoptosis as a result of its 
amyloid structure.  
 
Materials and methods 
Preparat ion of  recombinant  human endostat in f rom bacter ia  
Endostatin was purified from bacteria essentially as described5. In short, BL21(DE3) bacteria 
expressing endostatin were lysed in a buffer containing 8 M urea, 10 mM Tris (pH 8.0), 10 
mM imidazole and 10 mM β-mercaptoethanol. Following purification over Ni-agarose, the 
protein sample was extensively dialyzed against H2O. During dialysis endostatin precipitates 
as a fine white solid. Aliquots of this material were either stored at –80oC for later use, or 
were freeze-dried prior to storage.  
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Recombinant  human endostat in f rom yeast  
Endostatin produced by the yeast strain Pichia pastoris was kindly provided by Dr. Kim Lee 
Sim (EntreMed, Inc., Rockville, MA, USA).  
 
Preparat ion of  aggregated yeast -produced endostat in  
Soluble yeast endostatin was dialyzed overnight in 8 M urea and subsequently three times 
against H2O. Like bacterial endostatin, yeast endostatin precipitates as a fine white solid.    
 
Amylo id  β ̣  (Aβ )  and human is le t  amylo id  po lypept ide (hIAPP) 
Aβ1-40 (DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVV) and hIAPP 
(KCNTATCATQRLANFLVHSSNNFGAILSSTNVGSNTY) were obtained from the peptide 
synthesis facility at the Netherlands Cancer Institute (Amsterdam, the Netherlands). The 
freeze-dried peptides were resuspended in phosphate-buffered saline (PBS) and were 
allowed to form cross-βҏ structure over a period of three weeks at room temperature. Cross-β 
sheet formation was followed by Congo Red binding and examination of green birefringence 
under polarized light.  
 
Congo Red s ta in ing 
Freeze-dried bacterial endostatin was resuspended in either 0.1% formic acid or in 
dimethylsulfoxide (DMSO) and taken up in a glass capillary. The solvent was allowed to 
evaporate and the resulting endostatin material was stained with Congo Red (Sigma) 
according to the manufacturer’s protocol.  
 
Transmiss ion e lect ron microscopy (TEM)  
Endostatin samples were applied to 400 mesh specimen grids covered with carbon-coated 
collodion films. After 5 min. the drops were removed with filter paper and the preparations 
were stained with 1% methylcellulose and 1% uranyl acetate. After washing in H2O the 
samples were dehydrated in a graded series of EtOH and hexamethyldisilazane. 
Transmission electron micrographs were recorded at 60 kV using a JEOL-1 electron 
microscope. 
 
X-ray d i f f ract ion analys is   
Aggregated endostatin was solubilized in 0.1% formic acid and was taken up in a glass 
capillary. The solvent was then allowed to evaporate over a period of several days. 
Capillaries containing the dried samples were placed on a Nonius κCCD diffractometer. 
Scattering was measured using sealed tube MoKα radiation with a graphite monochromator 
on the CCD area detector for a period of 16 hours. Scattering from air and the glass capillary 
wall were subtracted using in-house software (VIEW/EVAL).     
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N1E-115 ce l l  cu l ture and d i f ferent iat ion 
N1E-115 mouse neuroblastoma cells were routinely cultured in Dulbecco’s modified Eagle’s 
medium (DMEM) containing 5% fetal calf serum (FCS), supplemented with antibiotics. Cells 
were differentiated into post-mitotic neurons by culturing them in DMEM containing 0.5% 
FCS, 1 mM cAMP and 1% DMSO for 48 hours. 
 
Fluorescein isoth iocyanate (FITC)- label ing and f luorescence microscopy  
Soluble (yeast-produced) endostatin was dialyzed against 0.01 M Na2B4O7, 0.15 M NaCl 
(pH 9.5) overnight. FITC was dissolved (1 mg/ml) in 0.1 M Na2CO3 (pH 9.5) and was added 
to the endostatin, Aβ or hIAPP solutions at 2 µg FITC/mg protein. After 4 hour incubation at 
room temperature free FITC molecules were removed by dialysis against 1 M Tris pH 7.5, 
and subsequently, against PBS. During this procedure endostatin stays soluble and 
becomes highly fluorescent. Aggregated FITC-labeled endostatin was prepared from soluble 
FITC-labeled endostatin as above. Freshly solubilized as well as pre-aggregated Aβ and 
hIAPP were labeled with FITC by the same protocol. Cells grown on glass coverslips were 
exposed to FITC-labeled soluble or aggregated endostatin (5 µM), freshly resuspended or 
pre-aggregated Aβ or hIAPP for 6 hours and were subsequently washed five times in PBS to 
discard unbound material. The coverslips were then fixed by addition of formaldehyde (3.7% 
in PBS). Following fixation, the cells were incubated for 30 min. in PBS-BSA(0.1%) 
containing Texas Red-conjugated phalloidin to stain the actin cytoskeleton. The coverslips 
were then washed twice with PBS and were subsequently mounted in Vectashield 
containing DAPI (to stain cell nuclei) and analyzed using a Leica DM-IRBE fluorescence 
microscope. Quantification of aggregate binding to cells was performed as follows: Ten 
random fields were selected in a blind manner (i.e., without knowledge of the coverslips’ 
identity) in the red channel (actin). Images were subsequently automatically taken in all 
three channels by using Qfluoro software. The images were then analyzed by assessing the 
number of FITC-labeled aggregates/field by using LEICA Qwin software. Alternatively, the 
samples were analyzed by confocal microscopy (LEICA) and images were processed using 
LEICA software.         
 
Analys is  o f  ce l l  death 
After exposure to endostatin or Aβҏ (25 µM, 24h) cells in the culture medium were collected 
and the remaining adherent cells were trypsinized and added to the detached cells in the 
medium thus obtaining the total pool of adherent and detached cells. Subsequently, the cells 
were stained with 0.02% Trypan blue and the percentage dead (Trypan blue-positive) cells 
was assessed using a Bűrker glass counter chamber. Triplicate samples were analyzed and 
200 cells were counted in each sample.  
 
Annexin-V label ing  
Cells were grown on glass coverslips and, following exposure to either soluble or 
aggregated (non-fluorescent) endostatin or Aβҏ (25 µM, 24 h), were fixed in the culture 
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medium using 3.7% formaldehyde. Subsequently, the cells were analyzed for the presence 
of exposed phosphatidyl-serine on the cell surface using FITC-labeled annexin V (Sigma) 
according to the manufacturer’s protocol. 
 
Results and discussion 
Bacter ia l  endostat in forms amylo id  f ibers  w i th  cross-β  s t ructure 
In solution, properly folded proteins or peptides form a stable three-dimensional structure. 
However, protein fragments (like endostatin) are often prone to (partial) denaturation. As a 
result, they may aggregate and become insoluble. Insoluble proteins may either exist as 
amorphous aggregates or as highly ordered amyloid deposits18. The latter structure results 
from extensive ‘cross-β sheet’ formation19. In cross-β sheets the polypeptide backbones are 
in a β-sheet conformation with hydrogen bonds between the separate polypeptide 
backbones. Congo Red is a dye that is used for the detection of cross-β ҏsheet-forming 
amyloid deposits, showing green birefringence under polarized light20. We found that 
insoluble endostatin, as it is produced from bacteria, binds Congo Red (Figure 1a). 
Furthermore, when examined under polarized light it exhibits the green birefringence that is 
characteristic for Congo Red-bound amyloid deposits.  
Next, we investigated whether cross-β sheets are indeed present in bacterial endostatin by 
performing X-ray diffraction analysis21. We found that the bacterial endostatin sample 
produced distinct reflection lines at 4.7 Å (hydrogen-bond distance), as well as at 10-11 Å 
(inter-sheet distance) (Figure 1b). It is important to note that the reflection lines at 4.7 Å and 
10-11 Å show maximal intensities at opposite diffraction angles (Figure 1b). The fiber axis 
with its 4.7 Å hydrogen bond repeat distance is oriented along the vertical capillary axis. This 
implies that the inter-sheet distance of 10-11 Å is perpendicular to these hydrogen bonds in 
the protein aggregates. This is consistent with the protein being in a cross-βҏ sheet 
conformation (See also Kranenburg et al.22). Intramolecular β-sheets in a globular protein 
cannot cause a diffraction pattern that is so ordered. A rough estimate of 54 Å for the 
crystallite size in the hydrogen bond direction is obtained from the width of the 4.7 Å 
reflection. This corresponds to about 11-12 β-strands connected by hydrogen bonds. The 
scattering of the 10-11 Å repeat is broad as usual. This is due both to the limited crystallite 
size in the inter-sheet direction and to variation in the inter-sheet distance. From the amount 
of background scattering it follows that only part of the protein is involved in cross-β sheet 
formation.   
Proteins and peptides that form cross-β sheets have the tendency to aggregate into fibrillar 
structures that can be visualized by transmission electron microscopy (TEM)23. Therefore, 
we examined the endostatin aggregates using TEM. Figure 1c shows that bacterial 
endostatin forms unbranched fibers with a diameter of approximately 300 Å (30 nm) and 
with lengths varying from 1500-5000 Å (15-500 nm). Characteristic amyloid peptides form 
fibrils with diameters ranging from 50-130 Å (5-13 nm)18 and with varying lengths up to 1 µm. 
Taken together, our results show that bacterial endostatin is a protein fragment with an 
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inherent propensity to form cross-β ҏsheets and to aggregate into relatively thick amyloid-like 
fibrils.  
 
D 
Figure 1.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Amyloid properties of endostatin produced in bacteria. (A) Endostatin was purified from bacteria and 
stained with Congo Red. Samples were analyzed by light microscopy using both polarized and non-
polarized light. The figure shows that endostatin binds Congo Red and exhibits green birefringence 
when examined under polarized light. (B) Endostatin samples were further analyzed by X-ray 
diffraction. The scattering as obtained on the 2D detector is color-coded by intensity on a linear 
scale. The scattering intensity decreases as white-yellow-red-blue-black. The pattern shows 
diffraction maxima at 4.7 Å and 10-11 Å. The fiber axis (hydrogen bond direction) with 4.7 Å repeat 
is oriented vertically and is indicated by the arrow. The 10-11 Å repeat is preferentially oriented 
perpendicular to that as indicated by the asterisk. Tangential scans along the 2θ scattering angles 
corresponding to both d-spacings in the lower panel show that the scattering at 4.7 Å is oriented 
vertically and that at 10-11 Å horizontally. (C) Endostatin samples were coated on a 400 mesh grid 
and were processed for transmission electron microscopy. Endostatin forms fibrils with a diameter 
of ~30 nm and lengths ranging from 150 to 500 nm. (D) Model of the endostatin fiber. The 
measured distances between individual peptide backbones (H-bonds) and between the distinct 
sheets are indicated, as well as the fiber axis (see also17). A rough estimate of 54 Å for the 
crystallite size along the fiber axis corresponds to about 11-12 β-strands connected by hydrogen 
bonds. 
A B C 
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Fibre axis
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Convers ion of  so lub le  yeast -produced endostat in  in to amylo id  endostat in   
In contrast to bacterial endostatin, endostatin produced in yeast is soluble, and neither binds 
Congo Red, nor forms amyloid fibrils when examined using TEM (not shown). A major 
difference in the isolation protocols is a denaturation step using 8 M urea during the isolation 
of endostatin from bacteria, but not from yeast. Since amyloid formation occurs via (partially) 
denatured intermediates18, we considered the possibility that this step may allow for the 
efficient stacking of endostatin monomers to form cross-β sheets. Therefore, we subjected 
soluble yeast endostatin to the same denaturation/renaturation protocol and examined the 
resulting preparation for cross-β sheet content using X-ray diffraction. Figure 2a shows that 
soluble endostatin produced in yeast does not show any signs of cross-β sheet formation. 
The diffraction pattern is typical for any amorphous globular protein and does not show a 
sharp reflection line at 4.7 Å. Furthermore, there is no perpendicular orientation of the 
diffuse reflection lines at 4.7 Å and 9-11 Å. The X-ray diffraction data are in line with our 
findings that soluble endostatin does not bind to Congo Red and does not form fibrils. 
However, after denaturation/renaturation we found extensive cross-β sheet formation in 
yeast-produced endostatin (Figure 2b). In addition to urea treatment, protein denaturation 
through freeze-thawing or heating also induced endostatin aggregation (not shown). We 
conclude that endostatin is a protein with a high propensity to form amyloid aggregates, a 
Figure 2.  
 
Conversion of soluble globular 
endostatin into amyloid 
endostatin. Endostatin pro-
duced in yeast was dialyzed 
against 8 M urea followed by 
extensive dialysis against H2O. 
During dialysis endostatin pre-
cipitates as a fine white solid. 
The samples were processed 
for X-ray diffraction analysis. 
(A) Diffraction pattern of 
untreated (yeast-produced) 
endostatin with no sign of 
cross-β sheet structure. (B) 
Diffraction pattern of urea-
treated endostatin with exten-
sive cross-β sheet formation. 
During solvent evaporation fibril 
formation occurred both verti-
cally and horizontally in the 
capillary, as evidenced by the occurrence of peaks at 90, 180, 270 and 0/360 degrees in the 
tangential scans corresponding to both d-spacings. The asterisk indicates the peak reflection of the 
10-11 Å d-spacing at 900. The arrow indicates the peak reflection of the 4.7 Å d-spacing at 1800. 
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process that is greatly enhanced when the protein undergoes (partial) denaturation. In this 
light it is interesting to note that the β- ҏsheet content measured in the endostatin crystal 
(25%) does not match the percentage of β-sheet content of the original solution (70%)17;24. 
This implies that the solution from which the crystal has grown contained a β-sheet-rich 
form(s) of endostatin that did not crystallize. Due to the intrinsic heterogeneity of cross-β 
sheet forming proteins, crystallization of such structures is notoriously difficult.     
 
Binding of  endostat in to  N1E-115 cel ls  requires cross-β  s t ructure 
The prototype amyloid protein is Aβ, a 40-42 amino-acid peptide that is found as insoluble 
aggregates in neuronal tissue and in the brain microvasculature of Alzheimer’s disease 
patients25. Like endostatin and many other amyloid proteins or peptides, Aβ is a naturally 
occurring cleavage product of a larger precursor protein25. In vitro, Aβ has toxic effects on 
both endothelial and neuronal cell types26-31. 
Based on the observed structural similarities between endostatin and Aβ we investigated 
whether endostatin would bind to and be toxic to neuronal cells. To this end we used the 
N1E-115 murine neuroblastoma cell line that can differentiate into post-mitotic neurons in 
vitro32.  First, we tested whether endostatin can bind to these cells. Soluble endostatin was 
labeled with FITC and was either left untreated or was treated to form amyloid aggregates 
as above. As controls we also used FITC-labeled amyloid β (Aβ) and human islet amyloid 
polypeptide (hIAPP). The latter peptides were used in two structural conformations: freshly 
resuspended (non-cross-β) and pre-aggregated (cross-β). Cells were exposed to soluble or 
aggregated endostatin, to Aβ or to hIAPP for 1 hour. Following extensive washing and 
fixation, binding of endostatin, Aβ and hIAPP to the cells was assessed by fluorescence 
microscopy. Figure 3a shows that soluble endostatin is found neither associated to the cells, 
nor inside the cells, nor on the matrix surrounding the cells. In contrast, the majority of 
amyloid endostatin is cell-associated. Some of the deposits localized to the matrix, and 
some were found inside the cells (see below). Like amyloid endostatin, both Aβ and hIAPP 
readily bound to the cells. Two distinct types of aggregates were observed. Small 
endostatin-like aggregates as well as larger aggregates that are not observed in the 
endostatin preparation. In the freshly resuspended (non-cross-β) peptides the small 
aggregates were not observed but larger aggregates were occasionally found to be cell-
associated (Figure 3). It is well known that the formation of extensive cross-β structure in 
these peptide aggregates may take days-weeks.  
When using high concentrations of soluble endostatin, we observed occasional protein 
aggregation in the tissue culture medium and these aggregates were found to bind to the 
cells (Figure 3a upper panel, arrow). This indicates once again the propensity of soluble 
endostatin to undergo structural changes leading to amyloid aggregation. Factors present in 
the medium or in the serum may promote this conversion.  
We reasoned that if cross-β structure underlies the binding of aggregated endostatin to the 
cells, amyloid β and hIAPP may compete for endostatin binding. We tested this by  
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Figure 3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Binding of amyloid aggregates to N1E-115 
neuroblastoma cells. (A) Neuronal N1E-115 cells,  
were incubated with either FITC-labeled 
aggregated amyloid endostatin, soluble endostatin, 
Aβ freshly resuspended, Aβ pre-aggregated for 
three weeks (Aβ amyloid), hIAPP freshly 
resuspended and hIAPP pre-aggregated for three 
weeks (hIAPP amyloid) (all at 5 µM) and washed. 
after 1 hour. The actin cytoskeleton was stained 
using Texas Red-conjugated phalloidin (red) and 
the DNA with DAPI (blue). All amyloid aggregates 
(left panels) bound N1E-115 cells. (B) N1E-115 
cells were pre-incubated for 6 hours with non-
fluorescent Aβ or hIAPP (at 5 µM) and the binding 
of FITC-labeled amyloid endostatin (1 hour, 5 µM) 
was subsequently tested as above. 
(C) Digital image analysis shows that pre-incubation of the cells with Aβҏ and, to a lesser extent, 
hIAPP diminishes endostatin binding (to 50 and 25% respectively), suggesting that the aggregates 
have common cellular binding sites. The bar diagram shows means of 10 randomly selected fields 
in the red channel to avoid bias.      
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incubating the cells for 6 hours with either Aβ or with hIAPP prior to incubation with amyloid 
endostatin for 1 hour. The binding of endostatin to the cells was then assessed by 
fluorescence microscopy and subsequent digital image analysis. Figure 3b and 3c show that 
Aβ and, to a lesser extent, hIAPP compete with amyloid endostatin for binding to the N1E-
115 cells. Thus, amyloid endostatin shares cellular binding sites with other amyloid peptides, 
even though these peptides and endostatin do not share any overt primary sequence 
homology. We next extended these observations by analysing the binding of endostatin, Aβ 
and hIAPP to N1E-115 cells in more detail. To this end we allowed binding of the FITC-
labeled aggregates to the cells as above and, following extensive washing and staining of 
the actin cytoskeleton with Texas Red phalloidin, the cell-bound aggregates were examined 
by confocal microscopy. Figure 4 shows images of single cells and of highly zoomed 
fragments of the cell surface in which discrete single aggregates are visible. We found that 
the majority of all three amyloid aggregates are in close proximity to the cortical actin-
cytoskeleton that is connected to the plasma membrane (Figure 4). In addition, some of the 
aggregates are found inside the cells (arrows), indicating that at least some internalization of 
the aggregates can take place. 
Figure 4. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Localization of cell-associated amyloid aggregates. N1E-115 cells were grown on glass coverslips 
and were incubated for 1 hour with FITC-labeled amyloid endostatin, Aβҏ and hIAPP. Actin was 
visualized using Texas Red-conjugated phalloidin. The coverslips were analyzed by confocal 
microscopy. Whole cell images (upper panel) show localization of all three amyloids mainly to the 
cell surface. In addition, some of the aggregates show intracellular localization (arrows) (Bar, 10 
µm). Zoomed images of cell surface areas (lower panel) shows that all three types of amyloid 
aggregates are in close proximity to the plasma membrane-bound cortical actin cytoskeleton (Bar, 2 
µm). 
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Amylo id  but  not  so lub le endostat in  is  cy totox ic  to  N1E-115 neuroblastoma 
ce l ls  
Next, we analyzed whether the distinct forms of endostatin would be cytotoxic to 
differentiated N1E-115 cells and compared their cytotoxicity with that induced by Aβ. Figure 
5a shows that amyloid but not soluble endostatin binds to differentiated N1E-115 cells as it 
does to the undifferentiated cells (Figures 3,4). Furthermore, we found that a 24-hour 
exposure of these cells to either Aβ or to amyloid endostatin induced cell death, whereas 
soluble endostatin or buffer controls had no effect on neuronal cell viability (Figure 5). 
Amyloid peptides may induce either apoptosis or necrosis in neuronal and endothelial cells. 
Annexin V strongly binds to exposed phosphatidyl-serine, a marker for apoptotic cell death. 
We found that cells treated with amyloid endostatin, but not those treated with soluble 
endostatin, are highly positive for fluorescent annexin V (Figure 5c), indicating that 
endostatin-induced cell death is apoptotic in nature.    
Interestingly, a recent report showed the production of endostatin by neuronal cells and the 
localization of endostatin to Aβ plaques in Alzheimer’s disease brain33. However, the 
structural basis of this interaction was not examined. Given our finding that endostatin, like 
Aβ, has the propensity to form cross-β structure, a cross-β type interaction may account for 
their co-localization in vivo. Taken together, it seems likely that endostatin may affect 
neuronal cell function and survival, also in vivo.  
In addition to using neuronal N1E-115 cells we also used bovine pulmonary aortic 
endothelial cells (BPAEC). We found that amyloid endostatin, but not soluble endostatin, is 
highly cytotoxic to these cells as it is to the neuronal cells. In contrast, neither soluble nor 
amyloid endostatin was cytotoxic to primary human umbilical vein endothelial cells (HUVEC) 
nor to human dermal microvascular endothelial cells (HDMEC)(not shown). At present we 
do not know what determines the sensitivity of (endothelial or neuronal) cells to amyloid 
endostatin. Possibly, amyloid endostatin may exert its toxic effects by activating amyloid 
receptors on the cell surface like receptor for advanced glycation end products (RAGE) or 
scavenger receptors like CD3634;35.  
Can amyloid toxicity explain the antiangiogenic effect of endostatin? We found the formation 
of liver metastases by C26 murine colon cancer cells to be sensitive to treatment with 
endostatin. In this model both soluble and amyloid endostatin inhibited tumor growth, but 
neither form caused tumor regression36. Given the propensity of soluble endostatin to 
aggregate and the inability to control this phenomenon in vivo, it is impossible to assign 
antitumor activity to a specific structural form of endostatin.  
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Concluding remarks 
Although many reports have shown effects of either soluble or insoluble endostatin on cell 
behavior3, it is far from clear which mechanisms underlie which phenomena. Induction of 
apoptosis and inhibition of cell migration seem to be the most commonly found cellular 
effects3. Our results provide an explanation for the observed cytotoxic effects of endostatin. 
Amyloid formation often occurs in protein fragments that are taken out of their natural 
context (i.e. the full length protein), presumably due to partial denaturation18. The 
hydrophobicity of the peptide sequence and the propensity of the sequence to form β-sheets 
are critical determinants of protein aggregation37. Recently it was found that two unrelated 
protein fragments (which, unlike Aβҏ are not related to any disease) become highly toxic 
upon aggregation38. Taken together, it seems likely that protein aggregation per se, 
independent of the primary amino-acid sequence, endows aggregated amyloid proteins with 
Figure 5. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Toxicity of amyloid endostatin. (A) N1E-115 cells were differentiated into post-mitotic neurons on 
glass coverslips and were subsequently treated overnight with either FITC-labeled soluble or with 
FITC-labeled amyloid endostatin. Following extensive washing and fixation, binding of endostatin to 
the cells was visualized with fluorescence microscopy. Merged bright field and fluorescence images 
are shown. Only amyloid endostatin binds to the differentiated neuronal cells. (B) Differentiated 
N1E-115 cells were treated for 24 hours with either buffer, soluble endostatin (25 µM) (Esol), amyloid 
endostatin (25 µM) (EAm), or with Aβҏ (25 µM). Cell viability was subsequently assessed by Trypan 
blue exclusion, counting both adherent and detached cells. The bar diagram shows means of 
triplicate samples. (C) N1E-115 cells were differentiated on glass coverslips and were subsequently 
treated with either soluble or with amyloid endostatin. Following fixation, the cells were stained with 
annexin V-FITC to visualize exposed phosphatidylserine. Detaching cell clusters that are associated 
with endostatin aggregates are highly positive for annexin V.           
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an inherent toxicity38. The results presented here suggest that endostatin can be added to 
the list of ‘toxic-when-aggregated’ proteins. It is to be expected that this list will become 
much longer in the near future. It is important to note that the extent of toxicity is determined 
to a large extent by the level of aggregation and the structural basis of aggregation38. These 
phenomena, in turn, greatly depend on a number of parameters including protein production 
and storage protocols, pH, and choice of solvents.  
Our results show that endostatin-induced cytotoxicity is restricted to the aggregated amyloid 
form. Endostatin is toxic to endothelial7-9 and neuronal (this study) cells. These cell types are 
also particularly sensitive to amyloid deposits26-31. Our finding that endostatin is a protein 
with amyloid properties may therefore explain the cell-type specificity of its cytotoxicity. If 
endostatin exerts its effect through cellular receptors, its bioactivity will depend on the 
expression of such receptors on the target cells. Therefore, we are presently studying 
whether endostatin can activate receptors that are known to bind to cross-β sheet peptides. 
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Summary 
Tissue-type plasminogen activator (tPA) regulates fibrin clot lysis by stimulating the 
conversion of plasminogen into the active protease plasmin1. Fibrin is required for efficient 
tPA-mediated plasmin generation and thereby stimulates its own proteolysis. Several 
regions in fibrin can bind to tPA1, but the structural basis for this interaction is not known. 
Amyloid β (Aβ) is a peptide aggregate that is associated with neurotoxicity in Alzheimer’s 
disease brain2. Like fibrin, it stimulates tPA-mediated plasmin formation3-5. Intermolecular 
stacking of peptide backbones in β-sheet conformation underlies cross-β structure in 
amyloid peptides6. We show here that fibrin-derived peptides adopt cross-β structure and 
form amyloid fibers. This correlates with tPA binding and stimulation of tPA-mediated 
plasminogen activation. Prototype amyloid peptides including Aβ and islet amyloid 
polypeptide (IAPP, associated with pancreatic β cell toxicity in type II diabetes7) have no 
sequence similarity to the fibrin peptides but also bind to tPA and can substitute for fibrin in 
plasminogen activation by tPA. Moreover, the induction of cross-β structure in an otherwise 
globular protein (endostatin) endows it with tPA-activating potential. Our results classify tPA 
as a multiligand receptor and show that the common denominator in tPA-binding ligands is 
the presence of cross-β structure.  
 
Materials and methods 
Pept ides 
The following peptides were synthesized (Pepscan Systems, Lelystad, The Netherlands):  
Fibrin peptides: FP13: KRLEVDIDKIRS; FP10: KRLEVDIDIK; 
Aβ: DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVV;  
hIAPP: KCNTATCATQRLANFLVHSSNNFGAILSSTNVGSNTY;  
chIAPP: SNNFGAILSS; cmIAPP: SNNLGPVLPP.  
Purity of the peptides was analyzed both by mass spectroscopy and by using high 
performance liquid chromatography (HPLC). The freeze-dried peptides were resuspended in 
phosphate-buffered saline (PBS). The short peptides FP13 and chIAPP immediately form 
cross-β sheet structure following resuspension as judged by CD spectroscopy and Congo 
Red binding. Cross-β sheet formation in the longer peptides Aβ and hIAPP required 
incubation at room temperature for three weeks. 
 
Endostat in  
Soluble recombinant globular human endostatin was kindly provided by Dr. Kim Lee Sim 
from Entremed Inc. (Rockville, Maryland, USA). Insoluble recombinant human endostatin 
was prepared from bacteria exactly as described8. 
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Plasmin act iv i ty  assay 
Plasminogen (1 µM) was incubated with tPA (200 pM) and the individual peptides (5 µM) or 
the control buffer without cofactor. Samples were taken from the reaction mixture at the 
indicated time points and plasmin generation was stopped by addition of ε-aminocaproic 
acid (εACA) (0.5 M) and EDTA (0.5 M). The chromogenic substrate S-2251 (Chromogenix 
AB, Mölndal, Sweden) was then added to the samples and plasmin activity was assessed by 
on-line measurement of S-2251 conversion at 405 nm.  
 
tPA act iv i ty  assay 
tPA, at the indicated concentrations, was mixed with the individual peptides (5 µM) or the 
control buffer without cofactor and the chromogenic substrate S-2765 (Chromogenix AB, 
Mölndal, Sweden). tPA activity was then assessed by on-line measurement of S-2765 
conversion at 405 nm. 
  
Sol id  phase b ind ing assay 
Peptide solutions were coated onto plastic 96-well plates. The plates were subsequently 
washed with phosphate-buffered saline (PBS) and were blocked in PBS containing 0.1% 
BSA. tPA was subsequently allowed to bind at the indicated concentrations. Binding of tPA 
to the peptides was assessed by using anti-tPA (PoAb 385R, American Diagnostica, 
Greenwich, CT) followed by horseradish peroxidase (HRP)-conjugated Swine-anti-Rabbit 
IgG (DAKO). Background tPA binding to the plastic wells was assessed in all experiments 
by omitting the tester peptides from the initial coating step. After extensive washing, HRP 
activity was measured by substrate (1,2-phenylenediamine) conversion and measurement of 
the OD at 490 nm. Background values were subtracted from the test values and Kd’s were 
calculated from the binding curves by using GraphPad Prism software (GraphPad Software, 
San Diego CA, USA).  
 
Congo red s ta in ing 
Single drops of peptide solutions in H2O were spotted onto glass coverslips and were 
subsequently air-dried. The peptide material was then stained with Congo Red (Sigma) 
according to the manufacturer’s protocol. 
 
Thiof lav in T b ind ing 
Thioflavin T was added to the peptide solutions (0.1 mg/ml) in 50 mM glycine (pH 9.0) at the 
indicated concentrations. Following excitation at 435 nm fluorescence emission was 
recorded at 485 nm in a Hitachi F4500 fluorescence spectrophotometer. Averaged values 
are shown of three independent measurements. 
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Circu lar  Dichro ism measurements 
Peptide solutions (0.1 mg/ml in H2O) were analyzed in a JASCO 600 CD spectropolarimeter. 
Averaged absorption spectra are shown of 5 single measurements from 190 to 240 nm. 
Ellipticity (Dg.cm2/dmol) is plotted against wavelength (nm). 
 
Transmiss ion e lect ron microscopy 
Peptide samples were applied to 400 mesh specimen grids covered with carbon-coated 
collodion films. After 5 min. the drops were removed with filter paper and the preparations 
were stained with 1% methylcellulose and 1% uranyl acetate. After washing in H2O, the 
samples were dehydrated in a graded series of EtOH and hexanethyldisilazane. 
Transmission electron micrographs were recorded at 60 kV using a JEOL-1 electron 
microscope. 
 
X-ray d i f f ract ion analys is  
Peptide solutions (1 mg/ml) were taken up in a glass capillary. The water was then allowed 
to evaporate over a period of several days. The samples were placed in the capillary, on a 
Nonius κCCD diffractometer. Scattering was measured using sealed tube MoKα radiation 
with a graphite monochromator on the CCD area detector for a period of 16 hours. 
Scattering from air and the capillary glass wall were subtracted using in-house software 
(VIEW/EVAL). The crystallite size was determined by the Scherrer formula 
Dav=(0.89λ)/(βcosθmax), in which Dav=average crystallite size in Ǻ; λ=wavelength; β=2θ width 
at half maximum value in radians. 
 
Results 
tPA-mediated p lasminogen act ivat ion by f ibr in-der ived pept ides  
One of the amino acid sequences within the fibrin β-chain that supports tPA binding and 
activation encompasses the 13 residues 148-1601. Based on the amino acid sequence of 
this region, we made two peptides: Fibrin-derived peptide 13 (FP13) (148-160: 
KRLEVDIDIKIRS) and FP10 (148-157: KRLEVDIDIK). First, we tested the capacity of the 
peptides to substitute for fibrin in stimulating tPA-mediated plasminogen activation. Addition 
of FP13, but not FP10, to a mixture of plasminogen and tPA lead to a potent increase in the 
generation of plasmin activity in time (Figure 1a).  
Next, we studied the ability of the peptides to bind to tPA by performing solid-phase binding 
assays. Surprisingly, we found that both peptides bound to tPA despite the fact that only 
FP13 activates tPA (Figure1 a-c). Since FP10 has a carboxy-terminal lysine residue (K), 
binding to this peptide could be mediated by the kringle domain(s) in tPA. In line with this 
notion, binding of FP10 to tPA is completely lost in the presence of the lysine analogue ε-
aminocaproic acid (εACA) (Figure 1d). In contrast, εACA inhibits the binding of tPA to FP13 
by only about 40%, indicating that this interaction is largely lysine-independent (Figure 1d).  
 
tPA is an amyloid receptor   101 
 
 
F ibr in-der ived pept ides form cross-  β ̣  sheets  
The above experiments show that the binding of tPA to the two peptides occurs through 
distinct types of interaction, one supporting tPA-mediated plasminogen activation, the other 
not. We considered the possibility that differences in the peptide structure could underlie the  
Figure 1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
tPA binding and plasminogen activation by fibrin-derived peptides. (A) Plasminogen (0.1 mg/ml) and 
tPA (200 pM) were incubated with the fibrin-derived peptides (5 µM) or with control buffer. The 
conversion of plasminogen into plasmin was followed over a period of time by measuring plasmin 
activity using a chromogenic substrate (S-2251). (B) Binding of FP13 to tPA. FP13 was coated onto 
plastic and was overlayed with the indicated concentrations of tPA. tPA binding was then assessed 
by using the polyclonal anti-tPA antibody 385R in an ELISA-type assay. (C) Binding of FP10 to tPA 
was assessed as in (B). (D) tPA binding to FP13 and FP10 was assessed as in (B) and (C) using 
200 nM tPA in the presence of the indicated concentrations of εACA. 
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difference in cofactor activity. The relative contribution of random coils, β-sheets and α-
helices to the structure of the peptides in solution was studied by circular dichroism 
measurements. Strikingly, we found that FP13 was in a 100% β-sheet conformation with a 
characteristic minimum at 215 nm and a maximum at 190 nm (Figure 2a). In contrast, FP10 
was completely random coiled with a minimum observed at 198 nm (Figure 2a). Therefore, it 
seems likely that structural differences underlie the differences in ability of these peptides to 
activate tPA. 
Given the high β-sheet content in FP13 and given the finding that amyloid β (Aβ) supports 
plasminogen activation by tPA3-5, we tested whether FP13 is an amyloid peptide with cross-
β sheet conformation. Congo Red binds to amyloid peptide aggregates, irrespective of the 
amino acid sequence9. Dried samples of FP10 and FP13 were stained with Congo Red and 
examined by light microscopy. Figure 2b shows that FP13 dried as aggregates that readily 
bound Congo Red, showing the characteristic green birefringence when examined under 
polarized light. In contrast, FP10 dried as a uniform film that did not bind Congo Red (not 
shown).  
Thioflavin T (ThT) is a fluorescent indicator of cross-β sheets in solution9. By incubating the 
peptide solutions with increasing concentrations of ThT and subsequent measurement of 
fluorescence emission, we found that FP13, but not FP10, enhanced ThT fluorescence 
(Figure 2c). Thus, the high content of β sheets in FP13 presumably reflects cross-β sheet 
conformation. The presence of cross-β sheets can be demonstrated by X-ray diffraction 
analysis10. When analyzed by X-ray diffraction (Figure 2d), FP13 caused a distinct diffraction 
pattern, with reflection maxima at 4.7, 11.7 and 23.4 Å. The fiber axis with its 4.7 Å hydrogen 
bond repeat distance is oriented along the vertical capillary axis. The 11.7 Å repeat is 
oriented perpendicular to that. The perpendicular orientation of the 4.7 Å and 11.7 Å 
distances is typical for cross-β sheets. The 23.4 Å reflection that, like the 11.7 Å reflection, is 
oriented horizontally, signals higher ordering in the inter-sheet direction. Rough estimation of 
the crystallite sizes from the width of the reflections gives 120 Å for the fiber direction and 
40-50 Å for the inter-sheet direction. This amounts to approximately 25 β-strands being 
hydrogen-bonded into an array of about 4 cross-β sheets. 
As a result of cross-β sheet formation, peptides may undergo fibrillogenesis6 and such fibers 
can be visualized using transmission electron microscopy (TEM). Single drops of peptide 
solutions were therefore examined by TEM. We found that FP13, but not FP10 (not shown), 
formed unbranched fibrils that were about 5 nm thick with lengths ranging from 250-1000 nm 
(Figure 2e). These dimensions are within the range of dimensions found for other amyloid 
peptides11. 
Thus, FP13 is an amyloid peptide with cross-β sheet conformation, it binds to tPA and it 
stimulates tPA-mediated plasminogen activation. In contrast, FP10 is in a random coil 
conformation and binds to tPA through its carboxy-terminal lysine residue without stimulating 
tPA-mediated plasmin formation.  
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Figure 2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Structural analysis of fibrin-derived peptides. (A)The 
absorbance of circularly polarized light by solutions of FP13 and 
FP10 (0.1 mg/ml) was analyzed in a circular dichroism 
spectropolarimeter at the indicated wavelengths. (B) Single 
drops of FP13 and FP10 (1 mg/ml in H2O) were air-dried and 
stained with Congo Red according to the manufacturer’s 
protocol. Microscopic analysis using non-polarized and 
polarized light shows that FP13, but not FP10 (not shown), 
binds Congo Red. (C) Solutions of FP13 and FP10 were 
incubated with the indicated concentrations of thioflavin T and 
fluorescence emission was measured at 485 nm. (D) X-ray 
diffraction analysis of FP13. The scattering as obtained on the 
2D detector is color-coded by intensity on a linear scale. The 
scattering intensity decreases as white-yellow-red-blue-black. 
The pattern shows diffraction maxima at 4.7, 11.7 and 23.4 Å. 
 In the lower panels, tangential scans along the 2θ scattering angles corresponding to all three d-
spacings show that the 4.7 Å scattering (hydrogen bonds) is oriented perpendicular to those at 11.7 
and 23.4 Å (1x and 2x inter-sheet distance). (E) Solutions of FP13 and FP10 were spotted on a 
carbon-coated grid and analyzed by transmission EM. FP13, but not FP10, shows unbranched 
amyloid-like fibers. Bar = 200 nm. 
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tPA b ind ing and p lasminogen act ivat ion by cross-β  sheet  pept ides 
i r respect ive of  the i r  amino ac id  sequence 
The above results prompted us to investigate the binding characteristics of several amyloid 
peptides to tPA. Aβ stimulates tPA-mediated plasmin formation3-5 but, to our knowledge, no 
binding data have been published. To test tPA binding to Aβ and to other amyloid peptides, 
we performed solid-phase binding assays and detected bound tPA by ELISA. Figure 3a 
shows that tPA binds to Aβ with high affinity (6.7 nM) as it does to the fibrin peptides. 
Human Islet Amyloid Polypeptide (hIAPP) is a 37-amino acid peptide with amyloidogenic 
properties that is found deposited in the Islets of Langerhans in the pancreas of type II 
diabetic patients. It acts as a diabetogenic factor, presumably by being toxic to the insulin-
producing β-cells7. The hIAPP amino acid sequence is unrelated to that of Aβ or the fibrin 
peptides. We found that, like Aβ and the fibrin peptides, hIAPP binds to tPA with high affinity 
(Kd=1.8 nM) (Figure 3b).  
Next, we tested the capacity of these two distinct pre-aggregated amyloid peptides (Aβ and 
hIAPP) to substitute for fibrin in stimulating tPA-mediated plasminogen activation. We found 
that both peptides greatly enhance tPA-mediated plasmin formation (Figure 3c). 
Interestingly, the same peptides did not stimulate tPA-mediated plasminogen activation 
when used immediately after solubilization (Figure 3c). Thioflavin T binding to both peptides 
increased gradually over a period of three weeks (not shown). Thus, the formation of cross-β 
structure in the peptides is accompanied by an acquired ability to enhance tPA-mediated 
plasmin generation.  
Whereas the rate of Aβ-stimulated plasmin formation is further enhanced during the 
reaction, that induced by hIAPP is not. We have found that during Aβ-stimulated plasmin 
formation limited proteolysis generates free internal lysines in Aβ (Kranenburg et al., 
submitted). This may enhance the reaction by allowing more plasminogen and tPA binding. 
The lack of further rate-enhancement during reactions with hIAPP may be explained by the 
fact that it has only one lysine residue that is located at the extreme N-terminus.  
One of the amyloidogenic regions in hIAPP encompasses amino acid residues 20–297;12-15. 
Diabetic mice, in contrast to humans, do not develop pancreatic amyloid because mouse 
IAPP (mIAPP) has a different amino acid sequence in this region and lacks the propensity to 
adopt cross-β structure. We tested the presence of cross-β structure in these ‘core’ regions 
in human and mouse IAPP (chIAPP, cmIAPP) by Congo Red binding and compared their 
ability to stimulate tPA-mediated plasminogen activation. As expected, Congo Red readily 
bound chIAPP, but not cmIAPP, showing green birefringence under polarized light (not 
shown). Figure 3d shows that chIAPP stimulated tPA-mediated plasmin formation, albeit 
less efficiently than the full length IAPP, whereas cmIAPP was ineffective. Taken together 
with the data on the fibrin peptides, we have shown that four amyloid peptides (FP13, Aβ, 
hIAPP, chIAPP) stimulate tPA-mediated plasmin formation, whereas two non-amyloid 
peptides (FP10, cmIAPP) do not. Therefore, the results strongly suggest that tPA binding 
and cofactor activity requires the presence of cross-β structure in the peptides. 
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Figure 3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 tPA binding and stimulation of plasminogen activation by Aβ and hIAPP.  The binding of tPA to (A) 
Aβҏ (B) hIAPP ҏ was tested as in Figure 1B. (C) The stimulation of tPA-mediated plasminogen 
activation by Aβ and hIAPP, either freshly resuspended or pre-aggregated for three weeks, was 
tested as in Figure 1A. (D) The activation of tPA by mouse and human “core” IAPP (cmIAPP, 
chIAPP) was tested as in Figure 1A. (E) FP13, hIAPP and Aβ were incubated with plasminogen and 
with increasing concentrations of tPA. Plasmin formation was then assessed as in Figure 1. The 
measured rates of plasmin generation in time with and without the peptides were then used to 
calculate the extent to which plasmin generation was stimulated by the peptides. These values were 
subsequently plotted against the tPA concentrations. The peptides loose their rate-enhancing effect 
at higher tPA concentrations. (F) tPA, either at 0.2 nM or at 2 nM, was incubated with FP13, Aβ and 
hIAPP together with S-2765, a chromogenic peptide substrate for tPA. tPA caused substrate 
conversion, but none of the cross-β peptides stimulated tPA enzymatic activity. 
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How do cross-β peptides cause enhanced plasminogen activation? Like fibrin, they could act 
as scaffolds by promoting the interaction between enzyme (tPA) and substrate 
(plasminogen). Alternatively, cross-β peptides may stimulate tPA enzymatic activity. With 
increasing tPA and plasminogen concentrations one would expect scaffold effects to 
diminish. In our assay, the tPA concentration is limiting. Therefore, we performed 
plasminogen activation assays with increasing concentrations of tPA, using FP13, hIAPP 
and Aβ as cofactors. Figure 3e shows that the stimulatory effect of the cross-β peptides on 
plasmin generation is lost with increasing concentrations of tPA. Next, we tested whether the 
cross-β peptides would stimulate tPA enzymatic activity. Figure 3f shows that none of the 
peptides tested (FP13, IAPP, Aβ) had a stimulatory effect on the conversion of the 
chromogenic peptide substrate S-2765 by tPA, neither at low (0.2 nM) nor at high (2 nM) 
concentrations of the enzyme. Thus, cross-β peptides act as scaffolds for efficient 
plasminogen conversion by tPA without modulating tPA activity.  
Finally, we tested whether cross-β sheet formation in larger proteins would also support tPA-
mediated plasminogen activation. Firstly, it should be noted that cross-β sheet formation 
occurs during the polymerization of fibrinogen into fibrin as measured by Raman 
spectroscopy16 and that this is accompanied by tPA-activating potential. Secondly, we have 
recently found that endostatin, a 20 kDa fragment of the extracellular matrix protein collagen 
XVIII, has the propensity to form cross-β structure and to aggregate into amyloid deposits 
(Figure 4a). Endostatin can also be isolated in a soluble globular form that does not form 
cross-β sheets (Figure 4a). These two forms of endostatin allowed us to compare the 
capacity of a single larger protein (20 kDa) in two distinct conformations (cross-β versus 
non-cross-β) in the stimulation of tPA-mediated plasminogen activation. Figure 4b shows 
that endostatin with cross-β structure potently stimulates tPA-mediated plasminogen 
activation like all the other cross-β peptides, but that globular endostatin has no effect. Thus, 
the correlation between cross-β structure and the ability to stimulate tPA-mediated 
plasminogen activation holds for (short) peptides as well as for larger proteins. 
 
Discussion 
Our results provide evidence that tPA is a multiligand receptor for proteins that display 
cross-β structure. Upon binding to tPA, all cross-β ligands tested stimulate tPA-mediated 
plasmin formation. The tPA-binding peptide sequences in fibrin have been identified1 but no 
structural data are available that show the basis of this interaction. Early data on the 
structural changes that are associated with the conversion of fibrinogen into fibrin show that 
this is accompanied by a general increase in β-sheet content and by the formation of 
hydrogen bonds between lateral fibrin molecules16. This type of interaction within the fibrin 
meshwork is similar to that underlying the cross-β sheet structure in amyloid peptide 
aggregates6. Furthermore, we show here that one of the isolated tPA-binding regions in 
fibrin that supports plasminogen activation has cross-β structure. Thus, also in fibrin, tPA 
may bind to cross-β sheet-forming regions. It has long been known that aged fibrin deposits  
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can bind Congo Red in tissue sections17. We have been able to corroborate these data in 
vitro by showing the selective staining of specific regions within a fibrin clot with Congo Red 
and by enhanced thioflavin T fluorescence during clot formation (O.K. and B.B., unpublished 
observations). In addition, serum amyloid P component (SAP), as well as Aβ itself, 
modulates the assembly and lysis of fibrin clots18-20. Taken together, the available data 
suggest that the control of fibrin assembly and fibrinolysis is regulated by cross-β structures 
and amyloid-binding proteins. The identification of tPA as a general cross-β sheet-binding 
molecule strongly reinforces this notion. In contrast to tPA, urokinase-type plasminogen  
Figure 4. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enhanced plasminogen activation by cross-β−structured endostatin. (A) X-ray diffraction analysis of 
two distinct forms of endostatin. The left panel shows globular endostatin with no detectable cross-β 
sheets. The right panel shows insoluble endostatin with abundant cross-β sheets. The scattering as 
obtained on the 2D detector is color-coded as in Figure 2D. The pattern shows diffraction maxima at 
4.7 and 10-11 Å. The fiber axis (hydrogen bond direction) with 4.7 Å repeat is oriented vertically. 
The 10-11 Å repeat is preferentially oriented perpendicular to that, as indicated by the asterisk. 
Tangential scans along the 2θ scattering angles corresponding to both d-spacings in the lower 
panel show that the scattering at 4.7 Å is oriented vertically with the maximum intensity at 1800 
indicated by the arrow. The reflection at 10-11 Å is oriented horizontally with the maximum at 900 
indicated by the asterisk. (B) Stimulation of tPA-mediated plasminogen activation by the two distinct 
forms of endostatin was assessed as in Figure 1A. 
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activator (uPA) is not activated by Aβ4. We are presently further investigating whether uPA is 
regulated by cross-β structure.  
Like fibrin, partially denatured proteins can stimulate tPA-mediated plasminogen 
activation21;22 and are prone to form cross-β sheets11. Our finding that the interaction of tPA 
with cross-β sheet peptides and proteins invariably leads to tPA-mediated plasminogen 
activation strongly suggests that these two phenomena are causally related. Thus, the 
formation of cross-β sheets endows protein aggregates (for instance endostatin) with tPA 
binding and plasminogen-activating potential. tPA may play a general role in the removal of 
cross-β sheet-containing (improperly folded) proteins by inducing their plasmin-mediated 
proteolysis. In this way tPA could prevent the accumulation of toxic protein aggregates in the 
circulation. Indeed, Aβ can induce its own destruction by activating the tPA/plasmin system 
in cultures of neuronal cells23;24. 
An important new insight is that protein aggregates, not necessarily related to any disease, 
are toxic to cells irrespective of their identity25. This implies that a common structural 
element rather than a specific amino acid sequence induces toxicity. Cross-β sheets are 
likely to represent such a sequence-independent structural element that can mediate toxic 
effects on cells. Hence, there must be molecular mediators of toxicity that recognize cross-β 
structure. With the discovery of tPA as a general cross-β sheet-binding protein we have 
identified a molecule that may contribute to the general cell toxicity induced by protein 
aggregates. Interestingly, tPA has been identified as an essential mediator of neuronal cell 
death following ischemia or excitotoxic injury in the brain26;27. By analogy, tPA may play a 
role in neuronal and endothelial cell death induced by Aβ and/or in IAPP-induced β-cell 
death.  
Further work is needed to assess whether activation of the tPA/plasminogen system by 
protein aggregates (including IAPP and Aβ) prevents toxicity of the aggregates through their 
destruction, or whether tPA plays a role in mediating toxicity. These possibilities are not 
mutually exclusive. A critical variable between distinct aggregates will be their differential 
sensitivity to plasmin-mediated destruction.  
 
Acknowledgements 
This work was supported, in part, by the Dutch Cancer Society (UU 1999-2114).  
 
References 
 1.  Nieuwenhuizen, W. Fibrin-mediated plasminogen activation. Ann N Y Acad Sci, 936: 237-246, 
2001. 
 2.  Selkoe, D. J. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev, 81: 741-766, 2001. 
 3.  Kingston, I. B., Castro, M. J., and Anderson, S. In vitro stimulation of tissue-type plasminogen 
activator by Alzheimer amyloid beta-peptide analogues. Nat Med, 1: 138-142, 1995. 
 4.  Wnendt, S., Wetzels, I., and Gunzler, W. A. Amyloid beta peptides stimulate tissue-type 
plasminogen activator but not recombinant prourokinase. Thromb Res, 85: 217-224, 1997. 
tPA is an amyloid receptor   109 
 
 5.  Van Nostrand, W. E. and Porter, M. Plasmin cleavage of the amyloid beta-protein: alteration of 
secondary structure and stimulation of tissue plasminogen activator activity. Biochemistry, 38: 
11570-11576, 1999. 
 6.  Lansbury, P. T., Jr. In pursuit of the molecular structure of amyloid plaque: new technology 
provides unexpected and critical information. Biochemistry, 31: 6865-6870, 1992. 
 7.  Hoppener, J. W., Ahren, B., and Lips, C. J. Islet amyloid and type 2 diabetes mellitus. N Engl J 
Med, 343: 411-419, 2000. 
 8.  Boehm, T., Folkman, J., Browder, T., and O'Reilly, M. S. Antiangiogenic therapy of experimental 
cancer does not induce acquired drug resistance. Nature, 390: 404-407, 1997. 
 9.  Elghetany, M. T. and Saleem, A. Methods for staining amyloid in tissues: a review. Stain Technol, 
63: 201-212, 1988. 
10.  Serpell, L. C., Fraser, P. E., and Sunde, M. X-ray fiber diffraction of amyloid fibrils. Methods 
Enzymol, 309: 526-536, 1999. 
11.  Rochet, J. C. and Lansbury, P. T., Jr. Amyloid fibrillogenesis: themes and variations. Curr Opin 
Struct Biol, 10: 60-68, 2000. 
12.  Nilsson, M. R., Nguyen, L. L., and Raleigh, D. P. Synthesis and purification of amyloidogenic 
peptides. Anal Biochem, 288: 76-82, 2001. 
13.  Goldsbury, C., Goldie, K., Pellaud, J., Seelig, J., Frey, P., Muller, S. A., Kistler, J., Cooper, G. J., 
and Aebi, U. Amyloid fibril formation from full-length and fragments of amylin. J Struct Biol, 130: 
352-362, 2000. 
14.  Jaikaran, E. T., Higham, C. E., Serpell, L. C., Zurdo, J., Gross, M., Clark, A., and Fraser, P. E. 
Identification of a novel human islet amyloid polypeptide beta-sheet domain and factors 
influencing fibrillogenesis. J Mol Biol, 308: 515-525, 2001. 
15.  Westermark, P., Engstrom, U., Johnson, K. H., Westermark, G. T., and Betsholtz, C. Islet amyloid 
polypeptide: pinpointing amino acid residues linked to amyloid fibril formation. Proc Natl Acad Sci 
U S A, 87: 5036-5040, 1990. 
16.  Hudry-Clergeon, G., Freyssinet, J. M., Torbet, J., and Marx, J. Orientation of fibrin in strong 
magnetic fields. Ann N Y Acad Sci, 408: 380-387, 1983. 
17.  Lendrum, A. C., Slidders, W., and Fraser, D. S. Renal hyalin. A study of amyloidosis and diabetic 
fibrinous vasculosis with new staining methods. J Clin Pathol, 25: 373-396, 1972. 
18.  Meyer, K., Smith, R., and Williams, E. C. Inhibition of fibrin polymerization by serum amyloid P 
component and heparin. Thromb Haemost, 57: 345-348, 1987. 
19.  Ku, C. S. and Fiedel, B. A. Modulation of fibrin clot formation by human serum amyloid P 
component (SAP) and heparin. J Exp Med, 158: 767-780, 1983. 
20.  Merkle, D. L., Cheng, C. H., Castellino, F. J., and Chibber, B. A. Modulation of fibrin assembly and 
polymerization by the beta-amyloid of Alzheimer's disease. Blood Coagul Fibrinolysis, 7: 650-658, 
1996. 
21.  Machovich, R. and Owen, W. G. Denatured proteins as cofactors for plasminogen activation. Arch 
Biochem Biophys, 344: 343-349, 1997. 
22.  Radcliffe, R. and Heinze, T. Stimulation of tissue plasminogen activator by denatured proteins and 
fibrin clots: a possible additional role for plasminogen activator? Arch Biochem Biophys, 211: 750-
761, 1981. 
23.  Tucker, H. M., Kihiko, M., Caldwell, J. N., Wright, S., Kawarabayashi, T., Price, D., Walker, D., 
Scheff, S., McGillis, J. P., Rydel, R. E., and Estus, S. The plasmin system is induced by and 
degrades amyloid-beta aggregates. J Neurosci, 20: 3937-3946, 2000. 
24.  Tucker, H. M., Kihiko-Ehmann, M., Wright, S., Rydel, R. E., and Estus, S. Tissue plasminogen 
activator requires plasminogen to modulate amyloid-beta neurotoxicity and deposition. J 
Neurochem, 75: 2172-2177, 2000. 
110 Chapter 7 
 
25.  Bucciantini, M., Giannoni, E., Chiti, F., Baroni, F., Formigli, L., Zurdo, J., Taddei, N., Ramponi, G., 
Dobson, C. M., and Stefani, M. Inherent toxicity of aggregates implies a common mechanism for 
protein misfolding diseases. Nature, 416: 507-511, 2002. 
26.  Chen, Z. L. and Strickland, S. Neuronal death in the hippocampus is promoted by plasmin-
catalyzed degradation of laminin. Cell, 91: 917-925, 1997. 
27.  Tsirka, S. E., Gualandris, A., Amaral, D. G., and Strickland, S. Excitotoxin-induced neuronal 
degeneration and seizure are mediated by tissue plasminogen activator. Nature, 377: 340-344, 
1995. 
  
 
 Chapter 8 
 
Brief report: Fibrin Degradation Products 
induce endothelial cell detachment and 
inhibit tumor growth 
 
Ar ie  Rei jerkerk  
Tom A.  Dr ix ler  
Col inda J .  M.  Aarsman 
Inne H.M.  Bore l  Rinkes 
Emi le  E.  Voest  
Mar t i jn  F .B.G.  Gebbink  
 
 
 
 
112 Chapter 8 
 
Summary 
Inhibition of angiogenesis is an attractive approach to inhibit tumor growth. Several 
endogenously produced proteolytic fragments have been identified that inhibit angiogenesis. 
We recently demonstrated that the angiogenesis inhibitor endostatin is a cofactor for tPA-
mediated plasminogen activation and induces tPA-mediated plasminogen-dependent cell 
detachment. During fibrinolysis tPA is activated by fibrin and fibrin fragments. Moreover, 
fibrin fragments are often found in the circulation of cancer patients. Therefore, we tested the 
hypothesis that fibrin fragments also induce endothelial cell detachment and inhibit tumor 
growth. We find that plasmin-generated fibrin degradation products (FDPs) induce 
detachment of bovine pulmonary endothelial cells and that FDPs inhibit the growth of 
subcutaneous tumors in mice. Our results support the idea that tPA-activating proteolytic 
fragments in general inhibit angiogenesis and tumor growth. 
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Introduction 
The hemostatic system maintains the liquid flow of blood vessels by regulating fibrin 
deposition and platelet adherence. Upon vessel injury the coagulation system is activated 
and initiates the formation of polymerized fibrin through cleavage of fibrinogen by thrombin. 
Fibrin together with activated platelets forms a provisional barrier that occludes the vessel. 
Activation of the fibrinolytic system is needed for clot lysis and repair of injury. The serine 
protease plasmin is involved in fibrin degradation. Plasmin is formed upon cleavage of the 
zymogen plasminogen by plasminogen activators, urokinase-type plasminogen activator 
(uPA) and tissue-type plasminogen activator (tPA). In contrast to uPA, tPA activity is 
stimulated by a cofactor. Fibrin and degraded fibrin are well known stimulators of tPA-
mediated plasminogen activation. 
The involvement of the hemostatic system in angiogenesis and cancer is becoming 
increasingly clear1. Fibrin as well as other extracellular matrix proteins that are part of a 
provisional matrix support endothelial cell attachment and facilitate migration and 
proliferation of endothelial cells. Platelets contain and secrete numerous regulators of 
angiogenesis2. Within the past decade proteins of the hemostatic system, and more 
particularly, cryptic fragments thereof, have been shown to inhibit tumor growth1. Examples 
of proteolytic fragments that inhibit tumor growth include angiostatin, endostatin, 
prothrombin fragments and anti-angiogenic antithrombin (chapter 9, table). Recently, we 
have shown that endostatin, a carboxy-terminal fragment of collagen XVIII, potently 
stimulates plasminogen activation by tPA and induces tPA-dependent plasminogen-
mediated endothelial cell detachment3;4. Fibrin degradation products (FDPs) also stimulate 
plasminogen activation through tPA. Moreover, FDPs are present endogenously in the 
circulation of patients with cancer5. Here, we tested the hypothesis that fibrin fragments with 
tPA stimulatory activity are anti-tumorigenic6.  
 
Materials and methods 
Reagents  
Human fibrinogen and Thioflavin T were purchased from Sigma Chemical Co (St. Louis, 
MO). Human thrombin was from American Diagnostica (Greenwich, CT). tPA and plasmin 
substrate S-2251 were from Chromogenix AB (Mölndal, Sweden). Urokinase was from 
Calbiochem (La Jolla, CA). 
 
Pur i f ica t ion o f  prote ins 
Plasminogen was purified by a modification of the procedure of Deutsch and Mertz33. 
Human plasma was diluted three times in H2O and passed through a lysine-Sepharose 
column equilibrated with 30 mM phosphate buffer (pH 7.4), 3 mM 
ethylenediaminetetraacetate (EDTA). After washing the column with 30 mM phosphate (pH 
7.4), 500 mM NaCl, 3 mM EDTA, the plasminogen was eluted with 30 mM phosphate (pH 
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7.4), 200 mM ε-aminocaproic acid (εACA), 3 mM EDTA. εACA acid was removed by 
extensive dialysis against H2O at 4oC and the plasminogen was stored at –80oC. Plasmin 
was produced as described in Walker and Nesheim34. In short, 1 mg/ml plasminogen in 50 
mM Tris (pH 8.0), 150 mM NaCl, 25% glycerol, 50 mM εACA was activated by the addition 
of 50 U/ml urokinase at 37oC. The solution was loaded onto benzamidine-Sepharose and 
plasmin was eluted with 50 mM Tris (pH 8.0), 150 mM NaCl containing 20 mM benzamidine. 
Plasmin containing fractions were precipitated by dialysis against 80% saturated ammonium 
sulphate, resuspended in 50% glycerol and stored at –20oC. Plasmin was characterized 
using S-2251 and SDS-PAGE analysis. 
 
Preparat ion of  f ib r in degradat ion products  
Cross-linked fibrin was made by incubating 5 mg/ml fibrinogen with 8 nM thrombin at 37oC in 
the presence of 5 mM CaCl2 for 5 hr. Fibrin degradation products were generated by 
digesting the fibrin clot with 35 nM plasmin overnight at 37oC. Plasmin was inactivated by 
addition of 1 mM diisopropyl fluorophosphate. 
 
Endothel ia l  ce l l  cu l ture 
Primary endothelial cells, bovine pulmonary arterial endothelial cells (BPAEC), were 
obtained from the American Type Culture Collection (Rockville, MD). BPAEC were cultured 
in Dulbecco’s Modified Essential Medium (DMEM) (Gibco Laboratories, Grand Island, NY) 
supplemented with 20% non heat-inactivated fetal calf serum (FCS) and antibiotics.  
 
Plasminogen act ivat ion assay 
Cofactor activity of FDPs was determined using a plasminogen activation assay. Different 
concentrations of FDPs were added to HBS buffer (20 mM Hepes, 4 mM KCl, 137 mM NaCl, 
3 mM CaCl2, 0.1 % BSA, pH 7.4) containing 50 µg/ml plasminogen. The reactions were 
started at 37oC by the addition of tPA at a final concentration of 30 U/ml. At different time 
points, 20 µl samples were taken and the reaction was stopped with 20 µl buffer containing 
150 mM εACA, 150 mM EDTA. Plasmin activity was determined in 96-well plates by adding 
20 µl chromogenic substrate S-2251 (2.5 mM). Increase in absorbance was measured at 
405 nm for 10 min and plasmin activity was calculated as ∆mOD/min. 
 
Detachment  assay 
BPAEC were seeded onto 24-well culture plates and grown to confluency. After washing 
with phosphate-buffered saline (PBS), FDPs were added in DMEM, containing 10% FCS. 
After 48 hours detached cells were removed and the remaining attached cells were counted 
after trypsinization. Percent endothelial cell detachment was calculated from the number of 
control cells – the number of treated cells / the number of control cells x 100%. 
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Tumor exper iments  
Male 6 to 8 week old BALB/c mice (General Animal Laboratory, University Medical Center 
Utrecht, The Netherlands) were used. All mice were fed a diet of animal chow and water ad 
libitum. Experiments were performed according to the guidelines of the Utrecht Animal 
Experimental Committee, University Medical Center (Utrecht, The Netherlands). C26 colon 
carcinoma cells were detached by brief trypsin exposure and after washing with PBS. 1x106 
C26 cells were inoculated subcutaneously. FDPs or control solvent was given by 
subcutaneous daily injection at a dose of 20 mg/kg/day. Tumor diameters were determined 
by calliper and volume was calculated with the formula: width2 x length x 0.52. 
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Results 
Fibrin degradation products (FDPs) were generated by cleaving polymerized fibrin with 
plasmin. FDPs stimulate tPA-mediated plasminogen activation (Figure 1). We investigated 
the effect of different concentrations of FDPs on confluent monolayers of bovine pulmonary 
artery endothelial cells (BPAEC). Treatment of endothelial cells with 1 µM FDPs for 48 hours 
did not cause morphological changes or cell detachment. However, incubation with 4 µM 
and 10 µM of FDPs resulted in 22.8 ± 0.2% and 33.7 ± 0.1% detachment respectively 
(Figure 2).  
Antitumorigenic activity of  FDPs was assessed in a subcutaneous tumor model.  All mice 
had palpable tumors from day 4. Tumor volumes were followed every two days until tumor 
morbidity in the control group necessitated the termination of the experiment. Treatment with 
FDPs significantly reduced tumor growth. While tumors in control mice grew steadily over 
the whole treatment period to approximately 2.7 cm3 at day 11 (Figure 3), treatment with 
FDPs (20 mg/kg/day) resulted in a significant inhibition of tumor growth during the injection 
period (75% from day 6). To establish the antitumorigenic potential of FDPs we compared 
tumor growth in mice treated with endostatin (10 mg/kg/day), an inhibitor of tumor growth 
that also stimulates tPA-mediated plasminogen activation4. Tumor growth inhibition by FDPs 
was similar to the effects elicited by endostatin.  
 
Figure 1. 
 
In vitro characterization of FDPs. Varying 
concentrations of plasmin-degraded fibrin were 
added to plasminogen and tPA. At several time 
points samples were taken and generated 
plasmin was analyzed using chromogenic 
substrate S-2251. Plasmin activity is shown as 
the rate of substrate conversion. 
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Figure 2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FDPs cause endothelial cell detachment. (A) Bovine pulmonary artery endothelial cells were 
incubated with different concentrations of FDPs for 48 hours resulting in concentration-dependent 
cell detachment. (B) Endothelial cell detachment was quantified by calculating the number of control 
cells – number of treated cells divided by the number of control cells x 100. 
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FDPs inhibit tumor growth. Mice (n=4/group) 
were inoculated subcutaneously with 1x106 C26 
colon carcinoma cells and treated daily with 500 
µg FDPs, 500 µg endostatin or control solvent. 
Treatment with FDPs reduced tumor volume to 
25 % of control at day 11. Values represent the 
mean volume ±SEM. 
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Discussion 
We show here that plasmin-generated fragments of fibrin, FDPs, induce endothelial cell 
detachment and inhibit tumor growth. 
Others have shown similar inhibitory effects using plasmin-derived fragments of fibrinogen. 
First, fibrinogen fragment D, which comprises the tPA-binding domain of plasmin-degraded 
fibrinogen, increases endothelial monolayer permeability7 and causes detachment of bovine 
capillary endothelial cells8. These authors further show that cell detachment was due to the 
induced expression of tPA and uPA, subsequently leading to increased plasmin formation8. 
Second, plasmin-generated fibrinogen fragment E inhibits endothelial cell migration and tube 
formation in vitro and tumor growth in mice9;10. We used plasmin generated fragments of 
polymerized fibrin, which are known to circulate in cancer patients, and show that these 
fragments are deleterious for endothelial cells in vitro. Moreover and for the first time, we 
show that these tPA-stimulating fragments of fibrin inhibit tumor growth in mice. 
Our data add FDPs to a substantial list of proteolytic fragments or denatured derivatives of 
plasma components that inhibit tumor growth (chapter 9). Little is known about the molecular 
mechanism(s) by which these endogenous proteins exert their actions. It has been shown 
that denatured proteins, either induced by proteolytic cleavage or denaturing agents, gain 
tPA-binding properties11-14. We noticed that many endogenous angiogenesis inhibitors, 
including endostatin3, have the property to stimulate tPA-mediated plasminogen activation. 
This implicates that this type of angiogenesis inhibitors may share a common pathway that 
is induced by tPA binding proteins (see also chapter 9).  
May activation of tPA reduce tumor growth? tPA is expressed by endothelial cells upon 
stimulation by angiogenic molecules like VEGF15;16, tumor necrosis factor, epidermal growth 
factor17;18, basic fibroblast growth factor19 and thrombin20. Numerous studies revealed high 
expression of tPA in several human tumors21-25 and clinical studies indicate that high tPA 
levels are associated with good prognosis in cancer patients26-28. Interestingly, fibrinolytic 
therapy using tPA potentially inhibits pulmonary seeding of intravenously injected mammary 
carcinoma cells in rats29;30. Others have shown that excessive plasminogen activation blocks 
angiogenesis in mice. Complete inhibition of tumor-induced angiogenesis in PAI-1 deficient 
mice was due to the uncontrolled elevation of plasmin activity31. In addition, treatment with 
pentoxifylline, an agent that releases tPA, inhibited human tumor implant-induced 
angiogenesis32. Our results further support the hypothesis that excessive plasminogen 
activation can lead to inhibition of angiogenesis and tumor growth.  
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Abstract 
Tumor growth requires proteolytic activity. As a consequence, protein breakdown products 
are present in the circulation of cancer patients. Within the past decade a large number of 
proteolytic fragments have been identified that inhibit angiogenesis and tumor growth. The 
mechanism(s) of action of these inhibitors is still poorly understood. We recently found that 
the effects of the angiogenesis inhibitor endostatin on endothelial cells is critically dependent 
on the presence of cross-β structure, a structure also present in amyloidogenic polypeptides 
in plaques of patients with amyloidosis, such as Alzheimer’s disease. We also showed that 
cross-β structure containing endostatin is a ligand for tissue-type plasminogen activator 
(tPA). We noted that many angiogenesis inhibitors stimulate tPA-mediated plasminogen 
activation. Since the presence of cross-β structure is the common denominator in tPA-
binding ligands, we hypothesize that these endogenous antiangiogenic proteolytic fragments 
share features with amyloidogenic polypeptides. We postulate that the cross-β structural 
fold, is present in these antiangiogenic polypeptide fragments and that this structure 
mediates the inhibitory effects. The hypothesis provides new insights in the potential 
mechanisms of antiangiogenesis and offers opportunities to improve the use of these 
inhibitory fragments.  
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Background 
Angiogenesis, the formation of new blood vessels out of pre-existing vasculature, occurs in 
physiological and pathological processes, including embryonic development, the menstrual 
cycle, wound healing, inflammation and tumor growth (for review see1). In 1971, Folkman 
postulated that tumor growth is dependent on angiogenesis2. Accumulating evidence 
indicates that drugs that target the growing vasculature are promising new therapeutics for 
the treatment of cancer. Based on the concept that a primary tumor produces inhibitors of 
angiogenesis that can inhibit the outgrowth of metastases, the first endogenous 
angiogenesis inhibitor, termed angiostatin, was purified in the laboratory of Folkman in 
19943. The identification of angiostatin prompted the search for other angiogenesis 
inhibitors, resulting in the isolation of endostatin4, prothrombin fragment 1 and 25, cleaved 
antithrombin III6, fibrin(ogen) fragments7 (and AR unpublished) and many other inhibitory 
polypeptide fragments. Commonly, such antiangiogenic polypeptides are proteolytically 
cleaved or denatured derivates of endogenous proteins. Endostatin, angiostatin and a 
thrombospondin peptide are currently being tested in clinical trials8-10. 
In 1997, Folkman and colleagues reported that treatment of experimental tumors with 
endostatin induced complete regression11. These magnificent results from animal studies 
fueled the great expectations that already accompanied the proposed use of antiangiogenic 
therapy with endogenous inhibitors of angiogenesis. Nobel laureate Watson was quoted as 
saying that “Judah is going to cure cancer in two years” and publications in the media did 
increase the hope for cure by many cancer patients. However, the initial results could not be 
reproduced by others and diminished the initial enthousiasm12. In fact, controversies 
regarding the antitumor effects of endostatin arose and initiated a heated discussion about 
its efficacy12. The variability in endostatin bioactivity is still unexplained. Originally, 
endostatin was purified from tissue culture supernatant. In the in vivo experiments that 
showed dramatic tumor regression a recombinant denatured and insoluble form of 
endostatin produced in Escherichia coli was used11. In a number of subsequent studies 
endostatin has been used from a number of different sources that caused less dramatic, 
minor or even no effects13-16. For studies in patients, a soluble globular form is used, 
produced in Pichia pastoris (http://entremed.com/pdfs/endostatin_factsheet.pdf). 
However, this globular form has no or very little effect on endothelial cells17. We found that 
only denatured endostatin is toxic to cells18. We wondered how our findings could explain 
the observed variability in endostatin bioactivity and to what extent our observations are of 
value for the use of other angiogenesis inhibitors.   
 
Inherent  tox ic i ty  of  unfolded prote ins   
Similar to certain antiangiogenic polypeptides, toxic polypeptides involved in conformational 
diseases like Alzheimer’s disease (AD), light-chain amyloidosis, pancreatic islet amyloidosis 
and spongiform encephalopathies are also proteolytic fragments or conformationally 
changed forms of proteins. Just recently a common mechanisms has been implied for such 
protein misfolding diseases. It was shown that toxicity is an inherent property of aggregates 
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of denatured proteins and is not related to the amino acid sequence composition of the 
protein19. Ultimately, structurally altered proteins are deposited as insoluble fibrillar 
aggregates and form plaques. Fibrillar aggregates are classified as amyloid fibrils based on 
the presence of cross-β structure. Cross-β structures in amyloid fibrils are stacked β-sheets 
likely composed of flat and non-twisted β-strands. This will result in a unique and flat 2D β-
sheet surface, not seen in globular proteins. Many studies have indicated a close 
relationship between the presence of amyloid depositions and vascular damage. First, 
transmissible spongiform disease is associated with the presence of the abnormal form of 
prion protein that aggregates into amyloid fibrils. These prion depositions are toxic to a wide 
variety of cells, including cerebral endothelial cells20. In addition to neuronal degeneration, 
AD patients exhibit significant cerebrovascular pathology21;22. Furthermore, it is known that 
patients with AD often suffer from stroke and that hemorrhages are frequently present23. In 
vitro experiments revealed that amyloid β increases permeability of endothelial cell 
monolayers and induces apoptosis24;25. Other studies have shown that smooth muscle cells 
and endothelial cells are damaged in cerebral blood vessels of AD cases25-27. We recently 
showed that insoluble endostatin forms amyloid fibrils, suggesting that endostatin may 
induce apoptosis as a consequence of its amyloid structure18;28. Interestingly, in AD 
Table. Overview of antitumorigenic proteins with tPA stimulating activity. 
 
 Effect on angiogenesis or tumor 
growth 
Stimulation of tPA-mediated 
plasminogen activation 
Endostatin O'Reilly et al., 1997 Reijerkerk et al., 2003 
Thrombospondin1 Volpert et al., 1998 Silverstein et al., 1985; Silverstein 
et al., 1984; Silverstein et al., 1986 
Angiostatin2 O'Reilly et al., 1994 unknown 
Denatured ATIII O'Reilly et al., 1999 Machovich and Owen, 1997 
Prothrombin fragments  Rhim et al., 1998 Machovich et al., 1999 
βpep25 (Anginex)  Griffioen et al., 2001 Reijerkerk, unpublished 
Maspin  Zou et al., 1994 Sheng et al., 1998 
Histidine-proline-rich glycoprotein Juarez et al., 2002 Silverstein et al., 1985; Borza and 
Morgan, 1997 
Fibrin(ogen) degradation products Chapter 8 and Brown et al., 2002 Stewart et al., 1998 
Calreticulin (fragments), vasostatin  Pike et al., 1999 binds tPA, Allen and Bulleid, 1997 
Amphoterin3  Huttunen et al., 2002 Parkkinen and Rauvala, 1991 
 
1 Thrombospondin also binds the multiligand cross-β structure receptor CD3635;52. 
2 Angiostatin that is tested in clinical trials is made in Pichia pastoris. The original experiments 
however were performed with angiostatin prepared by proteolytic cleavage with elastase, followed 
by purification on a lysine-sepharose column and subsequent dialysis against H2O3. The latter 
method of purification leaves the possibility that fragments are present with amyloid properties. We 
therefore suggest that different forms of angiostatin may also yield differences in bioactivity. 
3 Amphoterin also binds the multiligand cross-β structure receptor RAGE34. 
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endostatin colocalized with amyloid-β positive plaques that were surrounded by focal 
gliosis29. Is the cross-β structure a candidate common denominator among antiangiogenic 
polypeptide fragments? 
 
The tPA connect ion  
It is established that denatured proteins can stimulate plasminogen activation by the serine 
protease tissue-type plasminogen activator (tPA)30. Amyloid fibrils such as amyloid β and 
prion protein markedly stimulate plasminogen activation by t-PA31;32. We found that the 
presence of cross-β structure is a prerequisite for tPA binding to and stimulation of tPA-
mediated plasminogen activation by fibrinogen fragments, islet amyloid polypeptide (IAPP) 
and endostatin28. Moreover, this structure mediated tPA-dependent endostatin-induced cell 
detachment17. Activation of tPA by amyloid polypeptides may induce excessive degradation 
of extracellular matrix with subsequent loss of cell attachment sites resulting in cell 
detachment and apoptosis17;33. We noticed that many antiangiogenic compounds, generated 
through proteolytical cleavage or denaturation, similarly stimulate tPA-mediated 
plasminogen activation (Table).  
 
Hypothes is  
It is intriguing that unrelated proteins lacking sequence homology acquire antiangiogenic 
activity upon proteolytic cleavage or denaturation and at the same time acquire the ability to 
stimulate tPA-mediated plasminogen activation. Toxicity of aggregates of denatured proteins 
is also independent of the amino acid sequence19. Taken together, this suggests that a 
common antiangiogenic pathway may exist that is induced by tPA binding proteins. Thus, 
we hypothesize that antiangiogenic polypeptide fragments contain the cross-β structure and 
Figure. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Schematic representation of the hypothesis. 
Globular protein Unfolded protein/
Protein fragment
Pro-angiogenic
Binds cross-β receptor
(tPA, RAGE, CD36)
Anti-angiogenic
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that this structure is the common denominator responsible for their antiangiogenic and 
antitumor effects. If this hypothesis is correct, other multiligand cross-β structure receptors in 
addition to tPA may also mediate the antiangiogenic response. There is good evidence that 
at least two other multiligand receptors, CD36 and the receptor for advanced glycation end-
products (RAGE) are involved34;35. A schematic presentation of our hypothesis is illustrated 
in the figure. 
 
Impl icat ions 
If correct, our hypothesis implies that (i) it is relevant to look at structural properties of these 
polypeptide inhibitors, rather than at their primary amino acid sequence and consider the 
possibility that an active drug requires a cross-β structure. (ii) That the inhibitory effect of the 
drugs listed in Table may be improved by adding factors that are known to increase amyloid-
mediated toxicity, such as LPS, TNFα and IFNγ36;37. (iii) It is necessary to use these 
polypeptide fragments with caution as they have a high probability to form toxic aggregates.  
If our hypothesis is correct tumor derived endogenous circulating inhibitors may have 
antiangiogenic their activity also as consequence of the cross-β structure. Besides their 
antiangiogenic activity, these circulating proteolytic fragments may however then also 
contribute to some of the clinical complications of cancer, such as amyloidosis or bleeding 
events. Such circulating unfolded polypeptide fragments with amyloid properties may help to 
explain the bad clinical condition of cancer patients with advanced disease. 
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The hemostatic system serves to maintain normal blood flow and protects us against blood 
loss after injury. Upon vessel injury the coagulation cascade is activated and initiates the 
formation of a thrombus, consisting of fibrin and activated platelets. This clot provides a 
provisional barrier that occludes the vessel. Subsequent activation of the fibrinolytic cascade 
is needed for clot lysis and repair of injury. Tissue repair is dependent on the formation of 
new blood vessels, a process called angiogenesis. Angiogenesis is not only necessary for 
tissue repair. In 1971, Folkman postulated that angiogenesis is also important for tumor 
growth. It is now well established that the hemostatic system controls angiogenesis and 
tumor growth. Fibrin is present in tumors and facilitates angiogenesis by supporting 
endothelial and tumor cell attachment, migration and proliferation. Moreover, fibrin is 
important for metastasis of circulating tumor cells. Studies in mice lacking components of the 
fibrinolytic system, including plasminogen, plasminogen activator and plasminogen activator 
inhibitor-1 (PAI-1) have implicated a role of these proteins in angiogenesis and tumor 
development and metastasis. Markers of active fibrinolysis and coagulation circulate in 
blood of cancer patients. Interestingly, breakdown products of circulating proteins of the 
hemostatic system such as angiostatin (a fragment of plasminogen), prothrombin fragment 1 
and 2 and antiangiogenic antithrombin III (aaATIII) can inhibit tumor growth. 
 
The subject of this thesis focuses on the role of the plasminogen activation system in 
cancer. The plasminogen activation system regulates fibrinolysis and controls cell migration 
and invasion by plasmin-mediated matrix proteolysis. Plasmin is formed upon cleavage of 
the zymogen plasminogen by plasminogen activators, urokinase-type plasminogen activator 
(uPA) and tissue-type plasminogen activator (tPA). In contrast to uPA, plasminogen 
activation by tPA requires a cofactor. Fibrin and degraded fibrin are well known cofactors of 
tPA-mediated plasminogen activation. Plasmin cleaves its substrates behind a basic amino 
acid (lysine or arginine). Free carboxy-terminal lysines or arginines provide high affinity 
binding sites for plasminogen and facilitate efficient activation by plasminogen activators. 
This subsequently leads to the formation of more plasminogen binding sites resulting in an 
amplification loop for plasminogen activation. Besides fibrin, a variety of cell types also have 
carboxy-terminal lysine-dependent binding sites for plasminogen that can mediate 
plasminogen activation. Plasminogen activation can be inhibited by lysine analogues such 
as ε-aminocaproic acid (εACA) or tranexamic acid. Studies with these lysine analogues have 
indicated the importance of carboxy-terminal lysine residues in cancer and angiogenesis.  
Thrombin-activatable fibrinolysis inhibitor (TAFI, carboxypeptidase U, R or plasma 
procarboxypeptidase B) is made by the liver and circulates in blood in its inactive form. 
Active TAFI was first isolated from fresh serum in 1990. When converted into its active form 
by thrombin, plasmin or trypsin, TAFI is a carboxypeptidase B-type enzyme that specifically 
cleaves carboxy-terminal lysine or arginine residues from proteins. Removal of carboxy-
terminal lysines and arginines from fibrin abrogates efficient plasminogen binding and 
consequently leads to decreased plasmin formation. Experiments in mice have indicated 
that TAFI is a regulator of fibrinolysis in vivo. Thrombin-mediated activation of TAFI is 
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stimulated 1250-fold by the endothelial cell receptor thrombomodulin which is expressed on 
endothelial cells and in tumors. We tested the hypothesis that TAFI controls tumor growth. 
 
In chapter 1 we give a literature overview of the plasminogen activation system in cancer. In 
addition we summarize possible ways to interfere with tumor growth by targeting this 
system. We conclude that proper angiogenesis and tumor growth depends on a perfect 
balance of coagulation and fibrinolysis. Consequently, disturbance of this balance, either by 
inhibition, but also by overstimulation of the fibrinolytic system might inhibit angiogenesis 
and tumor growth. We postulate that the development of molecules that lead to excessive 
proteolysis in the tumor may be a powerful antiangiogenic and antitumorigenic approach.  
To clarify the role of proteins involved in the regulation of fibrinolysis during angiogenesis, 
we have studied corneal vessel formation in mice deficient for urokinase-type plasminogen 
activator (uPA), tissue-type plasminogen activator (tPA), plasminogen, plasminogen 
activator inhibitor-1 (PAI-1) and thrombin-activatable fibrinolysis inhibitor (TAFI) (chapter 2). 
Our results corroborate earlier findings that angiogenesis in the mouse cornea is dependent 
on PAI-1 and, albeit minoraly, plasminogen. Although it is widely accepted that plasminogen 
is an important mediator of angiogenesis, corneal angiogenesis can occur in the absence of 
plasminogen. Others reported the involvement of membrane-type matrix metalloproteinases 
that are essential in this process. Our results suggest the presence of plasmin-independent 
mechanisms that can activate these proteases during corneal angiogenesis. Interestingly, in 
previous studies, we have shown that corneal neovascularization was almost completely 
inhibited by continuous treatment with angiostatin, a fragment of plasminogen. The results 
described in this thesis suggest that the antiangiogenic effect of angiostatin in vivo may not 
only be mediated through inhibition of plasminogen function. The absence of tPA, uPA or 
TAFI did not affect the formation of new vessels in the cornea. Others have shown that uPA 
antagonists can inhibit corneal neovascularization in rabbits and angiogenesis in mice. Our 
results therefore indicate that the antiangiogenic effects of uPA inhibitors in vivo may be 
largely due to other activities than direct uPA inhibition. 
Given the importance of the plasminogen activation system in tumor growth and metastasis, 
we next investigated whether TAFI plays a regulatory role in these processes. We analyzed 
subcutaneous tumor growth and experimental- and spontaneous metastasis formation in 
TAFI-deficient mice (chapter 3). Conceivably, disturbance of tightly controlled plasminogen 
activation in TAFI-deficient mice might cause decreased primary tumor growth and tumor 
cell migration resulting in the formation of less experimental and spontaneous metastasis. 
On the other hand, increased plasminogen activation in the absence of TAFI could cause 
increased matrix degradation in the primary tumor resulting in increased tumor growth, 
efficient entrance of tumor cells into the circulation and elevated spontaneous metastasis 
formation. However, none of these possible effects were seen. We suggest two potential 
explanations for the lack of differences in tumor growth and metastasis in TAFI-deficient 
mice. First, TAFI-deficiency does not result in a significant change in plasmin formation due 
to the presence of other regulators that neutralize the effect of TAFI-deficiency on plasmin 
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activation or activity. An alternative explanation for the lack of effect on tumor growth is that 
excess plasmin in TAFI-deficient mice has no effect at all in the models used. A second 
explanation for our observations is that TAFI is not activated at all and does not regulate 
plasminogen activation in cancer and metastasis. Unfortunately, at present we cannot 
determine whether TAFI is activated in cancer. 
Furthermore, we have determined TAFI antigen and TAFI activity levels in patients with 
primary and metastasized prostate cancer (chapter 4). It is well known that the fibrinolytic 
and coagulation systems are activated in (metastatic) prostate cancer. In these patients 
TAFI could be activated and consumed by the coagulation (thrombin) and/or fibrinolytic 
(plasmin) system or either inactivated by increased plasmin activity in prostate cancer 
patients. However, we did not observe abnormal TAFI antigen or activity levels in these 
patients. In addition, TAFI antigen or activity was not associated with cancer progression 
and the incidence of thrombosis (chapter 4). 
 
The involvement of hemostatic system components in angiogenesis and cancer offers new 
possibilities for cancer treatment. Intriguingly, several antiangiogenic (cryptic) fragments of 
proteins regulating hemostasis, such as angiostatin and antiangiogenic antithrombin III 
(aaATIII), have been identified during the past decade. Our main challenge was to elucidate 
the mechanism of action of endostatin (chapter 5). Endostatin is a carboxy-terminal 
fragment of collagen XIII, and has originally been described as one of the most potent 
inhibitors of angiogenesis. In animal experiments different forms of endostatin are used. 
Although the soluble form of endostatin inhibits tumor growth, complete tumor regression 
has only been observed when using bacterially produced insoluble endostatin. Likely, these 
forms have different bioactivities. We found that insoluble endostatin, in contrast to soluble 
endostatin, stimulates plasminogen activation by tPA, induces plasminogen-mediated 
endothelial cell detachment and matrix degradation and is toxic to neuronal cells (chapter 
5,6). Endostatin-induced plasminogen activation, matrix degradation and endothelial cell 
detachment were inhibited by carboxypeptidase B treatment indicating an essential role for 
carboxy-terminal lysines. In line with this, cotreatment of mice with insoluble endostatin and 
carboxypeptidase B abolished the inhibitory effect of endostatin. Similarly, endostatin-
mediated stimulation of plasminogen activation by tPA was inhibited by the physiological 
regulator of plasminogen activation in plasma, TAFI. Thus in principle, TAFI could function 
as a regulator of the antitumor activity of endostatin.  
Whereas the structure of soluble, globular endostatin has been elucidated, the structure of 
insoluble endostatin has not. Insoluble proteins may occur as amorphous aggregates or as 
highly ordered ‘amyloid’ deposits in which the polypeptide backbones are stacked through 
intermolecular hydrogen bonds, forming a cross-β sheet. The cross-β structure is a hallmark 
of proteins or protein fragments in amyloid plaques of patients with amyloidosis, such as 
Alzheimer’s disease. Structure analyses revealed that insoluble endostatin forms amyloid 
fibers through extensive of cross-β structure formation (chapter 6). Interestingly, the effects 
of insoluble endostatin on plasminogen activation and endothelial and neuronal cells were 
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critically dependent on the presence of this structure (chapter 5,6,7). Since it is well 
established that there is great variability among preparations of amyloid aggregates and the 
resulting toxicity, our finding may explain some of the large differences in the results that have 
been obtained with various sources of endostatin.  
The above results prompted us to investigate the binding characteristics of several other 
amyloid peptides to tPA. We established that the cross-β structure is a common feature in 
other tPA-ligands, including fibrin peptides, islet amyloid polypeptide (IAPP, associated with 
pancreatic β cell toxicity in type II diabetes) and amyloid β (associated with Alzheimer’s 
disease), and responsible for their ability to stimulate tPA-mediated plasminogen activation 
(chapter 7). Our results have classified tPA as a multiligand cross-β structure binding protein. 
tPA may prevent the accumulation of toxic (improperly folded) proteins in the circulation by 
inducing plasmin-mediated proteolysis. Alternatively, tPA may mediate cross-β structure 
induced cell toxicity via excessive matrix degradation. tPA has already been implicated in 
smooth muscle cell apoptosis, neuronal cell toxicity and endothelial cell detachment. Thus, 
excessive formation of plasmin through activation of tPA may inhibit tumor growth. 
Fibrin degradation products (FDPs) also stimulate plasminogen activation through tPA. 
Moreover, FDPs circulate in blood of cancer patients. We tested the hypothesis that fibrin 
fragments also can induce endothelial cell detachment and inhibit tumor growth (chapter 8). 
We found that fibrin degradation products (FDPs) induce detachment of bovine pulmonary 
endothelial cells and inhibit the growth of subcutaneous tumors in mice. These results further 
strengthen the idea that tPA-activating proteolytic fragments in general can inhibit 
angiogenesis and tumor growth. 
To what extent may our observations be of value for the use of endostatin and other 
antiangiogenic fragments? In chapter 9 we discuss the possible implications of our findings. 
We found that endostatin can stimulate plasminogen activation by the serine protease tissue-
type plasminogen activator (tPA). We noticed that many antiangiogenic compounds, generated 
through proteolytical cleavage or denaturation stimulate tPA-mediated plasminogen activation. 
It is intriguing that unrelated proteins lacking sequence homology acquire antiangiogenic 
activity upon proteolytic cleavage or denaturation and at the same time acquire the ability to 
stimulate tPA-mediated plasminogen activation. Taken together, this suggests that a common 
antiangiogenic pathway may exist that is induced by tPA binding proteins. We hypothesize that 
antiangiogenic polypeptide fragments contain the cross-β structure and that this structure is the 
common denominator responsible for their antiangiogenic and antitumorigenic effects. Our 
results imply that it is relevant to consider the possibility that an active drug requires the 
formation of cross-β structure. However, a consequence of our hypothesis is that it is 
necessary to be cautious to use polypeptide fragments as they can have a high probability to 
form toxic aggregates. A final and intriguing implication of our hypothesis is that the presence 
of the cross-β structure in tumor-derived endogenous circulating inhibitors may be responsible 
for the antiangiogenic activity. Besides their antiangiogenic activity, these fragments may also 
contribute to some of the clinical complications, such as amyloidosis or bleeding events, which 
are observed in cancer patients with advanced disease. 
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Samenvatting in het Nederlands 
In mens en dier verzorgen bloed en bloedvaten de noodzakelijk aanvoer van zuurstof en 
voedsel naar de verschillende organen. Bij een verwonding worden bloedvaten beschadigd. 
Om te voorkomen dat er teveel bloedverlies optreedt, wordt er een bloedstolsel gevormd. 
Een complex systeem van eiwitten reguleert de vorming en de afbraak van een stolsel. Het 
systeem dat de vorming van een stolsel induceert wordt het stollingssysteem genoemd. Het 
systeem dat zorgt voor de afbraak van het stolsel heet het fibrinolytische systeem. Het 
stollingssysteem en het fibrinolytische systeem zorgen samen voor het in stand houden van 
een goede doorbloeding. Dit wordt hemostase genoemd.  
Een bloedstolsel ontstaat door samenklontering van bloedeiwitten en geactiveerde 
bloedplaatjes. Een stolsel voorkomt niet alleen verder bloedverlies, maar de in het stolsel 
aanwezige eiwitten en bloedplaatjes zorgen ook voor het herstel van het beschadigde 
weefsel. In eerste instantie herstellen ze de bloedvoorziening door de vorming van nieuwe 
bloedvaatjes te stimuleren. De vorming van nieuwe bloedvaatjes wordt angiogenese 
genoemd. Tijdens wondgenezing speelt het fibrinolytische systeem een cruciale rol. Het 
fibrinolytische systeem bestaat uit een cascade van enzymen (het plasminogeenactivatie 
systeem) dat zorgt voor de afbraak van het stolsel. 
De vorming van nieuwe bloedvaten (angiogenese) is niet alleen betrokken bij herstel van 
weefselschade. In 1971 poneerde Judah Folkman de hypothese dat angiogenese ook 
belangrijk is voor de groei van tumoren. Als tumoren groter worden dan enkele mm3 is de 
voedselvoorziening via diffusie niet meer toereikend en dient het bloedvatstelsel uitgebreid 
te worden. Uitgebreid onderzoek naar de betrokkenheid van het hemostase systeem bij 
angiogenese en kanker heeft inmiddels een duidelijke rol voor dit systeem in deze 
processen aangetoond. Stollingseiwitten zijn aanwezig in tumoren en faciliteren de hechting 
en migratie van cellen die de bloedvatwand bekleden (endotheelcellen) en van tumorcellen. 
Daarnaast is bekend dat stollingseiwitten een belangrijke rol spelen bij de uitzaaiing van 
tumoren. Verscheidene studies hebben aangetoond dat het fibrinolytische systeem 
betrokken is bij angiogenese, bij tumorgroei en bij het ontstaan van uitzaaiingen. Op basis 
van metingen van stollingseiwiten en fibrinolytsche parameters kunnen we concluderen dat 
het hemostase systeem geactiveerd is in kankerpatiënten. 
 
In dit proefschrift worden de resultaten beschreven van het onderzoek naar de rol van het 
fibrinolytische systeem bij de vorming van nieuwe bloedvaten in kanker. Bij kanker reguleert 
het fibrinolytische systeem de afbraak van extracellulaire matrix (opgebouwd uit 
componenten van een stolsel). De afbraak van deze matrix is noodzakelijk voor de groei en 
invasie van endotheel- en tumorcellen. Plasmine is één van de belangrijke enzymen voor de 
afbraak van extracellulaire matrix en wordt gevormd na activatie van het bloedeiwit 
plasminogeen. Twee enzymen kunnen voor de activatie van plasminogeen zorgen, tPA en 
uPA. tPA-gemedieerde plasminogeenactivatie neemt sterk toe in de aanwezigheid van een 
cofactor. De cofactor is vaak een afgebroken onderdeel van de extracellulaire matrix. De 
Samenvatting  137 
 
cofactor bind zowel tPA als plasminogeen en zorgt ervoor dat deze eiwitten in de positie 
komen die nodig is voor optimale activatie van plasminogeen. Plasmine knipt de eiwitten 
van de extracellulaire matrix specifiek na een lysine of arginine. Daardoor ontstaan er 
fragmenten met aan het eind een lysine of arginine. Deze eindstandige aminozuren 
fungeren als bindingsplaats voor plasminogeen en zijn belangrijk voor tPA-gemedieerde 
activatie van plasminogeen. Omdat meer plasmine resulteert in de vorming van meer 
eindstandige lysines of arginines die weer zorgen voor een toename in plasminogeen 
binding en activatie, ontstaat er een waterval effect. Plasminogeenactivatie wordt geremd 
door moleculen die lijken op lysine. Cyclokapron is een voorbeeld van een lysine-analoog 
dat daarom wordt gebruikt om bij bepaalde patiënten bloedingen te helpen voorkomen. 
Studies met dergelijke middelen hebben aangetoond dat eindstandige lysines belangrijk zijn 
bij angiogenese en kanker. 
Trombine-activeerbare fibrinolyse inhibitor (TAFI) wordt gemaakt door de lever en circuleert 
in bloed in een inactieve vorm. TAFI wordt geactiveerd door de enzymen trombine, plasmine 
en trypsine. Trombine-gemedieerde TAFI activatie neemt 1250 maal toe in aanwezigheid 
van trombomoduline, een eiwit dat aanwezig is op endotheel- en tumorcellen. Actief TAFI is 
een carboxypeptidase B-type enzym en verwijdert eindstandige lysines of arginines van 
eiwitten. Verwijdering van deze plasminogeen bindingsplaatsen in eiwitten resulteert in de 
afname van plasminogeenactivatie en fibrinolyse. Wij hebben uitgezocht of TAFI een rol kan 
spelen bij kanker. 
 
In hoofdstuk 1 wordt een overzicht gegeven van de huidige stand van zaken met 
betrekking tot het onderzoek naar de rol van het plasminogeenactivatie systeem bij kanker. 
Daarnaast zijn een aantal benaderingen samengevat die tot doel hebben dit systeem te 
gebruiken als aangrijpingspunt voor antitumor therapie. We concluderen dat angiogenese 
en tumorgroei afhankelijk is van een juiste afstemming van stolling en fibrinolyse. Dit 
betekent dat interventies die dit evenwicht opheffen, zoals remming, maar ook 
overactivering van het fibrinolytische systeem, leiden tot verminderde angiogenese en 
tumorgroei. We postuleren dat moleculen die overmatige fibrinolyse in de tumor induceren 
potentiële kandidaten zijn voor de behandeling van kanker. 
Om meer duidelijkheid te krijgen over de rol van het plasminogeenactivatie systeem in 
angiogenese hebben we gebruik gemaakt van een angiogenesemodel in het hoornvlies 
(cornea) van muizen deficiënt voor uPA, tPA, plasminogeen, PAI (een remmer van 
plasminogeenactivatie) en TAFI. In hoofdstuk 2 laten we zien dat angiogenese in de 
cornea van muizen sterk afhankelijk is van de aanwezigheid van PAI en in veel mindere 
mate van plasminogeen. In het verleden hebben we aangetoond dat angiostatine, een 
fragment van plasminogeen, de corneale angiogenese compleet kan remmen. Onze 
bevindingen suggereren dat het antiangiogene effect van angiostatine in muizen niet alleen 
bepaald wordt door remming van plasminogeen. De afwezigheid van plasminogeen-
activatoren, tPA en uPA was niet van invloed op de vorming van nieuwe bloedvaten in de 
cornea. Ook TAFI was niet van invloed op de vorming van bloedvaten in de cornea. Het feit 
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dat anderen hebben laten zien dat corneale angiogenese effectief geremd wordt door uPA-
antagonisten is opmerkelijk, en suggereert dat deze effecten bepaald worden door een 
activiteit anders dan uPA-remming. 
Omdat het plasminogeenactivatie systeem betrokken is bij tumorgroei en het ontstaan van 
uitzaaiingen, hebben we onderzocht of TAFI deze processen reguleert. Voor dit onderzoek 
hebben we tumorgroei van onderhuidse (subcutane) tumoren en de vorming van 
uitzaaiingen bestudeerd in muizen die geen TAFI maken (hoofdstuk 3). Het is denkbaar dat 
in de afwezigheid van TAFI, plasminogeenactivatie zodanig gedereguleerd wordt dat er 
overmatige matrixafbraak plaatsvindt, resulterend in verminderde tumorgroei en 
verminderde vorming van uitzaaiingen (zie ook hoofdstuk 1). Anderzijds kan het zijn dat 
verhoogde plasminogeenactivatie leidt tot versnelde matrixafbraak, tumorgroei en de 
vorming van uitzaaiingen. Echter, geen van deze effecten zijn waargenomen. Er zijn 
verschillende verklaringen mogelijk. In de eerste plaats is het mogelijk dat door de 
aanwezigheid van andere remmers van plasminogeenactivatie, bijvoorbeeld PAI, de 
afwezigheid van TAFI niet resulteert in een toename van plasmine. Een andere verklaring 
zou kunnen zijn dat overmatige plasminogeenactivatie geen effect heeft in onze modellen. 
In de tweede plaats zou het kunnen zijn dat TAFI niet geactiveerd wordt tijdens tumorgroei 
en de vorming van uitzaaiingen en dus ook niet plasminogeenactivatie reguleert. 
Het is bekend dat het coagulatie- en fibrinolytische systeem geactiveerd is in patiënten met 
kanker. Wij hebben TAFI antigeen en activiteit bestudeerd in bloed van patiënten met 
primaire en uitgezaaide prostaatkanker. Het zou kunnen zijn dat TAFI geactiveerd en 
verbruikt wordt door het coagulatie- (trombine) of fibrinolytisch (plasmine) systeem of 
mogelijk geïnactiveerd door verhoogde plasmine-activiteit in deze patiënten. Echter, TAFI 
concentratie en activatie zijn normaal in bloed van patiënten met prostaatkanker. Ook zijn de 
gemeten waarden niet geassocieerd met de progressie van de ziekte of met trombotische 
complicaties. 
 
De bevindingen uit het onderzoek naar de rol van het hemostase systeem in angiogenese 
en kanker hebben nieuwe mogelijkheden gegeven voor de ontwikkeling van nieuwe 
medicijnen voor de behandeling van kanker. In de afgelopen tien jaar zijn er verschillende 
angiogeneseremmers ontdekt. Het is opmerkelijk en interessant dat veel 
angiogeneseremmers proteolytische fragmenten zijn van eiwitten van het hemostase 
systeem. Ons onderzoek heeft zich gericht op de ontrafeling van het werkingsmechanisme 
van de angiogeneseremmer endostatine. Endostatine is een fragment van het extracellulaire 
matrixeiwit collageen XVIII en is in 1997 beschreven als de meest potente remmer van 
tumorgroei. Echter, het gebruik van verschillende vormen van endostatine in combinatie met 
uiteenlopende behandelingsresultaten heeft het onderzoek naar de werking van endostatine 
gecompliceerd. Alhoewel een oplosbare vorm van endostatine tumorgroei remt, is regressie 
van tumoren alleen waargenomen na behandeling met een gedenatureerde, onoplosbare 
vorm, gemaakt in bacteriën. Het is aannemelijk dat deze twee vormen een verschillende 
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biologische functie hebben. Wij hebben aangetoond dat de onoplosbare vorm van 
endostatine, in tegenstelling tot de oplosbare vorm, tPA-gemedieerde plasminogeenactivatie 
stimuleert. Endostatine-geïnduceerde plasminevorming resulteert in matrixafbraak en in het 
loslaten van endotheelcellen (hoofdstuk 5,6).  Stimulatie van plasminogeenactivatie, 
matrixafbraak en het loslaten van endotheelcellen wordt geremd door carboxypeptidase B. 
Dit impliceert dat carboxyterminale lysines een belangrijke rol spelen in deze endostatine-
geïnduceerde processen. In overeenstemming hiermee is de waarneming dat gelijktijdige 
behandeling van experimentele tumoren met carboxypeptidase B de antitumorale effecten 
van onoplosbaar endostatine opheft. Endostatine-gestimuleerde plasminogeenactivatie 
wordt op een vergelijkbare manier geremd door TAFI, een fysiologische regulator van 
plasminogeenactivatie. Het is niet ondenkbaar dat TAFI de werking van endostatine in 
muizen reguleert. 
We hebben de structuur van de onoplosbare vorm van endostatine opgehelderd. Het was 
bekend dat onoplosbare eiwitten voorkomen als amorfe aggregaten of als goed geordende 
fibrillen. In deze aggregaten en fibrillen zijn de polypeptiden met elkaar verbonden via 
waterstofbruggen en vormen ze een cross-β structuur. Deze structuur is een kenmerk van 
eiwitten of eiwitfragmenten zoals die worden gevonden in eiwitdeposities in patiënten met 
amyloidose. Bekende ziektes die gepaard gaan met de depositie van amyloid zijn de ziekte 
van Alzheimer en de gekke-koeienziekte. Door middel van gedetailleerde analyse hebben 
we aangetoond dat onoplosbaar endostatine ook cross-β structuren bevat en amyloid vormt 
(hoofdstuk 6). De door ons beschreven effecten van deze vorm van endostatine op tPA-
gemedieerde plasminogeenactivatie, op endotheelcellen en op neurale cellen was 
afhankelijk van de aanwezigheid van de cross-β structuur (hoofdstuk 5,6,7). Het is bekend 
dat de mate van aggregatie en de toxiciteit van verschillende preparaten van een amyloid 
eiwit sterk kan variëren. Mogelijk leveren onze bevindingen een verklaring voor de 
verschillen in activiteit tussen afzonderlijke preparaten van endostatine. 
De hiervoor beschreven resultaten hebben ons aangezet om de binding van tPA aan 
amyloide peptiden nader te bestuderen. We hebben aangetoond dat de cross-β structuur 
een algemeen voorkomende structuur is in fibrine peptiden, islet amyloid polypeptide (IAPP, 
geassocieerd met pancreas β cel toxiciteit in type II diabetes) and amyloid β (betrokken bij 
de ziekte van Alzheimer). Daarnaast is deze structuur  verantwoordelijk voor de eigenschap 
van deze peptiden om tPA-gemedieerde plasminogeenactivatie te stimuleren (hoofdstuk 
7). Onze resultaten typeren tPA als een algemeen cross-β structuur bindend enzym. We 
veronderstellen dus dat tPA, via plasmine- gemedieerde eiwitafbraak een belangrijke functie 
heeft in het voorkomen van een ongewenste opstapeling van toxische (gedenatureerde, 
verkeerd gevouwen) eiwitten in de bloedvaten. Het is ook goed mogelijk dat tPA juist 
betrokken is bij amyloid-geïnduceerde celdood (apoptose) als gevolg van overmatige 
matrixafbraak. Het is al bekend dat tPA een rol speelt bij de dood van gladde spiercellen en 
neuronale cellen. Het zou dus goed mogelijk kunnen zijn dat overmatige plasminevorming 
en matrixafbraak leidt tot celdood en remming van tumorgroei. 
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Afbraakproducten van fibrine, de belangrijkste component van een bloedstolsel, komen in 
verhoogde concentraties voor in bloed van kankerpatiënten, en kunnen ook 
plasminogeenactivatie door tPA stimuleren. Wij hebben getest of afbraakproducten van 
fibrine een effect hebben op de hechting van endotheelcellen en op de groei van kanker 
(hoofdstuk 8). Onze resultaten laten zien dat behandeling van endotheelcellen met 
afbraakproducten van fibrine het loslaten van deze cellen induceert. Daarnaast vonden we 
dat deze fragmenten, vergelijkbaar met endostatine, subcutane tumorgroei in muizen 
remmen. Deze resultaten vormen een nieuwe aanwijzing dat tPA-activerende proteolytische 
fragmenten in het algemeen angiogenese en tumorgroei kunnen remmen. 
In hoeverre zijn onze bevindingen van belang voor het gebruik van endostatine en andere 
antiangiogene fragmenten? In hoofdstuk 9 worden de mogelijke implicaties van onze 
resultaten bediscussieerd. Samengevat constateren we het volgende. De angiogenese- en 
tumorgroeiremmer endostatine stimuleert tPA-gemedieerde plasminogeenactivatie. 
Daarnaast weten we dat een aantal andere antiangiogene middelen, als proteolytisch 
fragment of gedenatureerd eiwit, ook plasminogeenactivatie door tPA stimuleren. 
Interessant is dat verschillende eiwitten (zonder homologie van aminozuur sequentie) 
antiangiogeen/antitumorigeen zijn na proteolyse of denaturatie en tegelijkertijd de potentie 
verwerven tPA-gemedieerde plasminogeenactivatie te stimuleren. Dit suggereert de 
aanwezigheid van een gemeenschappelijk antiangiogeen mechanisme dat wordt 
geactiveerd door tPA-bindende peptiden. Wij postuleren dat antiangiogene eiwitfragmenten 
de cross-β structuur bevatten en dat deze structuur de antiangiogene en antitumorigene 
activiteit bepaald. Onze resultaten impliceren verder dat de aanwezigheid van deze 
structuur niet onbelangrijk is voor de effectiviteit van antiangiogene polypeptide fragmenten. 
Aan de andere kant is de consequentie van onze hypothese dat we voorzichtig moeten zijn 
met het gebruik van dit type middelen in verband met mogelijke amyloid-gerelateerde 
toxiciteit op langere termijn. Naast de antiangiogene activiteit van circulerende 
eiwitfragmenten kan het ook zijn dat deze fragmenten bijdragen aan sommige klinische 
complicaties, zoals amyloidose en bloedingen, die waargenomen worden in patiënten met 
een ver gevorderd stadium van kanker. 
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Color figures
Chapter 1, Figure 1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Coagulation and fibrinolysis on the cell surface. Upon stimulation by VEGF, components that initiate 
and control coagulation and fibrinolysis are upregulated. The continuous formation and breakdown 
of the provisional matrix is of great importance for cell viability, growth and motility. Matrix 
components support adhesion of endothelial cells and degradation of the matrix is necessary for 
migration. RGD, amino acids involved in binding of extracellular matrix proteins by integrins; PAI, 
plasminogen activator inhibitor; αvβ3, integrin receptor for vitronectin and fibrin(ogen). 
Chapter 2, Figure 1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Corneal neovascularization in uPA-/-, tPA-/- and control mice.  (A) Photograph of a control mouse 
cornea 6 days after bFGF-coated pellet implantation.  (B) bFGF-induced vessel formation in 
corneas of uPA-/- (n = 5), tPA-/- (n = 6) and control (n = 24) mice was analyzed 6 days after pellet 
implantation and quantified. Corneal angiogenesis was unaffected in the absence of tPA or uPA. 
Values are the normalized mean ± SEM. 
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Chapter 3, Figure 1.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Effect of TAFI-deficiency on primary tumor growth. (C) 1 x 106 Lewis lung carcinoma cells were 
injected into the subcutaneous dorsa of mice and tumor volume was determined by calipation. No 
significant differences in tumor growth were observed between TAFI-deficient and wildtype mice. □ , 
TAFI-/-; ■ , wildtype. (D) Representative example of subcutaneous LLC of a TAFI-deficient mouse 
(left panel) and a wildtype mouse (right panel) 11 days after transplantation. Upper panel: skin side 
facing up, Lower panel: basal side facing up. 
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Chapter 3, Figure 2 A-C. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Effect of TAFI-deficiency on experimental pulmonary metastasis formation. 5 x 104 B16-BL6 
melanoma cells were injected intravenously in TAFI-deficient and wildtype mice by tail vein 
injection. Lungs were isolated after 14 days, fixed and pulmonary metastasis formation was 
quantified by counting the number of tumor foci. (A,B) Representative examples of lungs with 
metastatic foci of B16-BL6 melanoma in wildtype (A) and TAFI-deficient mice (B) 14 days after 
intravenous injection. (C) The number of pulmonary nodules in TAFI-deficient and wildtype mice 
was not significantly different. 
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Chapter 3, Figure 3 A-C. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Effect of TAFI-deficiency on spontaneous pulmonary metastasis formation. TAFI-deficient and 
wildtype mice underwent primary tumor resection 11 days after subcutaneous transplantation of 
LLC. After 14 days the lungs were removed and fixed in Bouin’s fixative. (A,B) Representative 
examples of metastatic pulmonary foci 14 days after tumor resection, indicating the presence of 
both small and large tumor nodules in wildtype (A) and TAFI-deficient (B) mice. (C) Quantification of 
the number of pulmonary metastatic foci revealed no significant difference between TAFI-deficient 
and wildtype mice. 
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Chapter 3, Figure 5.  
 
Histological analysis of 
lung metastases in TAFI-
deficient (A,C) and wild-
type (B,D) mice. Lungs 
were isolated 14 days 
after primary tumor 
resection, paraffin em-
bedded, sectioned and 
stained with hemato-
xylin/eosin. 
(A-D) Detailed analyses 
of the lungs revealed the 
presence of both paren-
chymal and pleural meta-
stases composed of pleo-
morphic anaplastic cells 
having vesicular nuclei 
with multiple nucleoli and 
showing normal and abnormal mitotic figures (arrows) in TAFI-deficient and wildtype mice. Many 
tumor nodules had large necrotic areas associated with local hemorrhage (arrowheads). 
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Chapter 3, Figure 4. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Histological analysis of primary tumors in TAFI-deficient (A,C,E,G) and wildtype (B,D,F,H) mice. 
Primary tumors of LLC were isolated 11 days after transplantation, paraffin embedded, sectioned 
and stained with hematoxylin/eosin. (A,B) Tumors in TAFI-deficient and wildtype mice both consist 
of closely packed anaplastic cells of different sizes with ample cytoplasm and show numerous 
normal as well as abnormal mitoses (arrows). (C,D) Tumors in both genotypes exhibited diffuse 
invasion into and destruction of adjacent muscle tissue. Arrows indicate normal muscle, arrowheads 
indicate tumor cell invasion surrounding individual myocytes. (E-F) Tumor invasion of the dermis. 
Arrows indicate normal epidermis. Arrowheads indicate infiltrating tumor cells in dermis. (G,H) 
Tumor invasion of the epidermis eventually leads to loss of keratinocytes and severe skin ulceration 
in both genotypes. Arrows indicate intact epidermis at the border of the ulceration. Arrowheads 
indicate crust formation. The asterisks indicate the tumor. 
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Chapter 6, Figure 1 A,B. 
 
Amyloid properties of endostatin produced 
in bacteria. (A) Endostatin was purified from 
bacteria and stained with Congo Red. 
Samples were analyzed by light microscopy 
using both polarized and non-polarized 
light. The figure shows that endostatin 
binds Congo Red and exhibits green 
birefringence when examined under 
polarized light. (B) Endostatin samples 
were further analyzed by X-ray diffraction. 
The scattering as obtained on the 2D 
detector is color coded by intensity on a 
linear scale. The scattering intensity 
decreases as white-yellow-red-blue-black. 
The pattern shows diffraction maxima at 4.7 
Å and 10-11 Å. The fiber axis (hydrogen 
bond direction) with 4.7 Å repeat is oriented 
vertically and is indicated by the arrow.  
The 10-11 Å repeat is preferentially oriented perpendicular to that as indicated by the asterisk. 
Tangential scans along the 2θ scattering angles corresponding to both d-spacings in the lower 
panel show that the scattering at 4.7 Å is oriented vertically and that at 10-11 Å horizontally.  
*
4.7Å
10-11Å
*
A B 
Chapter 6, Figure 2.  
Conversion of soluble globular endostatin into 
amyloid endostatin. Endostatin pro-duced in 
yeast was dialysed against 8 M urea followed 
by extensive dialysis against H2O. During 
dialysis endostatin pre-cipitates as a fine 
white solid. The samples were processed for 
X-ray diffraction analysis. (A) Diffraction 
pattern of untreated (yeast-produced) 
endostatin with no sign of cross-β sheet 
structure. (B) Diffraction pattern of urea-
treated endostatin with extensive cross-β 
sheet formation. During solvent evaporation 
fibril formation occurred both vertically and 
horizontally in the capillary, as evidenced by 
the occurrence of peaks at 90, 180, 270 and 
0/360 degrees in the tangential scans 
corresponding to both d-spacings. The 
asterisk indicates the peak reflection of the 
10-11 Å d-spacing at 900. The arrow indicates 
the peak reflection of the 4.7 Å d spacing at 
1800. 
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Chapter 6, Figure 3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Binding of amyloid aggregates to N1E-115 neuroblastoma cells. (A) Neuronal N1E-115 cells,  were 
incubated with either FITC-labeled aggregated amyloid endostatin, soluble endostatin, Aβ freshly 
resuspended, Aβ pre-aggregated for three weeks (Aβ amyloid), hIAPP freshly resuspended and 
hIAPP pre-aggregated for three weeks (hIAPP amyloid) (all at 5 µM) and washed. after 1 hour. The 
actin cytoskeleton was stained using Texas Red-conjugated palloidin (red) and the DNA with DAPI 
(blue). All amyloid aggregates (left panels) bound N1E-115 cells. (B) N1E-115 cells were pre-
incubated for 6 hours with non-fluorescent Aβ or hIAPP (at 5 µM) and the binding of FITC-labelled 
amyloid endostatin (1 hour, 5 µM) was subsequently tested as above.      
Aβ, amyloid Aβ, fresh
endostatin, amyloid endostatin, soluble
hIAPP, amyloid hIAPP, fresh
endostatin
Aβ > endostatin
hIAPP > endostatin 
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Chapter 6, Figure 4. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Localisation of cell-associated amyloid aggregates. N1E-115 cells were grown on glass coverslips 
and were incubated for 1 hour with FITC-labeled amyloid endostatin, Aβ ҏand hIAPP. Actin was 
visualized using Texas Red-conjugated phalloidin. The coverslips were analyzed by confocal 
microscopy. Whole cell images (upper panel) show localisation of all three amyloids mainly to the 
cell surface. In addition, some of the aggregates show intracellular localization (arrows) (Bar, 10 
µm). Zoomed images of cell surface areas (lower panel) shows that all three types of amyloid 
aggregates are in close proximity to the plasma membrane-bound cortical actin cytoskeleton (Bar, 2 
µm). 
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Chapter 6, Figure 5 A,C. 
Toxicity of amyloid endostatin. (A) N1E-
115 cells were differentiated into post-
mitotic neurons on glass coverslips and 
were subsequently treated overnight 
with either FITC-labeled soluble or with 
FITC-labelled amyloid endostatin. 
Following extensive washing and 
fixation, binding of endostatin to the 
cells was visualized with fluorescence 
microscopy. Merged bright field and 
fluorescence images are shown. Only 
amyloid endostatin binds to the 
differentiated neuronal cells.  
 (C) N1E-115 cells were differentiated on glass coverslips and were subsequently treated with either 
soluble or with amyloid endostatin. Following fixation, the cells were stained with annexin V-FITC to 
visualize exposed phosphatidylserine. Detaching cell clusters that are associated with endostatin 
aggregates are highly positive for annexin V.           
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Chapter 7, Figure 2 D,B. 
 
Structural analysis of fibrin-derived 
peptides. (B) Single drops of FP13 
and FP10 (1 mg/ml in H2O) were air-
dried and stained with Congo Red 
according to the manufacturer’s 
protocol. Microscopic analysis using 
non-polarized and polarized light 
shows that FP13, but not FP10 (not 
shown), binds Congo Red. (D) X-ray 
diffraction analysis of FP13. The 
scattering as obtained on the 2D 
detector is color-coded by intensity on 
a linear scale. The scattering intensity 
decreases as white-yellow-red-blue-
black. 
The pattern shows diffraction maxima at 4.7, 11.7 and 23.4 Å. In the 
lower panels, tangential scans along the 2θ scattering angles 
corresponding to all three d-spacings show that the 4.7 Å scattering 
(hydrogen bonds) is oriented perpendicular to those at 11.7 and 
23.4 Å (1x and 2x inter-sheet distance). 
unpolarized light 
B 
polarized light 
4.7Å
11.7Å
23.4Å
o
*
* o
D 
Chapter 7, Figure 4. 
 
Enhanced plasminogen activation by cross-
β−structured endostatin. (A) X-ray diffraction 
analysis of two distinct forms of endostatin. The 
left panel shows globular endostatin with no 
detectable cross-β sheets. The right panel shows 
insoluble endostatin with abundant cross-β 
sheets. The scattering as obtained on the 2D 
detector is color coded as in Figure 2D. The 
pattern shows diffraction maxima at 4.7 and 10-
11 Å. The fiber axis (hydrogen bond direction) 
with 4.7 Å repeat is oriented vertically. The 10-11 
Å repeat is preferentially oriented perpendicular 
to that, as indicated by the asterisk. Tangential 
scans along the 2θ scattering angles 
corresponding to both d-spacings in the lower 
panel show that the scattering at 4.7 Å is oriented 
vertically with the maximum intensity at 1800 
indicated by the arrow. The reflection at 10-11 Å 
is oriented horizontally with the maximum at 900 
indicated by the asterisk.  
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